Document:

EX-10.21

 Exhibit 10.21 
 Execution Version 
 Confidential Materials omitted and filed
separately with the Securities and Exchange Commission. 
 Triple asterisks denote omissions. 

OPTION FOR A LICENSE AGREEMENT 
 BY AND BETWEEN 
 MACROGENICS, INC. 

 AND 
 
LES LABORATOIRES SERVIER 
 AND 
 INSTITUT DE RECHERCHES SERVIER 
  

 Table of Contents 

 

							
	ARTICLE 1	 	DEFINITIONS	 	 	1	  
			
	ARTICLE 2	 	GOVERNANCE	 	 	14	  
			
	2.1	 	Alliance Business-Development Managers	 	 	14	  
	2.2	 	Alliance R&D Managers	 	 	14	  
	2.3	 	Project Directors	 	 	15	  
	2.4	 	Joint Executive Committee	 	 	15	  
	2.5	 	Joint Steering Committee	 	 	15	  
	2.6	 	Joint Research and Development Committee and Subcommittees	 	 	16	  
	2.7	 	Co-Chairpersons	 	 	17	  
	2.8	 	Committee Meetings	 	 	17	  
	2.9	 	Decisions	 	 	18	  
	2.10	 	Authority	 	 	19	  
	2.11	 	Representatives	 	 	19	  
			
	ARTICLE 3	 	RESEARCH AND DEVELOPMENT; EXCLUSIVE OPTION	 	 	19	  
			
	3.1	 	Research Overview	 	 	19	  
	3.2	 	Conduct of the Research Program	 	 	20	  
	3.3	 	Evaluation of Option Trigger Data Package; Option Exercise	 	 	20	  
			
	ARTICLE 4	 	GRANT OF RIGHTS; EXCLUSIVITY	 	 	22	  
			
	4.1	 	License Grant to Servier	 	 	22	  
	4.2	 	License Grant to MacroGenics	 	 	22	  
	4.3	 	Sublicenses	 	 	22	  
	4.4	 	Subcontracting	 	 	23	  
	4.5	 	MacroGenics Third Party Agreements	 	 	23	  
	4.6	 	Right of First Negotiation for Bi-Specific DARTs	 	 	24	  
	4.7	 	Rights Retained by the Parties	 	 	24	  
	4.8	 	Section 365(n) of the Bankruptcy Code	 	 	24	  
	4.9	 	Exclusivity	 	 	25	  
	4.10	 	Consequences of Development and Commercialization of Competing Products	 	 	25	  
	4.11	 	Diagnostics	 	 	25	  
			
	ARTICLE 5	 	DEVELOPMENT DURING THE LICENSE TERM	 	 	25	  
			
	5.1	 	Overview	 	 	25	  
	5.2	 	Servier Obligations	 	 	25	  
	5.3	 	Development Activities	 	 	26	  
	5.4	 	Updating and Amending Development Plan and Development Budget; Additional Development Activities	 	 	27	  
	5.5	 	Development Activities	 	 	30	  
	5.6	 	Exchange of Data	 	 	31	  

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

					
	ARTICLE 6	 	REGULATORY MATTERS	 	33
			
	6.1	 	Servier Regulatory Responsibility	 	33
	6.2	 	MacroGenics Regulatory Responsibility	 	33
	6.3	 	Communications with Regulatory Authorities	 	34
	6.4	 	Product Withdrawals and Recalls	 	35
	6.5	 	Pharmacovigilance; Safety Data Reporting	 	36
			
	ARTICLE 7	 	MANUFACTURING	 	36
			
	7.1	 	Transfer of MacroGenics Manufacturing Know-How	 	37
	7.2	 	Supply Agreements	 	37
			
	ARTICLE 8	 	COMMERCIALIZATION	 	38
			
	8.1	 	Overview	 	38
	8.2	 	Sales and Distribution	 	38
	8.3	 	Ex-Territory Sales	 	38
	8.4	 	Commercialization Plan for Licensed Territory	 	38
	8.5	 	Trademarks.	 	38
	8.6	 	Commercial Diligence	 	39
	8.7	 	Standards of Conduct	 	39
			
	ARTICLE 9	 	PAYMENTS	 	39
			
	9.1	 	Option Grant Fee	 	39
	9.2	 	License Grant Fee	 	39
	9.3	 	Development and Regulatory Milestones	 	40
	9.4	 	Sales Milestones	 	41
	9.5	 	Royalties	 	42
	9.6	 	Reports; Payments	 	43
	9.7	 	Methods of Payments	 	43
	9.8	 	Late Payments	 	43
	9.9	 	Taxes	 	44
	9.10	 	Books and Records; Audit Rights	 	44
			
	ARTICLE 10	 	OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS	 	44
			
	10.1	 	Inventorship	 	44
	10.2	 	Ownership	 	44
	10.3	 	Prosecution and Maintenance of Patents	 	45
	10.4	 	Third Party Infringement	 	47
	10.5	 	Patent Invalidity Claim	 	49
	10.6	 	Patent Term Extensions	 	50
	10.7	 	Patent Marking	 	50

  
 - ii -

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

					
	ARTICLE 11	 	CONFIDENTIALITY	 	50
			
	11.1	 	Confidentiality; Exceptions	 	50
	11.2	 	Authorized Disclosure	 	50
	11.3	 	Press Release; Disclosure of Agreement	 	51
	11.4	 	Existing Confidentiality Agreement	 	52
	11.5	 	Remedies	 	52
	11.6	 	Publications	 	52
	11.7	 	Return of Confidential Information	 	52
			
	ARTICLE 12	 	REPRESENTATIONS AND WARRANTIES	 	53
			
	12.1	 	Representations and Warranties of Both Parties	 	53
	12.2	 	Representations and Warranties of MacroGenics and its Affiliates	 	54
	12.3	 	Representation and Warranty of LLS	 	55
	12.4	 	Mutual Covenants	 	55
	12.5	 	Disclaimer	 	56
			
	ARTICLE 13	 	INDEMNIFICATION	 	56
			
	13.1	 	Indemnification by Servier	 	56
	13.2	 	Indemnification by MacroGenics	 	56
	13.3	 	Procedure	 	57
	13.4	 	Allocation	 	58
	13.5	 	 ***
	 	58
			
	ARTICLE 14	 	TERM AND TERMINATION	 	58
			
	14.1	 	Agreement Term; Expiration	 	58
	14.2	 	Termination for Cause	 	58
	14.3	 	Termination for Patent Challenge	 	59
	14.4	 	Termination for Convenience	 	59
	14.5	 	Termination for Insolvency Event	 	59
	14.6	 	Termination by Servier for Safety or Public Health Reasons	 	59
	14.7	 	Effect of Expiration or Termination	 	59
	14.8	 	Accrued Rights; Surviving Provisions of the Agreement	 	61
			
	 ARTICLE 15
	 	 STANDSTILL
	 	
			
	 15.1
	 	 Standstill
	 	
			
	ARTICLE 16	 	MISCELLANEOUS	 	62
			
	16.1	 	Disputes	 	62
	16.2	 	Arbitration Disputes	 	62

  
 - iii -

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

					
	16.3	 	Governing Law	  	64
	16.4	 	Assignment	  	64
	16.5	 	Force Majeure	  	64
	16.6	 	Notices	  	65
	16.7	 	Export Clause	  	66
	16.8	 	Waiver	  	66
	16.9	 	Severability	  	66
	16.10	 	Entire Agreement	  	66
	16.11	 	Independent Contractors	  	66
	16.12	 	Headings; Construction; Interpretation	  	67
	16.13	 	Further Actions	  	67
	16.14	 	Parties in Interest	  	67
	16.15	 	Performance by Affiliates	  	67
	16.16	 	Counterparts	  	67
		
	Exhibit A-1: Back-Up Program Antibodies	  	
	Exhibit A-2: MGA271	  	
	Exhibit B: MacroGenics Patents	  	
	Exhibit C: MacroGenics Third Party Agreements	  	
	Exhibit D: Press Release	  	

  
 - iv -

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 OPTION FOR A LICENSE AGREEMENT 

This Option for a License Agreement (this “Agreement”) is entered into and made effective as of the
24th day of November, 2011 (the “Effective
Date”), by and between MacroGenics, Inc. a corporation organized and existing under the laws of the State of Delaware and having a principal office located at 1500 East Gude Drive Rockville, MD 20850, USA (“MacroGenics”),
and Les Laboratoires Servier, a company organized and existing under the laws of France, having a principal office located at 50 rue Carnot 92284 Suresnes (“LLS”) and Institut de Recherches Servier, a company organized and existing
under the laws of France, having a principal office located at 3 rue de la République – 92150 Suresnes - France (“IdRS” and LLS and IdRS hereinafter collectively referred to as “Servier”). MacroGenics
and Servier are each referred to herein by name or as a “Party” or, collectively, as “Parties.” 
 RECITALS 
 WHEREAS, Servier possesses expertise in the Research,
Development, Manufacturing and Commercialization (each as defined below) of pharmaceutical products; 
 WHEREAS, MacroGenics
controls certain intellectual property related to certain antibodies targeting B7-H3, including the antibody known as MGA271; 

WHEREAS, Servier is interested in receiving an exclusive option to obtain a future license under which it may further research, develop
and commercialize such antibodies in the Servier Territory (as defined below), and MacroGenics is willing to grant Servier such an option to obtain a future license on the terms and conditions set forth in this Agreement; and 

WHEREAS the Parties are willing to set forth the terms and conditions of an option grant and an exclusive license to enable Servier to
research, develop and commercialize the above mentioned antibodies as further defined hereafter, upon exercise of the exclusive option by Servier. 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties hereto agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 As used in this Agreement, the following terms will have the
meanings set forth in this ARTICLE 1 unless context dictates otherwise: 
 1.1 “Accounting Standards” means,
with respect to a Person, generally accepted accounting principles as practiced in the United States or, to the extent applicable, IFRS (International Financial Reporting Standards). 

  
 1 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 1.2 “Affiliate” means, as to a Person, any other Person that, directly or
indirectly through one or more intermediaries, controls, is controlled by or is under common control with said first Person, regardless of whether such Affiliate is an Affiliate on the Effective Date or becomes an Affiliate after the Effective Date.
A Person shall be deemed to “control” another Person if it (a) owns, directly or indirectly, beneficially or legally, more than fifty percent (50%) of the outstanding voting securities or capital stock (or such lesser percentage
which is the maximum allowed to be owned by a Person in a particular jurisdiction) of such other Person, or has other comparable ownership interest with respect to any Person other than a corporation; or (b) has the power, whether pursuant to
contract, ownership of securities or otherwise, to direct the management and policies of the Person. 
 1.3 “Agreement
Term” means the period commencing on the Effective Date and ending on the expiration of this Agreement in accordance with the provisions of Section 14.1. 
 1.4 “Annual Net Sales” means aggregate Net Sales of Licensed Products by Servier or its Affiliates or Sublicensees in any Calendar Year, or in the first year and last year of the Royalty
Term, the portion of such Calendar Year during which the Royalty Term is in effect. 
 1.5 “Antibody(ies)”
means a monospecific molecule which comprises or contains: (a) at least one immunoglobulin variable domain or parts of such domain, variants, modifications or derivatives thereof; or (b) the nucleic acid consisting of a sequence of
nucleotides encoding (or complementary to a nucleic acid encoding) the foregoing molecules in (a). 
 1.6
“B7-H3” means the Target referred to as B7-H3, B7H3; 4Ig-B7-H3 or CD276 that is identified by Entrez Gene ID 80381. 
 1.7 “Back-Up Program Antibody(ies)” means the Antibodies identified in Exhibit A-1. 
 1.8 “Bi-Specific DART” means a dual affinity re-targeting molecule that binds to *** Targets, of which at least one of such Targets is B7-H3. 

1.9 “BLA” means a Biologics License Application and any amendments or supplements thereto filed with the FDA pursuant to
21 C.F.R. Part 601 or any other application required for the purpose of marketing and selling a biological product filed with a Regulatory Authority outside the United States, including with respect to the EU a Product License Application, Marketing
Authorization Application and/or manufacturing and importation license. 
 1.10 “Business Day” means a day on
which banking institutions in Washington, DC, USA and Paris, France are open for business, excluding any Saturday or Sunday. 

1.11 “Calendar Quarter” means a period of three (3) consecutive months ending on the last day of March, June,
September, or December, respectively. 
 1.12 “Calendar Year” means a period of time commencing on
January 1 and ending on the following December 31. 

  
 2 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 1.13 “Commercialization” or “Commercialize” means any
activities directed to obtaining pricing and/or reimbursement approvals, marketing, promoting, distributing, importing, offering to sell, and/or selling a product (including establishing the price for such product). 

1.14 “Commercially Reasonable Efforts” means with respect to a Party, such efforts that are consistent with the efforts
and resources normally used by *** relating to the Research, Development and Commercialization of products (a) that have scientific attributes similar to those of the relevant Program Antibody or Licensed Product in oncology,
(b) that are at a similar stage in their Research, Development, Commercialization or product life as the relevant Program Antibody or Licensed Product, and (c) that have commercial and market potential similar to the relevant Program
Antibody or Licensed Product, taking into account issues of intellectual property scope, subject matter and coverage, safety and efficacy, product profile, competitiveness with respect to Third Party products in the marketplace, proprietary position
and profitability (including pricing and reimbursement status achieved or likely to be achieved), and (d) solely owned by them or to which they have exclusive rights. If either Party grants a sublicense to an Affiliate or Third Party as
permitted under this Agreement, then, with respect to such sublicensee Commercially Reasonable Efforts shall mean the efforts and resources (as defined above in this Section 1.14) normally used by the Party granting the sublicense, qualified by
the items in clauses (a) – (d) inclusive. 
 1.15 “Competing Product” means (a) any product
that *** and is specifically indicated or developed for patients that ***; and (b) any Bi-Specific DART. 

1.16 “Complete” or “Completing” means, for a clinical trial, the date upon which all patients have
completed protocol-defined drug administration and study database lock has occurred. 
 1.17 “Control,”
“Controls,” “Controlled” or “Controlling” means, with respect to any item of or right under an intellectual property right, the possession (whether by ownership or license, other than pursuant to
this Agreement) of the ability of a Party to grant access to, or a license or sublicense of, such items or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such
Party would be required hereunder to grant the other Party such access or license or sublicense; provided that any intellectual property right that is licensed or acquired by a Party after the Effective Date *** and that would
otherwise be considered to be under the Control of such Party shall not be deemed to be under the Control of such Party if the application of such definition in the context of any licenses or sublicenses granted to the other Party under this
Agreement would require the granting Party to make any additional payments or royalties to a Third Party in connection with such license or sublicense grants, unless the other Party agrees to pay the additional payments or royalties to the Third
Party. 
 1.18 “Cover”, “Covering” or “Covered” means, with respect to a
product, technology, process or method that, in the absence of ownership of or a license granted under a Valid Claim, the manufacture, use, offer for sale, sale or importation of such product or the practice of such technology, process or method
would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue). 

  
 3 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 1.19 “Develop” or “Development” means drug development
activities relating to the development of compounds, products, or processes, and submission of information to a Regulatory Authority for the purpose of obtaining Regulatory Approval of a product. Development includes non-clinical activities,
pharmacology studies, toxicology studies, formulation, chemical analysis, bioanalytical analysis, material performance studies (such as measurements of stability, physical form, dissolution, or visual or spectroscopic analysis, and the like),
pharmacokinetic studies, clinical studies, biomarker and companion diagnostic discovery and development, regulatory affairs activities, and all other activities relating to seeking, obtaining or maintaining any Regulatory Approvals from the FDA or
any other applicable Regulatory Authority. 
 1.20 “Development Costs” means the costs and expenses incurred by
a Party or its Affiliates, attributable to, or reasonably allocable to, the Development of a Program Antibody or Licensed Product and that are consistent, if applicable, with the Development Budget and do not exceed the relevant amount set forth in
such Development Budget by more than *** unless approved in writing by the JRDC and such other costs as are expressly approved in writing by the JRDC as “Development costs”. “Development Costs” shall include
(a) Out-of-Pocket Costs and (b) FTE Costs of internal personnel that are attributable or reasonably allocable to the Development of such Program Antibody or Licensed Product determined in accordance with applicable Accounting Standards of
such Party. 
 1.21 “Diagnostic” means any companion diagnostic for a B7-H3 expressing tumor that is
(a) Developed in combination with a Program Antibody and/or Licensed Product; and (b) used in combination with a Licensed Product. 
 1.22 “Dollars” or “$” means the legal tender of the United States. 
 1.23 “EMA” means the European Medicines Agency, or any successor entity thereto. 
 1.24 “EU” means the European Union, as its membership may be altered from time to time, and any successor thereto. The member countries of the European Union as of the Effective Date
are Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and
United Kingdom as well as Norway and Iceland. 
 1.25 “Excluded Data” means any Know-How, other than Safety
Data, generated by a Party in the conduct of Development activities in accordance with a Development Collaboration Proposal where the other Party has declined to participate in such Development Collaboration Proposal and has not paid the Buy-In
Amount in accordance with Section 5.4.2(b)(iv). 
 1.26 “FDA” means the U.S. Food and Drug Administration,
or any successor entity thereto. 

  
 4 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 1.27 “FD&C Act” means the United States Federal Food, Drug, and
Cosmetic Act, as amended. 
 1.28 “Field” means all human fields of use. 

1.29 “First Commercial Sale” means the first sale of a Licensed Product by Servier, its Affiliates or its Sublicensees
for use or consumption of such Licensed Product in a country in the Servier Territory where Regulatory Approval of such Licensed Product has been obtained or otherwise permitted for sale by the Governmental Authority of such country. Sale of a
Licensed Product by Servier to an Affiliate of Servier or a Sublicensee of Servier shall not constitute a First Commercial Sale unless such Affiliate or such Sublicensee is the end user of a Licensed Product. In no event shall any sales for
premarketing, testing or sampling be deemed a First Commercial Sale. 
 1.30 “FTE” means *** of work
devoted to or in support of the Development or Manufacture of Program Antibodies and Licensed Product in accordance with a Global Development Plan or as required under Section 7.2, that is carried out by one or more qualified scientific or
technical employees or contract personnel of MacroGenics or its Affiliates, or Servier or its Affiliates, as measured in accordance with the relevant Party’s normal time allocation practices. 

1.31 “FTE Cost” means, for any period, the FTE Rate multiplied by the number of FTEs in such period. 

1.32 “FTE Rate” means a rate of *** per FTE per Calendar Year (pro-rated for the period beginning on the
Effective Date and ending at the end of the first Calendar Year) for personnel engaged in Development and Manufacturing activities. The FTE Rate is “fully burdened” and will cover ***. 

1.33 “Fully Burdened Manufacturing Cost” means with respect to a Program Antibody or Licensed Product, the aggregate of
internal and external costs of MacroGenics and its Affiliates to Manufacture such Program Antibody or Licensed Product, calculated as follows: (a) to the extent that MacroGenics or its Affiliates perform all or any part of the Manufacturing of
such Program Antibody or Licensed Product, the direct material costs *** and FTE Costs for such Manufacturing of such Program Antibody or Licensed Product ***, all calculated in accordance with applicable Accounting Standards as
consistently applied by MacroGenics or its Affiliates; and (b) to the extent that Manufacturing of such Program Antibody or Licensed Product is performed by a Third Party, the costs paid to such Third Party for such activities *** and the
reasonable direct FTE Costs incurred by MacroGenics or any of its Affiliates in managing and overseeing the Third Party relationship, determined in accordance with applicable Accounting Standards as consistently applied by MacroGenics or its
Affiliates. ***. 
 1.34 “Generic Competition” means, with respect to a given Calendar Quarter with
respect to a Licensed Product in any country, that during such Calendar Quarter, one (1) or more Third Parties sell in such country a Generic Product, such Generic Product shall be commercially available in such country and such Generic Product
shall have, in the aggregate, a *** or more 

  
 5 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
market share of the aggregate of Licensed Products and Generic Products (based on data provided by IMS Health Incorporated, Fairfield, Connecticut) as measured on a ***, or if such data is not
available, the Parties shall agree upon a methodology for estimating the percentage of unit sales based market share of Generic Products in such country. 
 1.35 “Generic Products” means, with respect to a particular Licensed Product commercialized by Servier in a particular country, any product (other than Licensed Products commercialized,
directly or indirectly, by Servier, its Affiliates or Sublicensees, or by any authorized distributors of Servier, its Affiliates or Sublicensees) that either (a) is a “follow-on biologic” (FOB) or biosimilar or equivalent version to a
Licensed Product, as defined by the competent Regulatory Authority, and administered in an equivalent dosage form as such Licensed Product or (b) for which a Third Party has received Regulatory Approval (based upon then-current applicable Laws
governing approval of biological products) whose application for approval relies to a large extent (but not exclusively) on data generated for a Licensed Product, including Regulatory Approval under section 505(b)(2) of the Federal Food Drug, and
Cosmetic Act. 
 1.36 “Global Clinical Trial” means a Phase 1 Clinical Trial, a Phase 2 Clinical Trial or a
Phase 3 Clinical Trial that may be applicable to obtaining Regulatory Approval of Licensed Products in both the Servier Territory and the MacroGenics Territory or relies on patient recruitment from both the Servier Territory and the MacroGenics
Territory. 
 1.37 “Good Clinical Practices” or “GCP” means the then-current standards,
practices and procedures (a) promulgated or endorsed by the FDA as set forth in the guidelines entitled “Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,” including related regulatory requirements imposed by the
FDA; (b) set forth in Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 and Commission Directive 2005//28/EC of 8 April 2005; (c) ICH Guideline for Good Clinical Practice E6; (d) equivalent
Laws of an applicable Regulatory Authority; and (e) all additional Regulatory Authority documents or regulations that replace, amend, modify, supplant or complement any of the foregoing. 

1.38 “Good Laboratory Practices” or “GLP” means the then-current good laboratory practice standards
promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, as such regulations may be amended from time to time, and the equivalent regulations promulgated by the equivalent Regulatory Authority in the jurisdiction where Development
activities are performed.  
 1.39 “Good Manufacturing Practices” or “GMP” means
then-current standards for the manufacture of pharmaceutical products, pursuant to (a) the FD&C Act (21 U.S.C. 321 et seq.); (b) relevant United States regulations in Title 21 of the United States Code of Federal Regulations (including
Parts 11, 210, and 211); (c) European Community Directives 2003/94 and 91/356/EC; (d) the European Community Guide to Good Manufacturing Practice for Medicinal Intermediate Products; (e) ICH Q7A Good Manufacturing Practice Guidance
for Active Pharmaceutical Ingredients; (f) equivalent Laws of an applicable Regulatory Authority at the time of Manufacture; and (g) all additional Regulatory Authority documents or regulations that replace, amend, modify, supplant or
complement any of the foregoing. 

  
 6 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 1.40 “Governmental Authority” means any United States federal, state or
local or any non-United States government, or political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police,
regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body. 
 1.41 “ICH” means the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 

1.42 “Identified Patents” means ***. 
 1.43 “IND” means an Investigational New Drug Application filed with FDA or a similar application filed with an applicable Regulatory Authority outside of the United States such as a
clinical trial application (CTA). 
 1.44 “Indication” means either (a) a discrete clinically recognized
form of a disease or ***. 
 1.45 “Initial Phase 1 Clinical Trial” means *** 

1.46 “Insolvency Event” means, with respect to any Party, the occurrence of any of the following: (a) such Party
shall commence a voluntary case concerning itself under any bankruptcy, liquidation or insolvency code; (b) an involuntary case is commenced against such Party and the petition is not dismissed, bonded or stayed within ninety (90) days
after commencement of the case; (c) a court-supervised custodian is appointed for, or takes charge of, all or substantially all of the property of such Party to continue undischarged or unstayed for a period of ninety (90) days;
(d) any order of relief or other order approving any such case or proceeding is entered; (e) such Party is adjudicated insolvent or bankrupt; and (f) such Party makes a general assignment for the benefit of creditors. 

1.47 “Joint IP” means all inventions and discoveries (and Patents claiming patentable inventions therein) first made or
discovered jointly by one or more employees, consultants or agents of MacroGenics or its Affiliates, together with one or more employees, consultants or agents of Servier or its Affiliates in the course of the Research, Development, Manufacture or
Commercialization of Program Antibodies and/or Licensed Product, 
 1.48 “Know-How” means all tangible and
intangible (a) information, techniques, technology, practices, trade secrets, inventions (whether patentable or not), methods, knowledge, know-how, skill, experience, data, results (including pharmacological, toxicological and non-clinical and
clinical test data and results, and Research or Development data, reports and batch records), analytical and quality control data, analytical methods (including applicable reference standards), full batch documentation, packaging records, release,
stability, storage and shelf-life 

  
 7 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
data, Manufacturing process information, results and descriptions, and software and algorithms and (b) compositions of matter, cells, cell lines, assays, animal models and physical,
biological or chemical material. 
 1.49 “Law” or “Laws” means all laws, statutes, rules,
regulations, orders, judgments, or ordinances having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision. 
 1.50 “Licensed Product” means any therapeutic or prophylactic product that comprises or incorporates a Program Antibody as an active pharmaceutical ingredient alone or in combination with
one or more other active agents. 
 1.51 “License Term” means the period commencing upon the License Grant Date
and ending on the date of expiration or termination of this Agreement in accordance with the provisions of ARTICLE 14. 

1.52*** 
 1.53
“MacroGenics Indemnitees” means MacroGenics, its Affiliates and the directors, officers and employees of MacroGenics and its Affiliates. 
 1.54 “MacroGenics IP” means the MacroGenics Know-How and the MacroGenics Patents. 
 1.55 “MacroGenics Know-How” means Know-How that is (a) Controlled by MacroGenics or its Affiliates on the Effective Date or thereafter during the Agreement Term; (b)(i) an
improvement, modification, enhancement or novel use of a Program Antibody or Licensed Product, or any improvement, modification or enhancement in the Manufacturing process or formulation of a Program Antibody or Licensed Product by or on behalf of
MacroGenics or its Affiliates; or (ii) disclosed by or on behalf of MacroGenics or its Affiliates to Servier or its Affiliates pursuant to this Agreement; and (c) necessary or useful to Research, Develop, Manufacture or Commercialize any
Program Antibody or Licensed Product in the Field in the Servier Territory. MacroGenics Know-How excludes MacroGenics’ interest in the Joint IP. 
 1.56 “MacroGenics Patents” means Patents Controlled by MacroGenics or its Affiliates on the Effective Date or thereafter during the Agreement Term that claim or are directed to
MacroGenics Know-How. The MacroGenics Patents existing as of the Effective Date are set forth on Exhibit B. MacroGenics Patents excludes MacroGenics’ interest in the Joint IP. 

1.57 “MacroGenics Territory” means the United States of America, Canada, Mexico, India, Japan, Korea and any Terminated
Territory. 
 1.58 “MacroGenics Third Party Agreements” means (a) the agreements which are set forth on
Exhibit C, and (b) any other agreement pursuant to which MacroGenics licenses or acquires Patents or Know-How that relates to the Program Antibodies or Licensed Products in 

  
 8 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
the Field in the Servier Territory after the Effective Date pursuant to an agreement with a Third Party, the terms and conditions of which have been approved (not to be unreasonably withheld) by
Servier before its execution by MacroGenics and which Servier and MacroGenics agree shall be deemed a MacroGenics Third Party Agreement, in which case Exhibit C shall be amended accordingly. For purposes of clarity, in the event that Servier
does not approve the terms and conditions of any such proposed agreement with a Third Party, nothing herein shall be deemed to preclude MacroGenics from entering into such agreement with a Third Party; provided that such agreement with a Third Party
shall not be deemed a MacroGenics Third Party Agreement hereunder. 
 1.59 “Major Indication” means any of the
following Indications: ***. 
 1.60 “Manufacture” or “Manufacturing” means all
activities related to the manufacturing of an Antibody or product, including test method development and stability testing, formulation, process development, manufacturing scale-up, manufacturing for use in non-clinical and clinical studies,
manufacturing for commercial sale, packaging, release of product, quality assurance/quality control development, quality control testing (including in-process, release and stability testing) and release of product or any component or ingredient
thereof, and regulatory activities related to all of the foregoing. 
 1.61 “Manufacturing Process Development
Costs” means the costs and expenses incurred by a Party or its Affiliates attributable to, or reasonably allocable to, the development of a Manufacturing process for Program Antibodies or Licensed Products (including ***).
“Manufacturing Process Development Costs” shall include (a) Out-of-Pocket Costs and (b) FTE Costs of internal personnel that are attributable or reasonably allocable to the development of a Manufacturing process for Program
Antibodies or Licensed Products determined in accordance with applicable Accounting Standards of such Party. 
 1.62
“MGA271” means the Antibody known as MGA271 which is described in Exhibit A-2. 
 1.63 “Net
Sales” means, in the case of sales by or for the benefit of Servier, its Affiliates, and its Sublicensees (the “Seller”) to independent, unrelated persons (“Buyers”) in bona fide arm’s length
transactions (except as provided below with respect to clinical trial samples), the gross amount billed or invoiced by Seller with respect to the Licensed Product, less the following deductions, in each case to the extent actually allowed and taken
by such Buyers and not otherwise recovered by or reimbursed to Seller in connection with such Licensed Product (“Permitted Deductions”): 
 *** 
 “Net Sales” shall not include any consideration received with
respect to a sale, use or other disposition of any Licensed Product in a country as part of a clinical trial necessary to obtain Regulatory Approval in such country. All of the foregoing elements of Net Sales calculations shall be determined in
accordance with IFRS or successor standards and guidelines thereto. In the case of transfers of Licensed Product between any of Servier, its Sublicensees, 

  
 9 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
and Affiliates of any of the foregoing, for subsequent sale, rental, lease or other transfer of such Licensed Products to Third Parties, Net Sales shall be the gross invoice
or contract price charged to the Third Party customer for that Licensed Product, less the deductions set forth in clauses *** above. 
 1.64 “Option Trigger Data Package” means the written report containing specified information and data on the results of the Initial Phase 1 Clinical Trial. The Option Trigger Data Package
shall include ***. 
 1.65 “Out-of-Pocket Costs” means, with respect to certain activities hereunder,
direct expenses paid or payable by either Party or its Affiliates to Third Parties and specifically identifiable and incurred to conduct such activities for a Licensed Product. 

1.66 “Patent” means (a) all patents and patent applications in any country or supranational jurisdiction, and
(b) any substitutions, divisionals, continuations, continuations-in-part, provisional applications, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like of any such
patents or patent applications. 
 1.67 “Person” means any individual, partnership, joint venture, limited
liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein. 
 1.68 “Phase 1 Clinical Trial” means a human clinical trial, other than the Phase 1 Dosing Clinical Trial, that is intended to initially evaluate the safety and/or pharmacological effect
of a product or that would otherwise satisfy the requirements of
 21 C.F.R. 312.21(a) or an equivalent clinical trial in a country other than the United States. 
 1.69 “Phase 2 Clinical Trial” means a human clinical trial for which the primary endpoints include a determination of dose ranges or an indication of efficacy of a product in patients
being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country other than the United States. 
 1.70 “Phase 3 Clinical Trial” means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in the
indication being investigated in a manner sufficient to obtain Regulatory Approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. §312.21(c), or an equivalent clinical trial in a
country other than the United States. 
 1.71 “PMDA” means the Japanese Pharmaceuticals and Medical Devices
Agency or any successor agency thereto. 
 1.72 “Program Antibody” means ***. 

  
 10 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 1.73 “Regulatory Approval” means the approval, license or authorization of
the applicable Regulatory Authority necessary for Development and/or Commercialization of a Program Antibody and/or a Licensed Product for a particular Indication. 
 1.74 “Regulatory Authority” means the FDA in the United States or any health regulatory authority in another country that is a counterpart to the FDA and holds responsibility for allowing
development of Program Antibodies and/or granting Regulatory Approval for a Licensed Product in such country, including the EMA, and any successor(s) thereto. 
 1.75 “Regulatory-Based Exclusivity Period” means, with respect to a Licensed Product, that period of time during which Servier or any of its Affiliates or Sublicensees has been granted
the exclusive legal right by a Regulatory Authority either to market and sell a Licensed Product in a country in the Servier Territory or the exclusive right to the use of or reference to clinical data in relation to a Licensed Product. 

1.76 “Regulatory Documentation” means, with respect to the Program Antibodies or Licensed Products, all INDs, BLAs, and
other regulatory applications submitted to any Regulatory Authority, copies of Regulatory Approvals, regulatory materials, drug dossiers, master files (including Drug Master Files, as defined in 21 C.F.R. §314.420 and any non-United States
equivalents), and any other reports, records, regulatory correspondence, meeting minutes, telephone logs, and other materials relating to Regulatory Approval of the Program Antibodies or Licensed Products (including any underlying safety and
effectiveness data whether or not submitted to any Regulatory Authority), or required to manufacture, distribute or sell Licensed Products including any information that relates to pharmacology, toxicology, chemistry, manufacturing and controls
data, batch records, safety and efficacy, and any safety database required to be maintained for Regulatory Authorities. 
 1.77
“Research” means the discovery, identification, research, characterization, modification, derivatization and optimization of pharmaceutical compounds. 
 1.78 “Research Plan” means a research plan developed by the Parties that sets forth the activities to be undertaken during the Research Term, which research plan may be amended from time
to time by the JRDC. 
 1.79 “Research Term” means the period commencing with the Effective Date and ending
***. 
 1.80 “Restricted Indication” means any ***. 

1.81 “Right of Reference or Use” means a “Right of Reference or Use” as that term is defined in 21 C.F.R.
§314.3(b), and any non-United States equivalents. 
 1.82 “Safety Data” means adverse event information
and other information (if any) required by one or more Regulatory Authorities to be collected or to be reported to such Regulatory Authorities under applicable Laws. 

  
 11 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 1.83 “Servier Collaboration IP” means the Servier Collaboration Know-How
and the Servier Collaboration Patents. 
 1.84 “Servier Collaboration Know-How” means Know-How that is
(a) Controlled by Servier or its Affiliates on the Effective Date or thereafter during the Agreement Term; (b) (i) an improvement, modification, enhancement or novel use of a Program Antibody or Licensed Product, or any improvement,
modification or enhancement in the Manufacturing process or formulation of a Program Antibody or Licensed Product by or on behalf of Servier or its Affiliates; or (ii) disclosed by or on behalf of Servier or its Affiliates to MacroGenics or its
Affiliates pursuant to this Agreement; and (c) necessary or useful to Research, Develop, Manufacture or Commercialize any Program Antibody or Licensed Product in the Field. Servier Collaboration Know-How excludes Servier’s interest in the
Joint IP. 
 1.85 “Servier Collaboration Patent(s)” means Patents Controlled by Servier and its Affiliates on
the Effective Date or thereafter during the Agreement Term claiming or directed to Servier Collaboration Know-How. 
 1.86
“Servier Indemnitees” means Servier, its Affiliates and the directors, officers and employees of Servier and its Affiliates. 
 1.87 “Servier Territory” means the entire world excluding the MacroGenics Territory. 
 1.88 “SFDA” means the Chinese State Food and Drug Administration or any successor agency thereto. 
 1.89 “Significant Patent” means any ***. 
 1.90
“Sublicensee” means a Third Party to whom a Party, as permitted under this Agreement, grants a license or sublicense, as the case may be, under the MacroGenics IP or Servier IP to Research, Develop, Manufacture, Commercialize or use
Program Antibodies and/or Licensed Products in the Field or otherwise grants rights to distribute, promote or sell Licensed Products in the Field. 
 1.91 “Target” *** 
 1.92 “Terminated Territory”
means with respect to a termination of this Agreement pursuant to Section 14, as applicable, (i) the country(ies) subject to such termination; and (ii) with respect to termination of this Agreement in its entirety, the Servier
Territory. 
 1.93 “Third Party” means any Person other than MacroGenics or Servier that is not an Affiliate of
MacroGenics or of Servier. 
 1.94 “United States” or “U.S.” means the United States of
America and all of its territories and possessions. 

  
 12 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 1.95 “Valid Claim” means (a) a claim of an issued patent that has not
expired or been abandoned, or been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the
allowable time period) ***. 
 1.96 Additional Definitions. Each of the following definitions is set forth in the
section of this Agreement indicated below: 
  

			
	 Definition:
	  	Section:
	 Alliance Business-Development Manager
	  	2.1
	 Alliance R&D Manager
	  	2.2
	 Arbitration Request
	  	16.2.1
	 Audited Party
	  	9.10
	 Auditing Party
	  	9.10
	 Bankruptcy Code
	  	4.8
	 Breaching Party
	  	14.2
	 Buy-In Amount
	  	5.4.2(b)(iv)
	 Buy-In Party
	  	5.4.2(b)(ii)
	 Clinical Supply Agreement
	  	7.2.1
	 Co-Chairperson
	  	2.7
	 Commercial Supply Agreement
	  	7.2.2
	 Commercialization Plan
	  	8.4
	 Commercializing Party
	  	8.1
	 Confidential Information
	  	11.1
	 De Minimis Overage Amount
	  	5.5.2(a)
	 Development Budget
	  	5.3.1
	 Development Collaboration Proposal
	  	5.4.2(b)
	 Disclosing Party
	  	11.1
	 Excess Overage Amount
	  	5.5.2(a)
	 Effective Date
	  	Preamble
	 Existing Confidentiality Agreement
	  	11.4
	 Global Development Plan
	  	5.3.1
	 ***
	  	***
	 IdRS
	  	Preamble
	 Indemnified Party
	  	13.3
	 Indemnifying Party
	  	13.3
	 Initial Development Budget
	  	5.5.2
	 Initiating Party
	  	10.4.3
	 Inspected Party
	  	6.3.2
	 JEC
	  	2.4.1
	 Joint Patents
	  	10.3.3(a)
	 JRDC
	  	2.6.1
	 JSC
	  	2.5.1
	 License Grant Date
	  	3.3.3(a)

  
 13 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

			
	 Definition:
	  	Section:
	 License Grant Fee
	  	9.2.1
	 LLS
	  	Preamble
	 Losses
	  	13.1
	 M&A Event
	  	16.4
	 MacroGenics
	  	Preamble
	 MacroGenics Product Patents
	  	10.3.1(a)
	 Non-Arbitrable Dispute
	  	16.1.2
	 Non-Breaching Party
	  	14.2
	 Option
	  	3.3.3(a)
	 Option Grant Fee
	  	9.1
	 Option Period
	  	3.3.3(a)
	 Party or Parties
	  	Preamble
	 Project Director
	  	2.3
	 Proposed Development Plan Amendment
	  	5.4.2(a)
	 Receiving Party
	  	11.1
	 Reconciliation Payment
	  	5.5.2(c)
	 Research Program
	  	3.1
	 Responsible Party
	  	10.3.3(b)
	 Royalty Term
	  	9.5.2
	 SDEA Agreement
	  	6.5.1
	 Servier
	  	Preamble
	 Servier Product Patents
	  	10.3.2(a)
	 Supplemental Data
	  	3.2.1

 ARTICLE 2 
 GOVERNANCE 
 2.1 Alliance Business-Development Managers. Within
thirty (30) days following the Effective Date, each Party shall appoint (and notify the other Party of the identity of) a representative to act as its business development alliance manager under this Agreement (“Alliance
Business-Development Manager”). The Alliance Business-Development Managers shall be there to coordinate any business related activities under this Agreement. The Alliance Business-Development Managers shall attend all JSC meetings and may
bring any matter in relation to business to the attention of any committee if such Alliance Business-Development Manager reasonably believes that such matter warrants such attention. Each Party may replace its Alliance Business-Development Manager
upon written notice to the other Party. 
 2.2 Alliance R&D Managers. Within thirty (30) days following the
Effective Date, each Party shall appoint (and notify the other Party of the identity of) a representative to act as its alliance research and development manager under this Agreement (“Alliance R&D Manager”). With regard to
Research and Development activities, the Alliance R&D Managers shall serve as 

  
 14 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
the primary contact points between the Parties and shall be primarily responsible for facilitating the flow of information, interaction and collaboration between the Parties and shall be
responsible for ensuring that the governance procedures and rules set forth herein are complied with. The Alliance R&D Manager shall attend the meetings of the JRDC and the JSC and may bring any matter in relation to the Research and Development
management to the attention of any committee, if such Alliance R&D Manager reasonably believes that such matter warrants such attention. Each Party may replace its Alliance R&D Manager upon written notice to the other Party. 

2.3 Project Directors. Within thirty (30) days following the Effective Date each Party shall appoint (and notify the other
Party of the identity of) a representative to act as its project director (“Project Director”). The Project Director shall be responsible for the follow-up of the respective Research and Development activities under this Agreement
on a regular basis. The Project Director shall attend the meetings of the JRDC, and may bring any matter in relation to the project management to the attention of the JSC, if such Project Director reasonably believes that such matter warrants such
attention. Each Party may replace its Project Director upon written notice to the other Party. 
 2.4 Joint Executive
Committee. 
 2.4.1 Composition. Promptly after the Effective Date, the Parties shall establish a joint executive
committee (the “JEC”). The JEC shall be comprised of up to three (3) senior executives from each Party. Either Party may, from time to time, invite additional representatives or consultants to attend JEC meetings, subject to
such representative’s and consultant’s written agreement to comply with confidentiality obligations substantially the same as those set forth in ARTICLE 11. Each Party shall bear its own expenses related to the attendance at JEC meetings
by its representatives. 
 2.4.2 Function and Powers of the JEC. The JEC shall manage the overall collaboration between
the Parties, resource allocation and major changes to the collaboration requiring amendments to this Agreement and shall resolve disagreements that may arise at the JSC. 
 2.5 Joint Steering Committee. 
 2.5.1 Composition. Promptly after the
Effective Date, the Parties shall establish a joint steering committee (the “JSC”). The JSC shall be comprised of three (3) named representatives of Servier and three (3) named representatives of MacroGenics (or such other
number as the Parties may agree) as well as each Party’s Alliance Business-Development Manager and Alliance R&D Manager. As soon as practicable after the Effective Date (but in no event more than thirty (30) days after the Effective
Date), each Party shall designate by written notice to the other Party its initial representatives on the JSC. Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other Party of
such change. These representatives shall have appropriate technical credentials, experience and knowledge. Either Party may, from time to time, invite additional representatives or 

  
 15 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
consultants to attend JSC meetings, subject to such representative’s and consultant’s written agreement to comply with confidentiality obligations substantially the same as those set
forth in ARTICLE 11. Each Party shall bear its own expenses related to the attendance at JSC meetings by its representatives. The JSC shall be co-chaired by a representative from each Party. 

2.5.2 Function and Powers of the JSC. The JSC’s responsibilities shall include: (a) coordinating the activities of the
Parties under this Agreement, including facilitating communications between the Parties with respect to the Development, Manufacture and Commercialization of Program Antibodies and Licensed Product; (b) providing a forum for discussion of the
Development, Manufacture, and Commercialization of Licensed Product; (c) reviewing and approving the Research Plan and the Global Development Plan and associated Development Budget and any annual or interim updates and proposed amendments
thereto; (d) reviewing and discussing Servier’s Commercialization Plan and related activities with respect to Licensed Products throughout the Servier Territory and (if applicable) the MacroGenics Territory, including pre-launch and
go-to-market strategies; (e) directing and overseeing the JRDC and any operating subcommittee established by the JSC, on all significant issues that fall within the purview of such committees; (f) attempting to resolve issues presented to
it by, and disputes within, the other committees, including the JRDC and any subcommittee, in accordance with Section 2.9; and (g) considering and acting upon such other matters as specified in this Agreement. 

2.5.3 Subcommittees. The JSC may establish and disband such subcommittees as deemed necessary by the JSC. Each such subcommittee
shall consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its representatives on written notice to the other Party or to send a substitute
representative to any subcommittee meeting. Each Party’s representatives and any substitute for a representative shall be bound by the obligations of confidentiality set forth in ARTICLE 11. Except as expressly provided in this Agreement, no
subcommittee shall have the authority to bind the Parties hereunder and each subcommittee shall report to the JSC. 
 2.6
Joint Research and Development Committee and Subcommittees. 
 2.6.1 Composition. Promptly after the Effective
Date, the Parties shall establish a joint research and development committee (the “JRDC”). The JRDC shall be comprised of three (3) named representatives of Servier and three (3) named representatives of MacroGenics (or
such other number as the Parties may agree) as well as each Party’s Project Director. As soon as practicable after the Effective Date (but in no event more than thirty (30) days after the Effective Date), each Party shall designate by
written notice to the other Party its initial representatives on the JRDC. Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change. These representatives
shall have appropriate technical credentials, experience and knowledge, and ongoing familiarity with the Research and Development activities hereunder. Either Party may, from time to time, invite additional representatives or consultants to attend
JRDC meetings, subject to such representative’s and consultant’s written agreement to comply with 

  
 16 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
confidentiality obligations substantially the same as those set forth in ARTICLE 11. Each Party shall bear its own expenses related to the attendance at JRDC meetings by its representatives. The
JRDC shall be co-chaired by a representative from each Party. 
 2.6.2 Function and Powers of the JRDC. The JRDC’s
responsibilities shall include: (a) during the Research Term, proposing the Research Plan, proposing any changes or amendments to the Research Plan for approval by the JSC; (b) during the Research Term, reviewing and monitoring progress
for all activities performed under the Research Program; (c) during the License Term, proposing the initial Global Development Plan, coordinating the activities of the Parties under and overseeing the implementation of the Global Development
Plan; (d) during the License Term, preparing annual and interim updates to the Global Development Plans; (e) during the Agreement Term, serving as a forum for and facilitating communications between the Parties with respect to the Research
and Development of Licensed Products, including any joint Development activities to be pursued by the Parties during the License Term; (f) during the License Term, monitoring and coordinating all regulatory actions, communications and
submissions for Licensed Products; (g) informal resolution of disagreements that may arise in the relation to the Parties activities under the Research Program and the Global Development Plan; and (h) considering and acting upon such other
matters as specified in this Agreement. 
 2.7 Co-Chairpersons. Each Party shall designate one of its members of the JSC
and JRDC, respectively, as a co-chairperson (each, a “Co-Chairperson”) of such committee. The Co-Chairpersons shall have the following roles and responsibilities: (a) to call meetings of the relevant committee, send notice of
each such meeting and designate the time, date and place of each such meeting; (b) to convene or poll the members of the relevant committee by other permitted means; (c) to establish a reasonably detailed agenda, including identification
of relevant supporting information and materials to be discussed during such meeting, for each meeting of the relevant committee, subject to the right of any member of such committee to add additional agenda items at any meeting; and (d) to
promptly draft and finalize minutes of each meeting of such committee, for review and approval by members of such committee at the following meeting. Each Co-Chairperson shall sign and date the final minutes. 

2.8 Committee Meetings. 
 2.8.1 Frequency. The JRDC and each of the subcommittees shall each hold at least one (1) meeting per Calendar Quarter at such times during such Calendar Quarter as the co-chairpersons elect to
do so and the JSC and JEC shall hold at least one (1) meeting per Calendar Year as the co-chairpersons elect to do so. 

2.8.2 Quorum; Location. Except where a Party fails to appoint a member or members to the JEC, JSC, JRDC or any subcommittee or
fails to participate in meetings of the JEC, JSC, JRDC or any subcommittee, meetings of the JEC, JSC, JRDC and subcommittees, respectively, shall be effective only if at least one (1) representative of each Party is present or participating.
The JEC, JSC, JRDC and subcommittees may meet either (a) in person at either Party’s facilities or at such locations as the Parties may otherwise agree or (b) by audio or video 

  
 17 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
teleconference; provided that no less than one (1) meeting during each Calendar Year shall be conducted in person. Additional meetings of the JEC, JSC, JRDC and subcommittees
may also be held with the consent of each Party, or as required under this Agreement, and neither Party shall unreasonably withhold its consent to hold such additional meetings. Each Party shall be responsible for all of its own expenses incurred in
connection with participating in all such meetings. 
 2.8.3 Cooperation. Each Party shall provide the JSC and JRDC such
information as required under the Research Plan or Global Development Plan, as applicable, or reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of activities under, as applicable,
the Research Plan or Global Development Plan. 
 2.9 Decisions. 

2.9.1 Initial Dispute Resolution Procedures. Subject to the provisions of this Section 2.9, actions to be taken by the JEC,
JSC, JRDC and each of the subcommittees shall be taken only following ***. If the JRDC or any subcommittee fails to reach unanimous agreement on a matter before it for decision for a period in excess of ***, the matter shall be
referred to the JSC. If the JSC fails to reach *** on a matter before it for decision for a period in excess of ***, the matter shall be referred to the JEC. 
 2.9.2 Conduct of Initial Phase 1 Clinical Trial. Notwithstanding any other provision in this Agreement, unless otherwise agreed upon to the contrary by the Parties, ***. MacroGenics shall
reasonably consult with Servier regarding the selection of Indications to be pursued in the expansion cohorts included in the Initial Phase 1 Clinical Trial and shall reasonably consider any input provided by Servier with respect thereto.
***. 
 2.9.3 Final Decision-Making. If the JEC fails to reach *** on a matter before it for decision for a
period in excess of ***, the following provisions shall apply: 
 (a) During the Research Term, if the JEC is unable to
resolve the matter within *** after the matter is referred to them, the matter shall be deadlocked until resolved by *** JEC consensus. 
 (b) During the License Term, the JEC representatives appointed by Servier shall have the deciding vote on any matter involving the Development or Commercialization of Program Antibodies and Licensed
Products in the Field in the Servier Territory and the JEC representatives appointed by MacroGenics shall have the deciding vote on any matter involving the Development or Commercialization of Program Antibodies and Licensed Products in the Field in
the MacroGenics Territory. 

  
 18 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 2.9.4 Exceptions. Notwithstanding the foregoing, neither Party shall exercise its
right to finally resolve a dispute pursuant to Section 2.9.3: 
 (a) in a manner that excuses such Party from any of its
obligations specifically enumerated under this Agreement; 
 (b) in a manner that negates any consent rights or other rights
specifically allocated to the other Party under this Agreement; 
 (c) during the License Term, to increase Development Costs
for the other Party for any Global Clinical Trial for a given Calendar Year by more than *** above the Initial Development Budget for such Global Clinical Trial; 
 (d) to resolve any dispute regarding whether a Party may conduct Development or Commercialization activities in the other Party’s territory; 

(e) to resolve any dispute regarding whether a milestone event set forth in Section 9.3 has been achieved; or 

(f) in a manner that would require the other Party to perform any act that it reasonably believes to be inconsistent with any Law or any
approval, order, policy or guidelines of a Regulatory Authority. 
 2.10 Authority. The JEC, JSC, JRDC and any
subcommittee shall have only the powers assigned expressly to it in this ARTICLE 2 and elsewhere in this Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement. In furtherance thereof, each Party shall
retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in the JEC, JSC, JRDC or any subcommittee unless such delegation or vesting of rights is expressly
provided for in this Agreement or the Parties expressly so agree in writing. 
 2.11 Representatives. For purposes of
clarity, a Party may appoint the same person to simultaneously serve as the Alliance Business Development Manager, Alliance R&D Manager, and/or Project Director for such Party and/or serve on multiple committees established pursuant to this
ARTICLE 2. 
 ARTICLE 3 
 RESEARCH AND DEVELOPMENT; EXCLUSIVE OPTION 
 3.1 Research Overview.
Pursuant to this Agreement and as further provided in this ARTICLE 3, MacroGenics and Servier shall conduct the research activities indicated in the Research Plan during the Research Term (the “Research Program”). Neither Party
warrants that the Research Program shall achieve any of the research objectives contemplated in the Research Plan. At the end of the Research Term, each Party’s obligation to conduct the Research Program shall cease unless the Parties mutually
agree to extend the Research Term. 

  
 19 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 3.2 Conduct of the Research Program. 

3.2.1 Research Plan. ***, the JRDC will prepare the Research Plan to be submitted for approval by JSC. The Parties may
mutually agree to specify in the Research Plan activities to be conducted by Servier to generate additional pre-clinical and clinical data to be shared by both Parties (the “Supplemental Data”). Servier shall disclose to MacroGenics
all Supplemental Data *** after the completion of such activities and MacroGenics shall have the right to use such Supplemental Data in order to Develop, obtain Regulatory Approval for and Commercialize Licensed Products. Both Parties
envision that the Supplemental Data ***. The availability and finalization of such Supplemental Data and/or any modification to the Initial Phase 1 Clinical Trial that the Parties may agree upon shall not in any way delay the timing of the
delivery of the Option Trigger Data Package to Servier in accordance with Section 3.3.2. To the extent that any provision of the Research Plan conflicts or is inconsistent with the provisions of this Agreement, the provisions of this Agreement
shall control. 
 3.2.2 Diligence. MacroGenics and Servier shall use Commercially Reasonable Efforts to conduct the
Research Program in a good scientific manner and in accordance with the Research Plan. 
 3.2.3 Expenses. Except as
otherwise set forth elsewhere in this Agreement, each Party shall bear its own costs and expenses of conducting the activities allocated to such Party under the Research Plan, including the costs of clinical supply of Program Antibodies and Licensed
Products.  
 3.2.4 Reports. MacroGenics and Servier shall provide written progress reports on the status of its
Research and Development activities under the Research Plan, including summaries of data generated in the Research Program, at least *** in advance of each JRDC meeting. 
 3.3 Evaluation of Option Trigger Data Package; Option Exercise. 
 3.3.1
Limited Evaluation License; Supply. MacroGenics hereby grants Servier an exclusive, royalty and other fee-free license, with the right to sublicense only to Servier’s Affiliates, under MacroGenics IP, to (a) conduct the activities,
if any, allocated to Servier under the Research Plan and (b) use the Option Trigger Data Package solely for purposes of evaluating Program Antibodies to determine whether to exercise its Option. 

3.3.2 Delivery of Option Trigger Data Package. MacroGenics shall provide Servier with the Option Trigger Data Package ***.

 3.3.3 Option Exercise. 
 (a) Servier shall have the exclusive option to obtain an exclusive license under MacroGenics IP to Research, Develop and Commercialize Program Antibodies and Licensed Products in the Field in the Servier
Territory (the “Option”). *** (“Option Period”). In the event Servier elects to exercise the Option, it shall, no later than the end of the last day of the Option Period, deliver to MacroGenics
(i) written notice specifying that Servier has elected to exercise the Option, and (ii) payment of the License Grant Fee. Provided Servier has properly 

  
 20 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
exercised the Option in accordance with the preceding sentence, the later of the date of the written notice and receipt by MacroGenics of the License Grant Fee shall be the “License Grant
Date” for purposes of this Agreement. The Research Term and Option Period will be deemed to have ended, and the License Term will be deemed to have commenced, on the License Grant Date. 

(b) Upon the exercise by Servier of the Option in accordance with this Section 3.3, the provisions set forth in Sections 4.1, 4.2
and 4.3 of this Agreement shall constitute the terms and conditions of the license and sublicense rights granted by MacroGenics to Servier with respect to Licensed Products and the MacroGenics IP in the Field in the Servier Territory, and by Servier
to MacroGenics with respect to Servier IP and Licensed Products in the Field in the MacroGenics Territory. During the period commencing on the Effective Date and ending on the expiration of the Option Exercise Period, MacroGenics will not grant a
license or other rights to any Third Party or take any other action that would prevent MacroGenics from being able to grant to Servier the license set forth in Section 4.1. In the event Servier does not exercise the Option during the Option
Exercise Period, Servier shall have no further rights hereunder with respect to MacroGenics IP and/or Licensed Products, the license granted to Servier under Section 3.3.1 shall terminate and the licenses and other rights granted under ARTICLE
4 shall have no force or effect. 
 (c) In the event Servier does not exercise its Option rights prior to the end of the Option
Period, (i) Servier’s Option shall expire and all right and interest with respect to the Program Antibodies, Licensed Products and MacroGenics IP shall revert to MacroGenics; (ii) Servier shall have no right to or interest in such
Program Antibodies, Licensed Products and MacroGenics IP; and (iii) Servier shall and hereby does assign and transfer to MacroGenics all right, title and interest in and to the Supplemental Data and the Servier Collaboration IP that is created
by or on behalf of Servier or its Affiliates, or both, whether solely or jointly with MacroGenics, in the course of conducting activities under the Research Plan. 

  
 21 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 ARTICLE 4 
 GRANT OF RIGHTS; EXCLUSIVITY 
 4.1 License Grant to Servier. Subject
to the terms of this Agreement, upon MacroGenics’ receipt of the License Grant Fee, MacroGenics shall and hereby does grant Servier (a) an exclusive, royalty-bearing, non-transferable (except in
accordance with Section 16.4) license, with the right to sublicense (subject to Section 4.3), under MacroGenics IP and MacroGenics’ and its Affiliates’ interests in Joint IP, to Research, Develop, Manufacture and Commercialize,
Program Antibodies and Licensed Products in the Servier Territory in the Field; (b) an exclusive, royalty-bearing, non-transferable (except in accordance with Section 16.4) license, with the right to
sublicense (subject to Section 4.3), under MacroGenics IP and MacroGenics’ and its Affiliates’ interests in Joint IP, to Research, Develop, Manufacture and Commercialize Diagnostics for use solely with Program Antibodies and Licensed
Products in the Field in the Servier Territory; and (c) a non-exclusive, royalty-bearing, non-transferable (except in accordance with Section 16.4) license, with the right to sublicense (subject to
Section 4.3), under MacroGenics IP and MacroGenics’ and its Affiliates’ interests in Joint IP, to Research, Develop and Manufacture Program Antibodies and Licensed Products in the MacroGenics Territory for the sole purpose of using,
offering for sale and selling Licensed Products in, and importing Program Antibodies and Licensed Products into, the Servier Territory in the Field; provided however, that Servier shall not, directly or indirectly, conduct clinical
trials or other clinical studies, including any investigator initiated studies, in the MacroGenics Territory using Program Antibodies or Licensed Products without the prior approval of the JRDC. 

4.2 License Grant to MacroGenics. Subject to the terms of this Agreement, upon MacroGenics’ receipt of the License Grant Fee,
Servier hereby grants MacroGenics: (a) an exclusive, royalty-free, non-transferable (except in accordance with Section 16.4) license, with the right to sublicense (subject to Section 4.3), under
Servier Collaboration IP and Servier’s and its Affiliates’ interest in Joint IP, to Research, Develop, Manufacture and Commercialize Program Antibodies and Licensed Products in the Field in the MacroGenics Territory; (b) an exclusive,
royalty-free, non-transferable (except in accordance with Section 16.4) license, with the right to sublicense (subject to Section 4.3), under Servier Collaboration IP and Servier’s and its
Affiliates’ interest in Joint IP, to Research, Develop, Manufacture and Commercialize Diagnostics for use solely with Program Antibodies and Licensed Products in the Field in the MacroGenics Territory; and (c) a non-exclusive,
royalty-free, non-transferable (except in accordance with Section 16.4) license, with the right to sublicense (subject to Section 4.3), under Servier Collaboration IP and Servier’s and its
Affiliates’ interest in Joint IP, to Research, Develop and Manufacture Program Antibodies and Licensed Products in the Servier Territory for the sole purpose of using, offering for sale and selling Licensed Products in, and importing Program
Antibodies and Licensed Products into, the MacroGenics Territory in the Field; provided however, that MacroGenics shall not, directly or indirectly, conduct clinical trials or other clinical studies, including any investigator
initiated studies, in the Servier Territory using Program Antibodies or Licensed Products without the prior approval of the JRDC. 
 4.3 Sublicenses. Each Party shall have the right to grant sublicenses within the scope of the licenses under Section 4.1 or 4.2, as applicable, solely to its Affiliates and to Third Parties

  
 22 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
that are conducting Research, Development, Manufacture and/or Commercialization activities with such Party or its Affiliates with respect to Program Antibodies and Licensed Products;
provided that any sublicense granted to Third Party collaborators under this Agreement shall be pursuant to a written agreement that subjects such sublicensee to all relevant restrictions and limitations set forth in this Agreement,
including the confidentiality provisions of ARTICLE 11. If either Party grants a sublicense to a Third Party as permitted by this Section 4.3, then such Party shall provide the other Party prompt written notice thereof and shall provide the
other Party with an executed copy of any such sublicense (redacted as necessary to protect confidential or commercially sensitive information). Except as otherwise agreed by the Parties in writing, each Party shall be jointly and severally
responsible with its sublicensees to the other Party for failure by its sublicensees to comply with this Agreement. 
 4.4
Subcontracting. Subject to the terms of this Agreement, each Party shall have the right to engage Affiliates, licensees, Sublicensees or Third Party subcontractors to perform activities ascribed to such Party, under this Agreement. Any
Affiliate, licensee or subcontractor to be engaged by a Party to perform a Party’s obligations under this Agreement shall meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to
the subcontracted activity; provided that any Party engaging an Affiliate, licensee or subcontractor hereunder shall remain principally responsible and obligated for such activities. In addition, each Party engaging a licensee,
Sublicensee or subcontractor shall obtain Control of any and all Know-How, Patents or other intellectual property rights created, discovered, invented, conceived or reduced to practice by such licensee, Sublicensee or subcontractor with respect to
any Program Antibody or Licensed Product so that the other Party is not impeded from carrying out its rights and responsibilities under this Agreement by such Know-How, Patents or other intellectual property rights. To the extent a Party cannot
obtain assignment of, or an exclusive license to, all Know-How, Patents and other intellectual property rights created, discovered, invented, conceived or reduced to practice by any licensee, Sublicensee or subcontractor engaged by such Party with
respect to any Program Antibody or Licensed Product or in the performance of activities under this Agreement at the time such Party initially enters into such arrangement with such licensee, Sublicensee or subcontractor, such Party shall bring such
matter to the JSC for the prior approval of such arrangement and for the express approval by the JRDC of the licensing terms and conditions with respect to such arrangement 
 4.5 MacroGenics Third Party Agreements. Servier acknowledges and agrees that the rights, licenses and sublicenses granted by MacroGenics to Servier under this Agreement are subject to the terms of
the MacroGenics Third Party Agreements. Servier covenants to comply with, and to cause its Affiliates and Sublicensees to comply with, the MacroGenics Third Party Agreements, and to take any action or provide any information reasonably requested by
MacroGenics, to prevent any potential breach of any terms of such MacroGenics Third Party Agreements. To the extent there is a conflict between the terms of any MacroGenics Third Party Agreement and the rights granted to Servier hereunder, the terms
of such MacroGenics Third Party Agreement shall control solely with respect to the Patents and Know-How owned or controlled by such Third Party licensor. MacroGenics shall not terminate or consent to the termination of the MacroGenics Third Party
Agreement without Servier’s prior reasonable consent if such termination would materially adversely affect Servier’s license granted 

  
 23 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
hereunder; however, for clarity, MacroGenics may (a) terminate any MacroGenics Third Party Agreement by acquiring all of the relevant intellectual property licensed thereunder, in which case
Servier agrees to consent to such termination of such MacroGenics Third Party Agreement; (b) terminate its obligation to make royalty and milestone payments by making a lump-sum payment; and (c) terminate its rights and obligations under a
MacroGenics Third Party Agreement by assigning such MacroGenics Third Party Agreement directly to Servier. 
 4.6 Right of
First Negotiation for Bi-Specific DARTs. If at any time during the Agreement Term MacroGenics desires to Develop with a Third Party and/or Commercialize with one or more Third Party(ies) one or more Bi-Specific DARTs in the Field other than in
the United States, MacroGenics shall notify Servier of its intent and propose to Servier to enter into negotiations to Develop and Commercialize the latter, identifying the applicable Bi-Specific DART(s) that is(are) proposed to be the subject of
such negotiations. Servier shall have *** from receipt of such written notice to notify MacroGenics in writing as to whether Servier desires to negotiate for such rights, and if Servier so notifies MacroGenics that it does desire to negotiate
for such rights, Servier shall have *** from the date of such notification to MacroGenics to negotiate and enter into a definitive agreement with MacroGenics for such rights; provided that, if either Servier does not provide
such written notice within such *** period or Servier and MacroGenics do not enter into a definitive agreement within such *** period, MacroGenics shall be free to enter into negotiations and agreements with Third Parties relating to
such Bi-Specific DART(s), provided however that if, within *** after such negotiations with Servier terminate, MacroGenics should ***, and Servier shall have a period of *** following receipt of the same to notify MacroGenics as
to whether Servier would be prepared to accept such terms (subject to execution of a mutually acceptable license agreement) in which case the Parties will use commercially reasonable efforts to conclude such license agreement within *** after
Servier notifies MacroGenics of the same. If the Parties can not conclude such license agreement or such *** period expires, the Parties agree that, MacroGenics shall be free to enter into negotiations and agreements with Third Party(ies)
relating to such Bi-Specific DARTs during the remainder of the Agreement Term without further obligation to Servier. 
 4.7
Rights Retained by the Parties. Any rights of MacroGenics or Servier, as the case may be, not expressly granted to the other Party pursuant to this Agreement shall be retained by such Party. Notwithstanding the exclusive licenses granted to
Servier pursuant to Section 4.1, MacroGenics retains the right to practice under the MacroGenics IP and Joint IP to perform (and to sublicense Third Parties to perform) its obligations under this Agreement and any supply agreement entered into
in accordance with ARTICLE 7, including for the purpose of performing its activities in connection with clinical trials for Licensed Products and any related manufacture of Program Antibodies and Licensed Products. 

4.8 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this Agreement
are and will otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended (the “Bankruptcy Code”), licenses of rights to “intellectual property” as
defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective 

  
 24 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
rights and elections under the Bankruptcy Code. Each Party agrees that the other Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and
elections under the Bankruptcy Code or any other provisions of applicable Law outside the United States that provide similar protection for “intellectual property.” The Parties further agree that, in the event of the commencement of a
bankruptcy proceeding by or against a Party under the U.S. Bankruptcy Code or analogous provisions of applicable Law outside the United States, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) such
intellectual property and all embodiments of such intellectual property, which, if not already in such Party’s possession, will be promptly delivered to it upon such Party’s written request thereof. Any agreements supplemental hereto will
be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code. 
 4.9 Exclusivity. For the period commencing with the Effective Date and ending on the*** of the Effective Date, other than with respect to the Development and Commercialization activities
pursuant to this Agreement or any agreement entered into between the Parties pursuant to Section 4.6, neither Party nor its Affiliates shall, directly or indirectly, (a) ***. 

4.10 Consequences of Development and Commercialization of Competing Products. *** 

4.11 Diagnostics. The Parties acknowledge and agree that each Party shall have the right to use Diagnostics in combination with
Competing Products Researched, Developed or Commercialized by such Party. 
 ARTICLE 5 

DEVELOPMENT DURING THE LICENSE TERM 
 5.1 Overview. During the License Term, Servier will, subject to the terms of this Agreement, be responsible for the Development of Licensed Products in the Field for the Servier Territory, and
(b) MacroGenics will remain responsible for Development of Licensed Products in the Field in the MacroGenics Territory. While the Parties may choose, at their sole discretion, to work together on particular projects, except as otherwise
provided in this Agreement, the Parties will operate independently in their activities for their respective Development of Licensed Products, but will provide access to certain information to the JRDC and to each other as expressly described in this
Agreement. 
 5.2 Servier Obligations. Servier shall use Commercially Reasonable Efforts to Develop Licensed Products in
the Servier Territory. Servier shall be deemed to not have used Commercially Reasonable Efforts to Develop Licensed Products in the Servier Territory, and MacroGenics shall have the right to terminate this Agreement in accordance with
Section 14.2, if at any point in time prior to the First Commercial Sale of a Licensed Product, Servier fails to undertake Development activities, with the intention of rapidly advancing a Licensed Product toward registration (and not for the
sole purpose of preserving rights hereunder) during at least the preceding ***. 

  
 25 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 5.3 Development Activities. 

5.3.1 Global Development Plan. During the License Term, the Development of Licensed Products under this Agreement shall be
conducted pursuant to a reasonably comprehensive written research and development plan (each, a “Global Development Plan”), which shall include a detailed budget for all Development Costs and Manufacturing Process Development Costs
(each, a “Development Budget”), and which shall include the resource allocations for the Parties based upon the general principle that the allocation shall endeavor to take advantage of the respective resources, capabilities and
expertise of MacroGenics and Servier, respectively. Within *** after the License Grant Date, the JRDC shall prepare an initial draft of the Global Development Plan for approval by the JSC. The Global Development Plan also shall set forth
the specific activities (including non-clinical and clinical studies to be conducted by each Party and the estimated timeline for Development of Licensed Products in order to obtain the data that the Parties intend will be useful, by both Parties,
to obtain Regulatory Approvals of the licensed Product in both the United States, and the EU, Servier shall be the sponsor of all clinical studies conducted in the Servier Territory and shall be solely responsible for Development activities and for
obtaining Regulatory Approval for Licensed Products in the Servier Territory, and MacroGenics shall be the sponsor of all clinical studies conducted in the MacroGenics Territory and shall be solely responsible for Development activities and for
obtaining Regulatory Approval for Licensed Products in the MacroGenics Territory. The JRDC shall discuss which Party(ies) shall be the sponsor of all clinical studies conducted in countries of both the MacroGenics Territory and the Servier
Territory. 
 5.3.2 Details in Global Development Plan. Without limiting Section 5.3.1, the Global Development Plan
shall set forth, among other things, the following activities to be undertaken jointly or coordinated by Servier and MacroGenics: 
 (a) any non-clinical studies, toxicology studies, pharmaco-economic studies, process development studies and other clinical studies, whether pre- or post-approval and whether sponsored or merely supported
by Servier or MacroGenics, in each case, together with all protocols, endpoints and investigators conducting such studies, with respect to Licensed Products in the Servier Territory and MacroGenics Territory; 

(b) regulatory plans and other elements of obtaining and maintaining Regulatory Approvals in the Field in each country in the Servier
Territory and MacroGenics Territory, consistent with the use of Commercially Reasonable Efforts; 
 (c) the timeline for
completing such Development activities; and 
 (d) the plans and timeline for preparing the necessary Regulatory Documentation
and for obtaining Regulatory Approval in the Field in the Servier Territory and MacroGenics Territory. 

  
 26 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 5.4 Updating and Amending Development Plan and Development Budget; Additional Development
Activities. 
 5.4.1 Development Plan Reviews and Updates. On or before January 1st of each Calendar Year during
the License Term, the JRDC shall review, update and approve the Global Development Plan (including the Development Budget contained therein) which shall cover the Development activities and Manufacturing process development activities to be
conducted with respect to the Development of Licensed Products for use in the Field during the upcoming Calendar Year, and the JRDC shall, on at least a quarterly basis, review and update, as appropriate, the then-current Global Development Plan
(including the Development Budget) to reflect any changes, reprioritizations of, or additions to the Global Development Plan. 

5.4.2 Amendments to Development Plan; New Development Collaboration Proposals. 

(a) Amendments to Development Plan. From time to time during the License Term, either Party may submit to the JRDC any proposed
amendment of the Global Development Plan to amend the then-currently approved Development activities (such proposed amendment, a “Proposed Development Plan Amendment”) for the JRDC’s review and JSC approval. Any proposed
amendment to the Global Development Plan shall contain, at a minimum, information supporting the rationale for the Proposed Development Plan Amendment related to Licensed Products from a scientific, regulatory and commercial standpoint, as well as
an estimated developmental critical path, and an estimate of the cost of such Development. The JRDC shall consider any submitted Proposed Development Plan Amendment during its next scheduled meeting. Once approved by the JSC (or otherwise resolved
pursuant to Section 2.9), each amended Global Development Plan (including the Development Budget contained therein) shall become effective and supersede the previous Global Development Plan and Development Budget as of the date of such approval
or at such other time as decided by the JSC. 
 (b) New Development Collaboration Proposals. If either Party proposes to
conduct new Development activities in connection with the Development of a Licensed Product not included in the then approved Global Development Plan, including any proposal to collaborate to *** (such proposal, a “Development
Collaboration Proposal”), such Party shall submit the Development Collaboration Proposal to the other Party through the JRDC. Every Development Collaboration Proposal shall include a proposal to collaborate with the other Party for such
Development activities so that, subject to the terms of this Agreement, with respect to the Development activities underlying the Development Collaboration Proposal, Servier shall be able to Develop Licensed Products for Commercialization in the
Field in the Servier Territory and MacroGenics shall be able to Develop Licensed Products for Commercialization in the Field in the MacroGenics Territory. 
 (i) In the event the other Party approves a Development Collaboration Proposal and the Parties agree to collaborate to conduct the Development activities underlying the Development Collaboration Proposal
with respect to Licensed Products, each Party shall use Commercially Reasonable Efforts to perform the activities allocated to it under the approved Development Collaboration Proposal, and the Parties shall share in the payment of Development Costs
incurred in connection with such activities in accordance with Section 5.5.1(a). 

  
 27 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 (ii) In the event the other Party declines to participate in and share the funding of such
activity (the “Buy-In Party”), the submitting Party may proceed with the activities described in such Development Collaboration Proposal at its sole expense unless the other Party reasonably objects to the conduct of such activity
as reasonably likely to result in a safety or public health issue that will have a material adverse effect in the Development or Commercialization of Program Antibodies and Licensed Product in its territory. Any disputes regarding whether an
activity is reasonably likely to result in a safety or public health issue that will have a material adverse impact on the Development and/or Commercialization of Program Antibodies and Licensed Products in a Party’s territory shall be referred
to the JRDC for a determination and resolved in accordance with Section 2.9; provided that neither Party shall have the right to exercise its final decision making authority pursuant to Section 2.9.3 with respect to such issue. 

(iii) Once during each Calendar Quarter following the commencement of, and until the completion of, the activities described in the
Development Collaboration Proposal, the Buy-In Party may request that the Party conducting such Development activity provide a summary of the current status of such Development activity, the Development Costs incurred to date, any significant
milestones achieved and any topline initial results of such Development activity. 
 (iv) The Buy-In Party may obtain access to
and use of the Excluded Data in accordance with the procedure described in this paragraph; provided that the Buy-In Party shall be provided access to Safety Data, at no cost, in accordance with the SDEA Agreement. At any time following the
commencement of the activities described in the Development Collaboration Proposal, the Buy-In Party shall provide the other Party with written notice of its election to buy-in to such Development, and promptly thereafter the other Party shall
provide the Buy-In Party with an invoice for *** of the cumulative Development Costs as well as the costs of clinical supply of the Program Antibody and/or Licensed Product used in connection with such Development incurred by a Party in the
generation of such data as of the date of the Buy-In Party’s written request (the “Buy-in Amount”), which invoice the Buy-In Party shall pay within *** after receipt. Each Party shall thereafter share, in accordance with
the allocation of costs set forth in Section 5.5.1(a), in the Development Costs incurred after the date of the Buy-In Party’s written request in connection with such Development activities under such Development Collaboration Proposal and
the Global Development Plan shall be amended to include such Development activities. 
 5.4.3 Unilateral Development Costs
and Manufacturing Process Development Costs. 
 (a) Servier Territory Exclusive Development Activities. Except as
provided in Section 5.5 and for Development activities conducted by a Party at its own expense pursuant to Section 5.4.2(b)(ii), Servier shall be responsible for *** of all Development Costs (whether incurred by Servier or
MacroGenics (if the activities and their cost are agreed to in advance in writing by Servier) or their respective Affiliates) set forth in the applicable Development Budget with respect to any Development activities that are conducted for the

  
 28 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
primary purpose of obtaining or maintaining Regulatory Approval for Licensed Products in the Field in any country or other regulatory jurisdiction in the Servier Territory. Servier shall disclose
to MacroGenics a summary of efficacy results and detailed safety information Controlled by Servier and generated in the course of such Development activities within *** after the completion of such activities, subject to the pharmacovigilence
provision under Section 6.5. MacroGenics may obtain access to and use Servier’s data (other than Safety Data which shall in all cases be exchanged, at no cost, in accordance with the SDEA) obtained in such exclusive development activities
if MacroGenics provides Servier with written notice of its election to buy-in such Development, and promptly thereafter Servier shall provide MacroGenics with an invoice for *** of the cumulative Development Costs as well as the costs *** in
connection with such Development incurred by Servier in the generation of such data as of the date of MacroGenics written request, which invoice MacroGenics shall pay within *** after receipt. 

(b) MacroGenics Territory Exclusive Development Activities. Except as provided in Section 5.5 and for Development activities
conducted by a Party at its own expense pursuant to Section 5.4.2(b)(ii), MacroGenics shall be responsible for *** of all Development Costs (whether incurred by Servier (if the activities and their costs are agreed to in advance in
writing by MacroGenics) or MacroGenics or their respective Affiliates) set forth in the applicable Development Budget with respect to any Development activities that are conducted for the primary purpose of obtaining or maintaining Regulatory
Approval for Licensed Products in the Field in any country or other regulatory jurisdiction in the MacroGenics Territory. MacroGenics shall disclose to Servier a summary of efficacy results and detailed safety information Controlled by Servier and
generated in the course of such Development activities within *** after the completion of such activities, subject to the pharmacovigilence provision under Section 6.5. Servier may obtain access to and use MacroGenics’ data (other
than Safety Data which shall in all cases be exchanged, at no cost, in accordance with the SDEA) obtained in such exclusive Development activities if Servier provides MacroGenics with written notice of its election to buy-in such Development, and
promptly thereafter MacroGenics shall provide Servier with an invoice for *** of the cumulative Development Costs as well as the costs *** in connection with such Development incurred by MacroGenics in the generation of such data as of the
date of Servier written request, which invoice Servier shall pay within *** after receipt. 
 (c) Servier ***
Funding. Servier shall reimburse MacroGenics for ***. 
 (d) Manufacturing Process Development Costs. Servier
and MacroGenics shall each be responsible for *** of each Manufacturing Process Development Cost provided the activity which resulted in such cost was conducted under the Global Development Plan. 

  
 29 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 5.5 Development Activities. 

5.5.1 Except for Development activities conducted by a Party at its own expense pursuant to Section 5.4.2(b)(ii), with respect to any
Development activities conducted for the primary purpose of obtaining or maintaining Regulatory Approval for Licensed Products both in the Servier Territory and in the MacroGenics Territory (including Development activities with respect to which a
Party has paid the Buy-in Amount in accordance with Section 5.4.2(b)(iv)) pursuant to the Development Plan: 
 (a) subject
to Section 5.5.2, Servier shall be responsible for *** and MacroGenics shall be responsible for *** of all Development Costs as well as the costs of clinical supply of the Program Antibody and/or Licensed Product used in connection with such
Development (in each case, whether incurred by Servier or MacroGenics or their respective Affiliates). For purposes of clarity, MacroGenics may seek reimbursement from Servier under Section 5.4.3(c) to apply to Development Costs for which
MacroGenics is responsible under this Section 5.5.1(a) to the extent such Development Costs are for Phase 2 Clinical Trials; 
 (b) each Party shall disclose to the other Party all clinical data and related Regulatory Documentation Controlled by such Party and generated in the course of such Manufacturing process development
activities and Development activities within ***; 
 (c) each Party shall have the right to use all clinical data and related
Regulatory Documentation Controlled by either Party and generated in the course of such Manufacturing process development activities and Development activities in order to Develop, obtain Regulatory Approval for and Commercialize Licensed Products
in the Field in such Party’s territory, in accordance with the terms of this Agreement; and 
 (d) each Party hereby
grants to the other Party a Right of Reference or Use to any and all such Regulatory Documentation with respect to Licensed Products in the Field in the other Party’s territory, and agrees to sign, and cause its Affiliates to sign, any
instruments reasonably requested by such other Party in order to effect such grant. 
 5.5.2 Development Costs Budget and
Timeline Overruns. 
 (a) Budget Overruns. With respect to any Development Costs which, pursuant to this Agreement
and/or a Global Development Plan or an approved Development Collaboration Proposal, are meant to be allocated between the Parties (rather than one Party being solely responsible for such Development Costs), each Party shall promptly inform the other
Party upon determining that it is likely to exceed the budget amounts set forth in the annual Development Budget for the activities such Party is responsible for under the Global Development Plan. To the extent that a Party (or its Affiliates or
Sublicensees) incurs Development Costs for the activities such Party is responsible for under the Global Development Plan for a particular Calendar Year which on an aggregate basis for that year exceed the Development Costs allocated for such
activity in the initial Development Budget that includes such activity (the “Initial Development Budget”) by *** or less (a “De Minimis Overage Amount”), then such De Minimis Overage Amount shall
automatically be included in the Development Budget for such year. However, to the extent that a Party (or its Affiliates or Sublicensees) incurs Development Costs for the activities such Party is responsible for under the Development Plan for a
particular Calendar Year which on an aggregate basis for that year exceed the Development Costs allocated for such activity in the Initial Development Budget by more than ***, the “Excess Overage Amount”), the Party that has
so exceeded its budget shall 

  
 30 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
provide to the JRDC a full explanation for so exceeding its budget and such Excess Overage Amount shall only be included in the Development Budget to the extent that the JRDC agrees to allow some
or all of the Excess Overage Amount to be included in the Development Budget as it considers equitable under the circumstances. To the extent that the JRDC does not agree to treat the Excess Overage Amount as Development Costs, the Party that has
exceeded its budget shall be solely responsible for the Excess Overage Amount. 
 (b) Timeline Overruns. Each Party
shall promptly inform the other Party upon determining that it is likely to miss a Development date set forth in the Global Development Plan. To the extent that a Party (or its Affiliates) misses such a date by *** or more, the Party that has
experienced such Development timeline failure shall provide to the JRDC a full explanation for such Development timeline failure. Such notification shall not serve to excuse a Party from its diligence or other obligations under this Agreement.

 (c) Reconciliation. Within *** following the end of each Calendar Quarter beginning with the License Grant
Date, each Party shall prepare and deliver to the other Party a quarterly report detailing its Development Costs and Manufacturing Process Development Costs incurred during such period, with each Party reporting on all Development Costs incurred
with respect to Development Collaboration Proposals. Each Party shall submit any additional information reasonably requested by the other Party related to the Development Costs and Manufacturing Process Development Costs included in its report
within *** of its receipt of such request. Within *** after the receipt of the report delivered by Servier pursuant to this Section 5.5.2(c), MacroGenics shall prepare and deliver to Servier a composite report that
(i) summarizes the Development Costs and Manufacturing Process Development Costs incurred by each Party for such Calendar Quarter; (ii) applies the percentage of such costs for which each Party is responsible for the total Development
Costs and Manufacturing Process Development Costs attributable to the Development and Manufacturing activities for such Calendar Quarter pursuant to Sections 5.4.3 and 5.5.1; and (iii) computes the amount due to MacroGenics or Servier, as
applicable, for such Calendar Quarter in order for the Parties to share the total Development Costs and Manufacturing Process Development Costs for such quarter based on the Development Plan and the principles set forth in Sections 5.4.3 and 5.5.1
(each, a “Reconciliation Payment”). The Party to whom a Reconciliation Payment is due shall issue an invoice to the other Party for the Reconciliation Payment, and such other Party shall pay all undisputed amounts within ***
after its receipt of the invoice. Each Party shall have the right to audit the records of the other Party with respect to any Development Costs and Manufacturing Process Development Costs included in such reports, in accordance with
Section 9.10. 
 5.6 Exchange of Data. During the License Term, the following shall apply: 

5.6.1 Initial Exchange of Data. Promptly after the License Grant Date, MacroGenics shall transfer to Servier the MacroGenics
Know-How related to Program Antibodies and Licensed Products (other than the MacroGenics Know-How related directly and solely to Manufacturing). Such transfer shall occur in a manner and following a reasonable schedule to be established by the
JSC. MacroGenics shall provide Servier with copies of 

  
 31 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
relevant material, information, reports and data, including pre-clinical data, clinical data, and any data that has been provided to Regulatory Authorities for the purpose of obtaining Regulatory
Approval. 
 5.6.2 Ongoing Exchange of Data. During the License Term, except as provided in Section 5.4.2(b)(iv)
with respect to Excluded Data, each Party shall provide to the other Party (a) all Know-How Controlled by such Party that is specified in the Global Development Plan to the extent necessary or useful for the Development or Commercialization of
Program Antibodies or Licensed Products in the other Party’s territory, and (b) any Know-How Controlled by such Party that is not specified in the Global Development Plan that such Party reasonably believes to be necessary or useful for
the Development or Commercialization of Program Antibodies or Licensed Products in the other Party’s territory, in a timely fashion and as promptly as possible for use by such other Party in accordance with this Section 5.6.2. Servier
shall only use and disclose to Third Parties such MacroGenics Know-How as may be necessary or useful for Development and Commercialization of Program Antibodies and/or Licensed Products in the Servier Territory; or as may otherwise be agreed by
MacroGenics and Servier. Servier may not use any MacroGenics Know-How (or permit any Third Party to use any MacroGenics Know-How) outside the Servier Territory, nor for any products other than the Licensed Products, except as may otherwise be agreed
by MacroGenics and Servier (including as provided in Sections 4.1 and 4.2). MacroGenics shall not use any Servier Know-How (or permit any Third Party to use any Servier Know-How) outside the MacroGenics Territory, nor for any products other than the
Licensed Products, except as may otherwise be agreed by MacroGenics and Servier. 
 5.6.3 Use. All preclinical,
non-clinical, analytical, manufacturing, and clinical data and associated reports disclosed by one Party to the other under this Agreement may be used by the receiving Party subject to the terms of this Agreement solely for the purpose of
Developing, Manufacturing and Commercializing Licensed Products in its respective territory. Each Party shall have the right to share any and all such data and other regulatory materials received from the other Party with its Affiliates and any
Third Party sublicensees or licensees in its respective territory solely for the purpose of Developing, Manufacturing and Commercializing Licensed Products in its respective territory. Access to and use of such data and regulatory materials are
given by each Party to the other Party without cost (except as otherwise provided herein) on an “as is” basis without any warranty of any kind. Each receiving Party accepts all risk and liability in relation to the use of the data and
regulatory materials received from the other Party and shall indemnify and hold harmless the Party providing such data and regulatory materials from any Third Party’s claim(s) based upon such data and regulatory materials as provided in ARTICLE
13. 
 5.6.4 Reports. In addition to information and reports required elsewhere in this Agreement, each Party shall
provide the other Party and the JRDC with a written annual report summarizing the major activities performed by it under the Global Development Plan during the previous year, conduct of non-clinical activities and clinical trials, information
regarding the status of Regulatory Approvals. The other Party shall have the opportunity to reasonably seek further explanation or clarification of matters covered in such reports and to 

  
 32 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
provide observations and suggestions to the disclosing Party regarding the subject matter thereof, and the disclosing Party shall provide such explanation or clarification and shall consider
such observations and suggestions in good faith. Furthermore, if after receiving such a report the receiving Party wishes to meet with the disclosing Party to discuss such report, the disclosing Party shall meet with the receiving Party at a site
reasonably requested by the receiving Party within *** after the disclosing Party’s requests such meeting. 

ARTICLE 6 

REGULATORY MATTERS 
 The provisions of this ARTICLE 6 shall apply during the License Term. 
 6.1
Servier Regulatory Responsibility. 
 6.1.1 During the License Term, Servier shall own and be responsible for preparing,
filing and maintaining all Regulatory Documentation and Regulatory Approvals that are required for the Development (unless otherwise agreed by the JRDC on the basis of section 4.2 above), Manufacture or Commercialization of the Program Antibodies or
Licensed Products in the Field in the Servier Territory and Servier shall otherwise be responsible for and have sole authority as to all interactions with Regulatory Authorities in the Servier Territory. Servier shall comply with all applicable Laws
in the Servier Territory, including local regulations and ICH guidelines. 
 6.1.2 Servier hereby grants to MacroGenics a Right
of Reference or Use to any Regulatory Documentation in the Servier Territory Controlled by Servier for use by MacroGenics in the MacroGenics Territory, and agrees to sign, and cause its Affiliates to sign, from time to time, promptly upon request,
any instruments reasonably requested by MacroGenics in order to further effect such grant. Servier shall permit any relevant Regulatory Authority to inspect any such Regulatory Documentation. Servier shall also permit MacroGenics, upon reasonable
notice, during regular business hours, to audit any such Regulatory Documentation; provided that, MacroGenics shall limit such audits by MacroGenics to a moderate frequency reasonably necessary in order for MacroGenics to perform the
Development and Commercialization of the Program Antibodies and Licensed Product. 
 6.2 MacroGenics Regulatory
Responsibility. 
 6.2.1 MacroGenics shall own and be responsible for preparing, filing and maintaining all Regulatory
Documentation and Regulatory Approvals that are required for the Development (unless otherwise agreed by the JRDC on the basis of section 4.1 above), or Commercialization of Program Antibodies or Licensed Products in the Field in the MacroGenics
Territory and MacroGenics shall otherwise be responsible for and have sole authority as to all interactions with Regulatory Authorities in the MacroGenics Territory. MacroGenics shall comply with all applicable Laws in the MacroGenics Territory,
including local regulations and ICH guidelines. 

  
 33 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 6.2.2 MacroGenics hereby grants to Servier a Right of Reference or Use to any Regulatory
Documentation in the MacroGenics Territory Controlled by MacroGenics for use by Servier in the Servier Territory, and agrees to sign, and cause its Affiliates to sign, from time to time, promptly upon request, any instruments reasonably requested by
Servier in order to further effect such grant. MacroGenics shall permit any relevant Regulatory Authority to inspect any such Regulatory Documentation. MacroGenics shall also permit Servier, upon reasonable notice, during regular business hours, to
audit any such Regulatory Documentation; provided that, Servier shall limit such audits by Servier to a moderate frequency reasonably necessary in order for Servier to perform the Development and Commercialization of the Program
Antibodies and Licensed Product. 
 6.3 Communications with Regulatory Authorities. 

6.3.1 For purposes of this Article 6.3, “material” shall mean any ***. Servier shall be responsible for all submissions to, and
communications and interactions with, Regulatory Authorities in the Servier Territory with respect to Program Antibodies and Licensed Products (unless otherwise agreed by the JRDC on the basis of section 4.2 above), and MacroGenics shall be
responsible for submissions to, and communications and interactions with, Regulatory Authorities in the MacroGenics Territory with respect to Program Antibodies and Licensed Products (unless otherwise agreed by the JRDC on the basis of section 4.1
above). In connection therewith: 
 (a) Servier shall keep MacroGenics reasonably informed regarding Servier’s (or its
Affiliate’s or Sublicensee’s) regulatory strategy, planned regulatory submissions and material communications with the Regulatory Authorities in the Servier Territory. with respect to the Program Antibodies and Licensed Products, including
any material changes to such strategy, submissions or communications. Servier shall provide MacroGenics with copies of material regulatory submissions to, and material communications with the *** relating to the Program Antibodies and Licensed
Products. To the extent permitted by Regulatory Authorities, MacroGenics shall have the right to have a senior, experienced employee participate as an observer in meetings with the *** or their agents, as well as participate in internal meetings or
discussions of Servier occurring immediately before or after, and related to, such meetings, and shall be provided with advance access to Servier’s materials prepared for such meetings. MacroGenics shall also have the right to review and
comment upon any correspondence with the *** or their agents related to such meetings. Servier shall provide MacroGenics regularly prepared minutes of material meetings with the *** *** regarding Program Antibodies and Licensed Products in the Field
in the Servier Territory and available material teleconference reports with the *** pertaining to Program Antibodies and Licensed Products in the Field in the Servier Territory. 

(b) MacroGenics shall keep Servier reasonably informed regarding MacroGenics’ (or its Affiliate’s or Sublicensee’s)
regulatory strategy, planned regulatory submissions and material communications with the *** with respect to the Program Antibodies and Licensed Products, including any material changes to such strategy, submissions or communications. MacroGenics
shall provide Servier with copies of material regulatory 

  
 34 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
submissions to, and material communications with the *** relating to the Program Antibodies and Licensed Products. To the extent permitted by Regulatory Authorities, Servier shall have the right
to have a senior, experienced employee participate as an observer in meetings with the *** or its agents, as well as participate in internal meetings or discussions of MacroGenics occurring immediately before or after, and related to, such meetings,
and shall be provided with advance access to MacroGenics’ materials prepared for such meetings. Servier shall also have the right to review and comment upon any correspondence with the *** or its agents related to such meetings. MacroGenics
shall provide Servier regularly prepared minutes of material meetings with the *** regarding Licensed Products in the Field in the MacroGenics Territory and available material teleconference reports with the *** pertaining to Licensed Products in
the Field in the MacroGenics Territory. 
 6.3.2 If either Party or its Affiliates or subcontractors (each, an
“Inspected Party”) are to be inspected by a Government Authority regarding the development, manufacture, registration or commercialization of a Licensed Product, the Inspected Party shall promptly notify the other Party of the
inspection in writing as soon as reasonably practicable, and in advance, if any such inspection is a scheduled inspection. The Inspected Party shall, where practicable, permit representatives of the other Party to participate as observers with
respect to such inspection, and shall provide the other Party with a written report of any such inspection, noting with specificity any records or documents reviewed by the regulatory inspector, and including copies of any FDA 483s (or their
non-U.S. equivalent) or written communications provided by or to any Government Authority relating to such inspection. The Inspected Party will use Commercially Reasonable Efforts to provide an opportunity for the other Party to assist in responding
to any issues or concerns relating to such inspections, and shall provide copies of all communications to and from any Government Authority relating thereto to the other Party. The Parties shall cooperate in good faith and otherwise mutually support
any regulatory inspections of facilities, clinical sites, contract manufacturers or the like with respect to Licensed Products, including by using Commercially Reasonable Efforts to make available such facilities, documents, information and/or
personnel as are reasonably necessary or useful for such regulatory inspections by a Government Authority. 
 6.4 Product
Withdrawals and Recalls. If any Regulatory Authority (a) threatens, initiates or advises any action to remove any Licensed Product from the market in any country of the world, or (b) requires or advises either Party or such
Party’s Affiliates or sublicensees to distribute a “Dear Doctor” letter or its equivalent regarding use of any Licensed Product in any country of the world, then Servier (if such action is in the Servier Territory) or MacroGenics (if
such action is in the MacroGenics Territory), as applicable, shall notify the other Party of such event within *** (or sooner if required by applicable Law) after such Party becomes aware of the action, threat, advice or requirement (as
applicable). The JRDC will discuss and attempt to agree upon whether to recall or withdraw such Licensed Product; provided, however, that if the Parties fail to agree within an appropriate time period or if the matter involves a safety issue that,
in order to protect patient safety, does not allow for sufficient time for a discussion at the JRDC level, Servier shall decide whether to recall or withdraw such Licensed Product in the Servier Territory and shall undertake any such recall or
withdrawal in the Servier Territory at its own cost and expense, and MacroGenics shall decide whether to recall or withdraw such Licensed Product in the MacroGenics Territory and shall undertake any such recall or withdrawal in the MacroGenics
Territory at its own cost and expense. 

  
 35 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 6.5 Pharmacovigilance; Safety Data Reporting. 

6.5.1 Pharmacovigilance. *** after the License Grant Date the Parties shall negotiate in good faith a safety data exchange
agreement governing the collection, investigation, reporting, and exchange of information concerning adverse drug reactions/experience, Licensed Product quality and Licensed Product complaints, sufficient to permit each Party to comply with its
legal obligations (the “SDEA Agreement”). The SDEA Agreement will be promptly updated if required by changes in legal requirements. 
 6.5.2 Safety Data Reporting. 
 (a) Each Party shall keep the other Party
informed about any adverse drug reactions such Party becomes aware or is informed about regarding the use of a Licensed Product. As between the Parties, Servier shall be responsible for reporting all adverse drug reactions/experiences to the
appropriate regulatory authorities in countries in the Servier Territory, and MacroGenics shall be responsible for reporting all adverse drug reactions/experiences to the appropriate regulatory authorities in the MacroGenics Territory, in accordance
with the appropriate laws and regulations of the relevant countries and authorities. Servier shall ensure that its Affiliates and Sublicensees comply with such reporting obligations in the Servier Territory and MacroGenics shall ensure that its
Affiliates and sublicensees (other than Servier and its Sublicensees) comply with such reporting obligations in the MacroGenics Territory. These reporting obligations shall apply to other adverse events as described in the SDEA Agreement, including
adverse events occurring from product overdose or from product withdrawal, as well as any toxicity, sensitivity, failure of expected pharmacological action, or laboratory abnormality which is, or is thought by the reporter, to be serious or
associated with relevant clinical signs or symptoms. 
 (b) Each Party will designate a pharmacovigilance liaison to be
responsible for communicating with the other Party regarding the reporting of adverse drug reactions/experiences. Each Party (the “Notifying Party”) shall notify the other Party in writing of all information coming to the Notifying
Party’s attention, regardless of the origin of such information, and including such information coming to its attention through clinical and non-clinical sources (including journal publications and other media), regarding adverse drug
experiences associated with the Licensed Product, whether in the Servier Territory or in the MacroGenics Territory. 
 ARTICLE
7 
 MANUFACTURING 
 The provisions of this ARTICLE 7 shall apply during the License Term. 

  
 36 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 7.1 Transfer of MacroGenics Manufacturing Know-How. 

7.1.1 At Servier’s request and sole expense, and on a schedule and a product comparability plan agreed upon by the Parties,
MacroGenics shall disclose (and provide copies, as applicable) to either Servier or the Third Party manufacturer that is mutually acceptable to both Parties, all MacroGenics Know-How necessary or useful to enable Servier or such Third Party
manufacturer (as appropriate) *** to Manufacture Licensed Product based on a manufacturing process ***. For clarity, nothing in this Section 7.1 with respect to MacroGenics’ obligation to transfer MacroGenics Know-How to
Servier shall limit MacroGenics’ right to use any such MacroGenics Know-How to fulfill MacroGenics’ obligations to Manufacture and supply Licensed Product to Servier under this Agreement or the Supply Agreement. In addition,
MacroGenics shall, at Servier’s sole expense, make available to Servier, on a reasonable consultation basis, advice of its technical personnel as may reasonably be requested by Servier in connection with such transfer of MacroGenics
Know-How. MacroGenics shall thereafter during the Agreement Term, continue to promptly and regularly disclose any material new MacroGenics Know-How related to Manufacturing Program Antibodies and Licensed Products to Servier or to the Third
Party manufacturer mentioned above at Servier’s cost. 
 7.1.2 Servier and/or its Third Party manufacturer shall use the
MacroGenics Know-How transferred under Section 7.1.1 solely for the purpose of Manufacturing Program Antibodies and finished Licensed Products in accordance with the terms and conditions of this Agreement, and for no other purpose. 

7.1.3 Servier acknowledges and agrees that MacroGenics may condition its agreement to transfer any MacroGenics 
Know-How to a Third
Party manufacturer on the execution of a confidentiality agreement between such Third Party manufacturer and MacroGenics that contains terms substantially equivalent to those of ARTICLE 11. 

7.2 Supply Agreements. 
 7.2.1 Clinical Supply Agreement. *** following the Effective Date, the Parties shall enter into good faith negotiations regarding the terms of a clinical supply agreement, pursuant to which
MacroGenics shall provide clinical supply of Program Antibodies and/or Licensed Products for (a) *** (b) at MacroGenics’ option, Clinical Trials of Licensed Products conducted by Servier and its Affiliates and Sublicensees
other than *** of Licensed Products to be conducted by Servier and its Affiliates and Sublicensees (the “Clinical Supply Agreement”). The cost for such supply of Program Antibodies and/or Licensed Products for Clinical Trials
shall be equal to MacroGenics’ Fully Burdened Manufacturing Cost; ***. The Fully Burdened Manufacturing Cost for supply of Program Antibodies and/or Licensed Products for clinical trials used by Servier in connection with the Development
of a Program Antibodies and/or Licensed Products outside the Global Development Plan shall be invoiced by MacroGenics on a quarterly basis. 
 7.2.2 Commercial Supply Agreement. Following the License Grant Date, if requested by Servier, the Parties shall enter into good faith negotiations regarding the terms of a quality and supply
agreement, pursuant to which MacroGenics shall provide commercial supply of Program Antibodies and/or Licensed Products to Servier and its Affiliates and Sublicensees (the “Commercial Supply Agreement”). 

  
 37 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 ARTICLE 8 
 COMMERCIALIZATION 
 The provisions of this ARTICLE 8 shall apply during the
License Term. 
 8.1 Overview. Servier shall have sole control and responsibility for the Commercialization of
Licensed Products in the Servier Territory and shall bear all costs and expenses associated with the Commercialization of Licensed Products in the Servier Territory. MacroGenics shall have sole control and responsibility for the Commercialization of
Licensed Products in the MacroGenics Territory and shall bear all costs and expenses associated with the Commercialization of Licensed Products in the MacroGenics Territory. The Party with responsibility for Commercialization in a territory and
field shall be referred to as the “Commercializing Party” for such territory. 
 8.2 Sales and
Distribution. It is understood that as between the Parties, the Commercializing Party shall be solely responsible for handling all returns, order processing, invoicing and collection, distribution, and receivables for Licensed Products in
the applicable territory and indication. 
 8.3 Ex-Territory Sales. Subject to applicable Law, neither
Party shall engage in any advertising or promotional activities relating to Licensed Product directed primarily to customers or other buyers or users of Licensed Product located outside its territory or accept orders for Licensed Products from or
sell Licensed Products into such other Party’s territory for its own account or for the Commercializing Party’s account, and if such other Party receives any order for Licensed Products in the Commercializing Party’s territory, it
shall refer such orders to the Commercializing Party for acceptance or rejection. 
 8.4
Commercialization Plan for Licensed Territory. Servier shall pursue Commercialization of Licensed Products in the Servier Territory, in accordance with its normal business practices for its internal products at a similar
stage. Servier shall deliver an initial Commercialization plan to MacroGenics no later than *** prior to the anticipated date of the first filing of the first BLA for a Licensed Product in the Servier Territory (the
“Commercialization Plan”). After the establishment of the initial Commercialization Plan, Servier shall prepare updates and amendments to such Commercialization Plan at least annually and deliver such updated Commercialization
Plan to MacroGenics no later than March 31st of each
Calendar Year. 
 8.5 Trademarks. 
 8.5.1 Generally. Servier and its Affiliates shall select their own trademarks under which they will market Licensed Products (provided that no such trademark shall contain the word
“MacroGenics”) and shall own such trademarks. MacroGenics and its Affiliates shall select their own trademarks under which they will market Licensed Products (provided that no such trademark shall contain the word
“Servier” or “Les Laboratoires Servier”) and shall own such trademarks. 

  
 38 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 8.5.2 Acknowledgement. Servier shall use, in connection with all packaging,
literature, labels and other printed matters, to the extent required by Law, and where reasonably practicable in light of space limitations, an expression to the effect that the Licensed Products were developed under license from MacroGenics,
together with the MacroGenics logo. The provisions of this Section 8.5.2 shall not apply to primary packaging of the Licensed Products. Primary packaging shall mean packaging that is in direct contact with the Licensed Products or the Licensed
Products themselves, including vials, blister packs, tablets and capsules.  
 8.5.3 Housemarks. Neither Party
shall, and shall ensure that its Affiliates and sublicensees will not, make any use of the trademarks or house marks of the other Party or its Affiliates or licensees (including their corporate names) or any trademark confusingly similar thereto.

 8.6 Commercial Diligence. During the License Term, Servier shall use Commercially Reasonable Efforts to
Commercialize the Products throughout the Servier Territory.
 8.7 Standards of Conduct. Each Party shall in all
respects comply with all applicable Laws and applicable guidelines concerning the advertising, sales and marketing of prescription drug products in Commercializing Products under this Agreement, including any applicable local anti-bribery laws.

 ARTICLE 9 
 PAYMENTS 
 9.1 Option Grant Fee. In consideration for the Option as
granted by MacroGenics to Servier hereunder and to review the Option Trigger Data Package, Servier shall pay MacroGenics a non-refundable, non-creditable payment of Twenty Million Dollars ($20,000,000) (the “Option Grant Fee”)
within *** after the Effective Date and the date of receipt of the corresponding invoice. 
 9.2 License Grant Fee.

 9.2.1 Upon exercise of the Option and *** after the date of receipt of the corresponding invoice, Servier shall pay
MacroGenics a non-refundable, non-creditable payment (the “License Grant Fee”) of 
  

	 	(a)	*** if by the date of the exercise of the Option, ***; or 

  

	 	(b)	*** if by the date of the exercise of the Option, ***; or 

  

	 	(c)	*** if by the date of the exercise of the Option, ***. 

  
 39 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 9.2.2 If Servier pays MacroGenics the License Grant Fee according to Section 9.2.1(a)
or (b), Servier will, within *** after the date of receipt of the corresponding invoice, pay MacroGenics *** until Servier has paid MacroGenics a total of thirty million ($30,000,000) under Sections 9.2.1 and 9.2.2. 

9.3 Development and Regulatory Milestones. 

9.3.1 Research Term Development Milestones. Servier shall pay to MacroGenics the non-refundable,
non-creditable amount of Ten Million Dollars ($10,000,000) upon closing of the first subject in the first expansion cohort of the initial Phase 1 Clinical Trial, but in no event before October 1st, 2012. 

9.3.2 License Term Development and Regulatory Milestones. During the License Term, for each milestone set forth in
Section 9.3.2, Servier shall pay the corresponding *** amount indicated for that milestone for the first instance of its achievement: 
  

			
	 Milestone Event
	  	Payment
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***

 In no event shall the total of the amounts paid under this Section 9.3.2 exceed ***.

 9.3.3 Milestone Payments. Servier shall make the milestone payments required by Section 9.4.1 and 9.3.2 in
accordance with Section 9.3.6. If an event described in a clause in Section 9.3.2 occurs before or concurrently with another event described in a preceding clause in Section 9.3.2, Servier shall also pay the milestone payment
described in such earlier clause when the milestone payment described in such later clause is paid. 

  
 40 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 9.3.4 Follow-On Products. 

(a) Subject to the terms of this Agreement, ***. 
 (b) If prior to the time at which a milestone payment pursuant to Section 9.3.4(a) is to be made with respect to a subsequent Licensed Product, the first Licensed Product has been substituted by a
subsequent Licensed Product or development of the first Licensed Product has been discontinued, then the achievement by such subsequent Licensed Product of a milestone event to the extent the corresponding milestone payment under Section 9.3.2
has not been made with respect to such substituted or discontinued first Licensed Product, shall be deemed to be achievement of the corresponding milestone event under Section 9.3.2 by the first Licensed Product entitling MacroGenics to the
corresponding milestone payment under Section 9.3.2. 
 9.3.5 Reductions in Milestones Payable for Phase 3 Clinical
Trials. In the event that the conduct by Servier of a Phase 1 Clinical Trial or Phase 2 Clinical Trial for Licensed Product in accordance with the Research Plan results in Servier, its Affiliates or Sublicensees conducting a Phase 3 Clinical
Trial for Licensed Product under the Global Development Plan in the same Indication as that studied in such Phase 1 Clinical Trial or Phase 2 Clinical Trial, ***. Prior to the initiation of any such Phase 3 Clinical Trial, Servier
shall provide MacroGenics ***. MacroGenics shall have the right to have an independent public accountant reasonably acceptable to Servier audit Servier’s books and records solely for purposes of verifying such Development Costs, upon
reasonable advance notice and during Servier’s business hours, subject to the confidentiality provisions of ARTICLE 11. 

9.3.6 Notification; Payment. Servier shall promptly notify MacroGenics in writing of the first achievement of each of the
milestones under this Section 9.3 (other than milestones under Section 9.3.1) and the corresponding milestone payment shall be due within *** after receipt of the corresponding invoice from MacroGenics. 

9.4 Sales Milestones. 
 9.4.1 Sales Milestone Payments. Servier shall make the *** payments to MacroGenics set forth below upon the earliest achievement of each of the corresponding milestone events by the first Licensed
Product to achieve such milestone: 
  

			
	 Milestone Event
	  	Payment
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***

  
 41 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 9.4.2 Payment of Milestones. Servier shall make the milestone payments required by
Section 9.4.1 in accordance with Section 9.6. If an event described in a clause in Section 9.4.1 occurs before or concurrently with another event described in a preceding clause in Section 9.4.1, Servier shall also pay the
milestone payment described in such earlier clause when the milestone payment described in such later clause is paid. By way of example, if, during March 2015, ***, Servier shall pay MacroGenics the milestone payments set forth in both Sections
9.4.1(a) and (b). 
 9.5 Royalties. 
 9.5.1 Servier shall pay MacroGenics royalties on Net Sales of Licensed Products at the following rates with respect to all such Net Sales of such applicable Licensed Products achieved during the
applicable Calendar Year: 
  

			
	 Annual Net Sales Threshold
	  	Royalty Rate
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***

 9.5.2 Royalty Term. Servier’s royalty obligations to MacroGenics under this Section 9.5
shall expire on a country-by-country and Licensed Product-by-Licensed Product basis on the later of: *** 
 9.5.3
Third Party Royalty Offset.
 (a) If after the License Grant Date, Servier, its Affiliates or its Sublicensee or
designee (i) is required, as agreed by the Parties in good faith, ***, to obtain a license from any Third Party under an Identified Patent controlled by such Third Party in order to Manufacture, Develop, Commercialize or import a Program
Antibody and/or a Licensed Product in any country in the Servier Territory, and pursuant to such license ***, or (ii) is required by any court of competent jurisdiction, due to infringement of an Identified Patent controlled by such Third Party
in any country(ies) in the Servier Territory, ***, then Servier may deduct from the milestones (other than the milestone set forth in Section 9.3.1) and/or royalties that would otherwise be due to MacroGenics on Net Sales resulting from the
sales of such Licensed Product in such country in a Calendar Quarter *** of the amount paid by Servier to such Third Party with respect to such Licensed Product for such country during such Calendar Quarter; ***. 

(b) If, (i) in order to Manufacture, Develop, Commercialize or import a Program Antibody and/or a Licensed Product in any country
in the Servier Territory, Servier or 

  
 42 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
its Affiliates or Sublicensees *** under a MacroGenics Third Party Agreement listed in Exhibit C as of the Effective Date ***, or (ii) after the License Grant Date, Servier or its
sublicensee or designee: (A) is required, as agreed by the Parties in good faith, ***, to obtain a license from any Third Party under Patents (other than Identified Patents) controlled by such Third Party in order to make, have made, use, sell,
offer for sale or import a Program Antibody and/or a Licensed Product in any country in the Servier Territory, and pursuant to such license ***, or (B) is required by any court of competent jurisdiction, due to infringement of patent rights
(other than Identified Patents) controlled by such Third Party in any country(ies) in the Servier Territory, to pay such a royalty to such a Third Party based on sales of such Licensed Product in such country(ies), then Servier may deduct from the
milestones and/or royalties that would otherwise be due to MacroGenics on Net Sales resulting from the sales of such Licensed Product in such country in a Calendar Quarter *** of the amount paid by Servier to such Third Party with respect to
such Licensed Product for such country during such Calendar Quarter; ***. 
 9.5.4 If at any time following the First
Commercial Sale, Generic Competition exists in any country of the Servier Territory, Servier shall deduct *** from the royalties that would otherwise be due to MacroGenics on Net Sales resulting from the sales of such Licensed Product in such
country during the applicable Calendar Quarter in which such Generic Competition exists. 
 9.6 Reports; Payments. Within
*** after the end of each Calendar Quarter during which there are Net Sales giving rise to a payment obligation under Section 9.4 or 9.5, Servier shall submit to MacroGenics a report identifying for each Licensed Product, the Net Sales for such
Licensed Product for each country in the Servier Territory for such Calendar Quarter, the calculation of royalties (including gross sales and all deductions taken from gross sales), and the royalties and the sales milestones payable to MacroGenics.
Within *** of the delivery of each such report, Servier shall pay to MacroGenics all royalties and sales milestones payable by it under Sections 9.4 and 9.5. 
 9.7 Methods of Payments. 
 9.7.1 All payments due under this Agreement shall
be paid in Dollars ***, by wire transfer to a bank in the United States designated in writing by MacroGenics. 
 9.7.2 For the
purposes of determining the amount of any sales milestone payment under Section 9.4 or royalties due for the relevant Calendar Quarter under Section 9.5, the amount of Net Sales in any non-Euro currency shall be converted into Euro using
the average of daily closing rates of exchange published by European Central Bank for the monthly period in which Net Sales are accounted. 
 9.8 Late Payments. Any amount owed by Servier to MacroGenics under this Agreement that is not paid on or before the date such payment is due shall bear interest at a rate per annum equal to the
lesser of (a) ***, or (b) the highest rate permitted by applicable Law, calculated on the number of days such payments are paid after such payments are due and compounded monthly. ***. 

  
 43 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 9.9 Taxes. All payment due and payable under this Agreement will
be made without any deduction or withholding for on account of any tax by application of the Tax Treaty in force between France and The United States since August 31st 1994 and in accordance with its amendment signed January 13th 2009 which came into force retroactively January 1st 2009, unless such deduction or withholding tax is required by
applicable laws. If the paying Party is so required to deduct or withhold, such Party shall (a) promptly notify the other Party of such requirement, (b) pay to the relevant authorities the full amount required to be deducted or withheld
promptly upon the earlier of determining that such deduction or withholding is required or receiving notice that such amount has been assessed against the other Party, and (c) promptly forward to the other Party an official receipt (or
certified copy), or other documentation reasonably acceptable to the other Party evidencing such payment to such authorities. 

9.10 Books and Records; Audit Rights. Each Party (the “Audited Party”) shall keep (and, in the case of Servier,
shall cause its Affiliates and Sublicensees to keep) complete, true and accurate books and records in accordance with its Accounting Standards in sufficient detail for the other Party (the “Auditing Party”) to determine the payments
due and costs incurred under this Agreement. Each Auditing Party shall have the right, once annually at its own expense, to have an independent, certified public accounting firm of nationally recognized standing, selected by the Auditing Party and
reasonably acceptable to the Audited Party, review any such records of the Audited Party in the location(s) where such records are maintained by the Audited Party upon reasonable notice (which shall be no less than *** prior notice) and during
regular business hours and under obligations of strict confidence, for the sole purpose of verifying the accuracy of the amounts paid under this Agreement within a *** period preceding the date of the request for review. The report of such
accounting firm shall be limited to a certificate stating whether any report made or invoice or payment submitted by the Audited Party during such period is accurate or inaccurate and the actual amounts of Development Costs and the amount of any Net
Sales, milestone or royalty discrepancy. No other information shall be provided to the Auditing Party. The Audited Party shall receive a copy of each such report concurrently with receipt by the Auditing Party. Should such inspection lead to the
discovery of a discrepancy to the Auditing Party’s detriment, the Audited Party shall pay the amount of the discrepancy within *** after its receipt from the accounting firm of the certificate showing the amount of the discrepancy. The Auditing
Party shall pay the full cost of the review unless the underpayment of milestones, royalties and/or Development Costs, is greater than *** of the amount due for the applicable period, in which case the Audited Party shall pay the reasonable costs
charged by such accounting firm for such review. 
 ARTICLE 10 

OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS 
 10.1 Inventorship. Inventorship for patentable inventions conceived or reduced to practice during the course of the performance of activities pursuant to this Agreement shall be determined in
accordance with patent laws where the invention was invented. 
 10.2 Ownership. Subject to the licenses and rights
granted to Servier under this Agreement, MacroGenics shall own the entire right, title and interest in and to all inventions and 

  
 44 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
discoveries (and Patents claiming patentable inventions therein) first made or discovered solely by employees or consultants of MacroGenics or acquired solely by MacroGenics in the course of
Research, Development, Manufacture or Commercialization of Program Antibodies and/or Licensed Products. Subject to the licenses and rights granted to MacroGenics under this Agreement, Servier shall own the entire right, title and interest in and to
all inventions and discoveries (and Patents claiming patentable inventions therein) first made or discovered solely by employees or consultants of Servier or acquired solely by Servier in the course of Research, Development, Manufacture or
Commercialization of Program Antibodies and/or Licensed Product. The Parties shall jointly own any Joint IP. 
 10.3
Prosecution and Maintenance of Patents. 
 10.3.1 MacroGenics Patents. 

(a) MacroGenics shall have the sole right to, at MacroGenics’ discretion, file, prosecute, and maintain (including the defense of
any interference or opposition proceedings), all MacroGenics Patents. ***. MacroGenics shall provide to Servier copies of all prosecution filings related to MacroGenics Patents comprising claims Covering Program Antibodies and/or Licensed Products
(“MacroGenics Product Patents”) sent to or received from patent offices in the Servier Territory, unless otherwise directed by Servier, and, with respect to patent applications having information not previously filed that is
intended to be submitted to patent offices in the Servier Territory, shall provide Servier with a draft of each such filing within *** in advance of submission, provide Servier an opportunity to provide comments on and make request of
MacroGenics concerning such filings and shall consider in good faith any comments regarding such draft application that Servier may timely provide. In addition, MacroGenics shall provide to Servier such other information related to prosecution of
the MacroGenics Patents in the Servier Territory as Servier may from time to time reasonably request to allow Servier to track prosecution and maintenance of such Patents. If Servier no longer desires to retain its license under any MacroGenics
Patent in the Servier Territory, and desires to ***, it shall have the right to terminate such license to such Patent, and ***, upon *** written notice. Following such *** period, the Patent(s) referenced in such notice shall no longer
be deemed a MacroGenics Patent(s) and Servier shall have no rights hereunder with respect to such Patent. 
 (b) Subject to the
requirements and limitations of the MacroGenics Third Party Agreements, with respect to the filing, prosecution and maintenance of the MacroGenics IP, including any rights of, and time-frames for, such Third Party licensors to comment on and review
any filings and correspondence related thereto, in the event MacroGenics decides not to file a patent application on MacroGenics Know-How specific to Program Antibodies and/or Licensed Product in a country of the Servier Territory, or decides to
abandon prosecution of any claim of a MacroGenics Product Patent in a country of the Servier Territory or decides to not otherwise maintain or extend any MacroGenics Product Patent in a country of the Servier Territory, MacroGenics shall give
Servier written notice sufficiently in advance thereof. Unless MacroGenics’ discontinuation of filing, prosecution or maintenance of such MacroGenics Product Patent is in order to effect a settlement or to avoid an interference, opposition or
other 

  
 45 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
proceeding in which the validity of such MacroGenics Product Patent may be determined or because another MacroGenics Product Patent of similar claim scope is being prosecuted or has been issued,
Servier shall have the first right to file, prosecute, maintain and extend, as the case may be, such MacroGenics Product Patent, in Servier’s name, in such country. 
 10.3.2 Servier Collaboration Patents 
 (a) Servier shall have the sole
right to, at Servier’s discretion, file, prosecute, and maintain (including the defense of any interference or opposition proceedings), all Servier Collaboration Patents. MacroGenics shall reimburse Servier for the Out-of-Pocket Costs incurred
in the filing, prosecution and maintenance of the Servier Collaboration Patents in the MacroGenics Territory. Servier shall provide to MacroGenics copies of all prosecution filings related to Servier Collaboration Patents comprising claims Covering
Program Antibodies and/or Licensed Products (“Servier Product Patents”) sent to or received from patent offices in the MacroGenics Territory, unless otherwise directed by MacroGenics, and, with respect to patent applications having
information not previously filed that is intended to be submitted to patent offices in the MacroGenics Territory, shall provide MacroGenics with a draft of each such filing *** in advance of submission, provide MacroGenics an opportunity to
provide comments on and make request of Servier concerning such filings and shall consider in good faith any comments regarding such draft application that MacroGenics may timely provide. In addition, Servier shall provide to MacroGenics such other
information related to prosecution of the Servier Collaboration Patents in the MacroGenics Territory as MacroGenics may from time to time reasonably request to allow MacroGenics to track prosecution and maintenance of such Patents. If MacroGenics no
longer desires to retain its license under any Servier Collaboration Patent in the MacroGenics Territory, and desires to cease payment of the costs of prosecution and maintenance thereof, it shall have the right to terminate such license to such
Patent, and terminate reimbursement to Servier of such costs, upon *** written notice. 
 (b) In the event Servier
decides not to file a patent application on Servier Collaboration Know-How specific to Program Antibodies and/or Licensed Product, or decides to abandon prosecution of any claim of a Servier Product Patent or decides to not otherwise maintain or
extend any Servier Product Patent, Servier shall give MacroGenics written notice sufficiently in advance thereof. Unless Servier’s discontinuation of filing, prosecution or maintenance of such Servier Product Patent is in order to effect a
settlement or to avoid an interference, opposition or other proceeding in which the validity of such Servier Product Patent may be determined or because another Servier Product Patent of similar claim scope is being prosecuted or has been issued,
MacroGenics shall have the first right to file, prosecute and maintain or extend at its costs, as the case may be, such Servier Product Patent, in MacroGenics’ name, in such country. 

10.3.3 Joint IP. 
 (a) MacroGenics shall have the first right, at MacroGenics’ discretion, to file, prosecute, and maintain (including the defense of any interference or opposition proceedings), all Patents claiming
patentable inventions included in the Joint IP (“Joint Patents”) 

  
 46 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
in the MacroGenics Territory, in the names of both MacroGenics and Servier. Servier shall have the first right, at Servier’s discretion, to file, prosecute, and maintain (including the
defense of any interference or opposition proceedings), all Joint Patents in the Servier Territory, in the names of both MacroGenics and Servier. 
 (b) With respect to Joint Patents, if the Party with the responsibility for filing, prosecuting and maintaining such Patents in accordance with clause (a) above (the “Responsible
Party”) elects not to seek or continue to seek or maintain patent protection on any Joint Patent in its territory, the other Party shall have the right to seek, prosecute and maintain patent protection on such Joint Patent in the other
Party’s name and the Responsible Party shall assign its entire right, title and interest in such Joint Patent to the other Party. The Responsible Party shall use Commercially Reasonable Efforts to make available to the other Party its
authorized attorneys, agents or representatives, and to assist the other Party in obtaining and maintaining such patent protection. The Responsible Party shall sign or use Commercially Reasonable Efforts to have signed all legal documents necessary
to file and prosecute such patent applications or to obtain or maintain such patents. 
 (c) The Parties shall establish
procedures to coordinate the filing and prosecution of Joint Patent. With respect to Joint Patents, the Responsible Party shall provide the other Party, within *** after submitting or receiving such filings or correspondence, with copies of all
filings and correspondence submitted to and received from patent offices and, with respect to substantive filings and correspondence to be submitted to patent offices, shall use reasonable efforts to provide the other Party with drafts of such
filings and correspondence reasonably in advance of submission and shall consider in good faith any comments regarding such filings and correspondence that the other Party may timely provide. 

(d) Each Party shall be responsible for the costs and expenses it occurs in connection with the filing, prosecution and maintenance of
Joint Patents. 
 10.4 Third Party Infringement. 
 10.4.1 Notice. Each Party shall promptly report in writing to the other Party any known or suspected (i) infringement of any of the MacroGenics Patents, Servier Patents or Joint Patents,
(ii) unauthorized use or misappropriation of any of the MacroGenics Know-How, Servier Know-How or Joint Know-How of which such Party becomes aware, or (iii) notification under the Biologics Price Competition and Innovation Act of 2009, as
amended, or similar law, from a biosimilar applicant arising from the filing of an application for the Regulatory Approval of a Generic Product intending to show that the Generic Product is biosimilar to any Licensed Product that is a reference
product for which a claim of infringement of any of the MacroGenics Patents, Joint Patents or Servier Patents by the manufacture or sale of the Generic Product could reasonably be asserted, and shall provide the other Party with all available
evidence regarding such known or suspected infringement or unauthorized use. 
 10.4.2 Enforcement Rights. Subject to the
requirements and limitations of the MacroGenics Third Party Agreements with respect to the enforcement of Patents, including any 

  
 47 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
rights of, and timeframes for, such Third Party licensors to comment on and review any filings or materials related thereto, the Parties agree: 

(a) Servier shall have the first right, but not the obligation, to initiate a lawsuit or take other reasonable action to enforce the
Joint Patents and MacroGenics Product Patents in the Field in the Servier Territory to the extent such infringement or misappropriation involves the Development, Manufacture, use or Commercialization of a product or product candidate that is or may
be competitive with the Program Antibodies or Licensed Products being Developed or Commercialized hereunder. Notwithstanding the foregoing sentence, Servier shall not initiate any such lawsuit or other enforcement action asserting any such Joint
Patents or MacroGenics Product Patents without first consulting with MacroGenics and giving good faith consideration to any reasonable objection from MacroGenics regarding Servier’s proposed course of action. MacroGenics shall cooperate in the
prosecution of such suit as may be reasonably requested by Servier; provided that Servier shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by MacroGenics in connection with
such cooperation. In connection with any such proceeding, Servier shall not enter into any settlement admitting the invalidity of, or otherwise impairing MacroGenics’ rights in, MacroGenics IP or Joint IP without the prior written consent of
MacroGenics. Any recoveries resulting from such an action brought by Servier in accordance with this clause (a) shall be applied as follows: 
 (i) First, to reimburse each Party for all Out-of-Pocket Costs in connection with such proceeding (on a pro rata basis, based on each Party’s respective litigation costs, to the extent the recovery
was less than all such litigation costs); and 
 (ii) ***. 

(b) MacroGenics shall have the first right, but not the obligation, to initiate a lawsuit or take other reasonable action to enforce the
Joint Patents in the Field in the MacroGenics Territory. Notwithstanding the foregoing sentence, MacroGenics shall not initiate any such lawsuit or other enforcement action asserting any such Joint Patents without first consulting with Servier and
giving good faith consideration to any reasonable objection from Servier regarding MacroGenics’ proposed course of action. Servier shall cooperate in the prosecution of such suit as may be reasonably requested by MacroGenics; provided
that MacroGenics shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by Servier in connection with such cooperation. In connection with any such proceeding, MacroGenics shall not
enter into any settlement admitting the invalidity of, or otherwise impairing the Parties’ rights in Joint IP without the prior written consent of Servier. Any recoveries resulting from such an action brought by MacroGenics in accordance with
this clause (b) shall be applied as follows: 
 (i) First, to reimburse each Party for all Out-of-Pocket Costs in
connection with such proceeding (on a pro rata basis, based on each Party’s respective litigation costs, to the extent the recovery was less than all such litigation costs); and 

  
 48 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 (ii)***. 
 (c) If Servier does not initiate a lawsuit or take other reasonable action pursuant to Section 10.4.2(a) with respect to any Joint Patents or Servier Product Patents (i) if there is no time
limit for the filing of such action, within *** following the notice of alleged infringement or following a biosimilar applicant’s failure to act or (ii) if there is a time limit for the filing of such action (including those set
forth in applicable Laws) within at least *** before the time limit, then MacroGenics shall have the right (in cases where MacroGenics has standing), but not the obligation, to initiate such lawsuit or take such other action, after providing
*** notice to Servier and giving good faith consideration to Servier’s reason(s) for not initiating a lawsuit or taking other action. For this purpose, Servier shall cooperate in the prosecution of such suit as may be reasonably
requested by MacroGenics; provided that MacroGenics shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by Servier in connection with such cooperation. Any recoveries
resulting from such an action brought by MacroGenics in accordance with this clause (c) will be *** after payment of each Party’s costs and expenses. 
 (d) If MacroGenics does not initiate a lawsuit or take other reasonable action pursuant to Section 10.4.2(b) with respect to any Joint Patents (i) if there is no time limit for the filing of
such action, within *** following the notice of alleged infringement or following a biosimilar applicant’s failure to act or (ii) if there is a time limit for the filing of such action (including those set forth in applicable Laws)
within at least *** before the time limit, then Servier shall have the right (in cases where Servier has standing), but not the obligation, to initiate such lawsuit or take such other action, after providing *** notice to MacroGenics
and giving good faith consideration to MacroGenics’ reason(s) for not initiating a lawsuit or taking other action. For this purpose, MacroGenics shall cooperate in the prosecution of such suit as may be reasonably requested by Servier;
provided that Servier shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by MacroGenics in connection with such cooperation. Any recoveries resulting from such an action
brought by Servier in accordance with this clause (d) will be *** after payment of each Party’s costs and expenses. 

10.4.3 Conduct of Certain Actions; Costs. The Party initiating legal action shall have the sole and exclusive right to select
counsel for any suit initiated by it pursuant to Section 10.3.2 or 10.3.3 (the “Initiating Party”). Unless otherwise expressly provided, the Initiating Party shall bear its own out-of-pocket costs incurred in any such legal
action, including the fees and expenses of the counsel selected by it. The other Party shall have the right to participate and be represented in any such legal action (in cases where such other Party has standing) by its own counsel at its own
expense. 
 10.5 Patent Invalidity Claim. Each Party shall promptly notify the other in the event of any legal or
administrative action by any Third Party against a Joint Patent, MacroGenics Patent or Servier Patent of which it becomes aware, including any nullity, revocation, reexamination or compulsory license proceeding. Servier shall have the first right,
but not the obligation, at its expense, to defend against any such action relating to the Servier Patents. MacroGenics shall 

  
 49 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
have the first right, but not the obligation, at its expense, to defend against any such action relating to the MacroGenics Patents or the Joint Patents. If MacroGenics does not defend against
any such action involving a MacroGenics Product Patent or a Joint Patent, then Servier shall have the right, but not the obligation, to defend such action at Servier’s expense. 

10.6 Patent Term Extensions. The Parties shall cooperate with each other in obtaining patent term extensions or supplemental
protection certificates or their equivalents in any country, where applicable to Joint Patents, MacroGenics Patents and Servier Patents. 
 10.7 Patent Marking. Servier shall comply with the patent marking statutes in each country in which a Licensed Product is sold by Servier, its Affiliates and/or its Sublicensees. 

ARTICLE 11 

CONFIDENTIALITY 
 11.1 Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that the receiving Party (the “Receiving
Party”) shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any Know-How in any form (written, oral, photographic, electronic, magnetic, or otherwise) that
is disclosed to it by the other Party (the “Disclosing Party”) or otherwise received or accessed by a Receiving Party in the course of performing its obligations or exercising its rights under this Agreement (collectively,
“Confidential Information”), except to the extent that it can be established by the Receiving Party that such Confidential Information: 
 11.1.1 was in the lawful knowledge and possession of the Receiving Party prior to the time it was disclosed to, or learned by, the Receiving Party, or was otherwise developed independently by the
Receiving Party, as evidenced by written records kept in the ordinary course of business, or other documentary proof of actual use by the Receiving Party; 
 11.1.2 was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; 

11.1.3 became generally available to the public or otherwise part of the public domain after its disclosure and other than through any
act or omission of the Receiving Party in breach of this Agreement; or 
 11.1.4 was disclosed to the Receiving Party, other
than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others. 
 11.2 Authorized Disclosure. Except as expressly provided otherwise in this Agreement, a Receiving Party may use and disclose Confidential Information of the Disclosing Party as follows: 

11.2.1 under appropriate confidentiality provisions similar to those in this Agreement, in connection with the performance of its
obligations or exercise of rights granted or reserved in this Agreement; 

  
 50 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 11.2.2 to the extent such disclosure is reasonably necessary in filing or prosecuting patent
and copyright applications, prosecuting or defending litigation, complying with applicable governmental regulations (including the rules and regulations of any stock exchange or NASDAQ), conducting non-clinical activities and clinical activities,
preparing and submitting filings to Regulatory Authorities or is otherwise required by Law; provided, however, that if a Receiving Party is required by Law to make any such disclosure of a Disclosing Party’s Confidential
Information (other than a disclosure to a Regulatory Authority in a filing required by Law) it will give reasonable advance notice to the Disclosing Party of such disclosure requirement and shall furnish only that portion of the Disclosing
Party’s Confidential Information that the Receiving Party is legally required to furnish; 
 11.2.3 in communications with
existing or prospective acquirers, investors, consultants, advisors, licensees or collaborators or others on a need to know basis, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement; or

 11.2.4 to the extent mutually agreed to in writing by the Parties. 

11.3 Press Release; Disclosure of Agreement. 
 11.3.1 On or promptly after the Effective Date, the Parties shall jointly issue a public announcement of the execution of this Agreement in the form attached hereto as Exhibit D. Neither Party
shall issue any subsequent press release or make other disclosures regarding this Agreement or the Parties’ activities hereunder, or any results or data arising hereunder, except (a) with the other Party’s prior written consent;
(b) in accordance with Section 11.6; or (c) for any disclosure that is reasonably necessary to comply with applicable securities exchange listing requirements or other applicable Laws. Notwithstanding the foregoing, to the extent
information regarding this Agreement has already been publicly disclosed, either Party may subsequently disclose the same information to the public without the consent of the other Party. Each Party shall be permitted to disclose the terms of this
Agreement, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement, to any actual or potential acquirers, merger partners, licensees, sublicensees, investors and professional advisors on a need
to know basis. 
 11.3.2 Each Party shall, if practicable, give the other Party a reasonable opportunity to review those
portions of all filings with the United States Securities and Exchange Commission (or any stock exchange, including Nasdaq, or any similar regulatory agency in any country other than the United States) describing the terms of this Agreement
(including any filings of this Agreement) prior to submission of such filings, and shall give due consideration to any reasonable comments by the non-filing Party relating to such filing, including the provisions of this Agreement for which
confidential treatment should be sought. 

  
 51 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 11.4 Existing Confidentiality Agreement. For the avoidance of doubt, any information
disclosed by MacroGenics to Servier prior to the Effective Date pursuant to the Non-Disclosure Disclosure Agreement between MacroGenics and Servier dated *** (the “Existing Confidentiality Agreement”) shall be treated as
Confidential Information for all purposes under this Agreement. 
 11.5 Remedies. In the event a Party breaches the
confidentiality obligations set forth in this ARTICLE 11, the other Party shall be entitled to seek, in addition to any other right or remedy it may have, at Law or in equity, a temporary injunction, without the posting of any bond or other
security, enjoining or restraining the breaching Party from any violation or threatened violation of this ARTICLE 11. 
 11.6
Publications. Neither Party nor its Affiliates shall publish or publicly disclose the results of any of the Research or Development activities conducted by either Party under this Agreement without the prior written consent of the other
Party, except as expressly permitted in this Section 11.6 or otherwise in this Agreement. The Parties recognize that it may be useful or required to publish or publicly disclose the results of Research and Development work on Program Antibodies
and Licensed Products, and each Party (and its Affiliates) shall be free to publish or publicly disclose such results, subject to the prior review by the other Party for patentability and protection of its Confidential Information as described in
this Section 11.6. The Party that desires to publish results hereunder shall provide the other Party with a copy of such proposed abstract, manuscript, or presentation no less than *** prior to its intended submission for publication.
The reviewing Party shall respond in writing promptly and in no event later than *** after receipt of the proposed material, with one or more of the following: (a) comments on the proposed material, which the publishing Party shall
consider in good faith, (b) a specific statement of concern, based upon the need to seek patent protection, or (c) an identification of the reviewing Party’s Confidential Information that is contained in the material reviewed. In the
event of concern over patent protection, the publishing Party agrees not to submit such publication or to make such presentation that contains such information until the reviewing Party is given a reasonable period of time, and in no event less than
***, to seek patent protection for any material in such publication or presentation which it believes is patentable. Any Confidential Information of the reviewing Party shall, if requested by the reviewing Party, be removed by the other
Party. 
 11.7 Return of Confidential Information. Upon the expiration or termination of this Agreement, the Receiving
Party shall return to the Disclosing Party all Confidential Information received by the Receiving Party from the Disclosing Party (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy: (a) any notes, reports
or other documents prepared by the Receiving Party which contain Confidential Information of the Disclosing Party; and (b) any Confidential Information of the Disclosing Party (and all copies and reproductions thereof) which is in electronic
form or cannot otherwise be returned to the Disclosing Party. Alternatively, upon written request of the Disclosing Party, the Receiving Party shall destroy all Confidential Information received by the Receiving Party from the Disclosing Party (and
all copies and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party which contain Confidential Information of the 

  
 52 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
Disclosing Party. Nothing in this Section 11.7 shall require the alteration, modification, deletion or destruction of archival tapes or other electronic back-up media made in the ordinary
course of business; provided that the Receiving Party shall continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE 11 with respect to any Confidential Information contained in such archival tapes or other
electronic back-up media. Any requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such destruction. Notwithstanding the foregoing,
(i) the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s Confidential Information solely for the purpose of determining the Receiving Party’s continuing obligations under this ARTICLE 11 and
(ii) the Receiving Party may retain the Disclosing Party’s Confidential Information and its own notes, reports and other documents (A) to the extent reasonably required (i) to comply with applicable Law and regulatory
requirements; (ii) to exercise the rights and licenses of the Receiving Party expressly surviving expiration or termination of this Agreement; and (iii) to perform the obligations of the Receiving Party expressly surviving expiration or
termination of this Agreement; or (B) to the extent it is impracticable to do so without incurring disproportionate cost. Notwithstanding the return or destruction of the Disclosing Party’s Confidential Information, the Receiving Party
shall continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE 11. 
 ARTICLE 12

 REPRESENTATIONS AND WARRANTIES 
 12.1 Representations and Warranties of Both Parties. Each Party hereby represents and warrants to the other Party, as of the Effective Date, that: 

12.1.1 such Party is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and
has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; 
 12.1.2 such Party
has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; 
 12.1.3 this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with the terms hereof;

 12.1.4 the execution, delivery and performance of this Agreement by such Party does not conflict with any agreement or any
provision thereof, or any instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Law of any court, governmental body or administrative or other agency having jurisdiction over such Party; and

 12.1.5 no government authorization, consent, approval, license, exemption of or filing or registration with any court or
governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Laws currently in effect, is 

  
 53 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
or will be necessary for, or in connection with, the transaction contemplated by this Agreement, or for the performance by it of its obligations under this Agreement, except as necessary to
conduct clinical trials or to seek or obtain Regulatory Approvals. 
 12.2 Representations and Warranties of MacroGenics and
its Affiliates. ***, MacroGenics and its Affiliates hereby represent and warrant to Servier that: 
 12.2.1 As of the
Effective Date, MacroGenics is the owner of, or has Control via a license to, the MacroGenics Patents listed on Exhibit B; 
 12.2.2 There are not as of the Effective Date, nor have there been over the *** period immediately preceding the Effective Date, any claims, lawsuits, arbitrations, legal or administrative or regulatory
proceedings, charges, complaints or investigations by any Government Authority (except in the ordinary administrative course of the granting of patents and proceedings relating thereto) or by any Third Party relating to the MacroGenics Patents or
MacroGenics Know-How; 
 12.2.3 As of the Effective Date, to MacroGenics’ and its Affiliates knowledge, the exercise by
Servier of the rights and licenses granted to Servier by MacroGenics under this Agreement shall not infringe any rights owned or controlled by any Third Party in the Servier Territory; 

12.2.4 As to the Effective Date, to MacroGenics’ and its Affiliates knowledge *** it has not (i) employed and has not used a
contractor or consultant that has employed, any individual or entity debarred by the FDA (or subject to a similar sanction of EMA), or, (ii) employed any individual who or entity that is the subject of an FDA debarment investigation or
proceeding (or similar proceeding of EMA), in the conduct of any pre-clinical activities or clinical studies of Program Antibodies; 
 12.2.5 As to the Effective Date, MacroGenics has the right to grant all rights and licenses it purports to grant to Servier with respect to the MacroGenics IP under this Agreement and it has not granted
any license, right or interest in, to or under MacroGenics IP to any Third Party that is inconsistent with the licenses and rights granted to Servier under Section 4.1; 
 12.2.6 As of the Effective Date, to MacroGenics and its Affiliates’ knowledge the MacroGenics IP are all of the Patents and Know-How Controlled by MacroGenics or its Affiliates which are reasonably
necessary for the Development, Manufacture, Commercialization of the Program Antibody and/or Licensed Products in the Field in the Servier Territory; 
 12.2.7 To MacroGenics knowledge, the Research and Development of the Program Antibody and the Licensed Product prior to the Effective Date by or on behalf of MacroGenics has been carried out without
infringing any Patent owned or controlled by a Third Party; 

  
 54 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 12.2.8 As of the Effective Date, to MacroGenics’ knowledge, there are no activities by
Third Party that would constitute infringement or misappropriation of the MacroGenics IP; 
 12.2.9 As of the Effective Date, to
MacroGenics’ knowledge, there is no reason for MacroGenics or a count of competent jurisdiction to reasonably conclude that the MacroGenics Patents are invalid or unenforceable. To MacroGenics’ knowledge, the claims included in any issued
MacroGenics Patent are valid and in full force and effect. All fees required to be paid to the governmental authorities prior to the Effective Date to prosecute or maintain the MacroGenics Patent in the Servier Territory have been filed and have
been paid; 
 12.2.10 MacroGenics has maintained prior to the Effective Date and, unless agreed to otherwise by Servier and
except as provided in this Agreement, during the Agreement Term will maintain and keep in full force and effect all agreements and filings (including Patent filings) necessary to perform its obligations hereunder; and 

12.2.11 As of the Effective Date, to MacroGenics and its Affiliates’ knowledge, all material Safety Data arising from the Initial
Phase 1 Clinical Trial has been provided to Servier. 
 12.3 Representation and Warranty of LLS. LLS hereby represents
and warrants to MacroGenics that IdRS is an Affiliate of LLS. 
 12.4 Mutual Covenants. Each Party hereby covenants to
the other Party that: 
 12.4.1 Such Party shall comply with all applicable Laws in connection with this Agreement and the
transactions contemplated hereby. 
 12.4.2 All employees of such Party or its Affiliates working under this Agreement will be
under the obligation to assign all right, title and interest in and to their inventions and discoveries, whether or not patentable, to such Party as the sole owner thereof; 
 12.4.3 To its knowledge *** such Party will not (a) employ or use any contractor or consultant that employs, any individual or entity debarred by the FDA (or subject to a similar sanction of EMA) or,
(b) employ any individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA), in each of clauses (a) and (b) in the conduct of its activities under this Agreement;

 12.4.4 Such Party shall perform its activities pursuant to this Agreement in compliance in all material respects with GLP,
GCP and cGMP (including those specified by the ICH), in each case as applicable; and 
 12.4.5 Neither Party shall, during the
Agreement Term grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted or to be granted to the other Party hereunder
pursuant to the provisions of ARTICLE 4. 

  
 55 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 12.5 Disclaimer. Except as otherwise expressly set forth in this Agreement, NEITHER
PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing except as otherwise expressly set forth in this Agreement, each Party disclaims any warranties with regards to: (a) the success of any study or test
commenced under this Agreement, (b) the safety or usefulness for any purpose of the technology or materials, including any compounds, it provides or discovers under this Agreement; or (c) the validity, enforceability, or non-infringement
of any intellectual property rights or technology it provides or licenses to the other Party under this Agreement. 
 ARTICLE
13 
 INDEMNIFICATION 
 13.1 Indemnification by Servier. Servier shall defend, indemnify and hold harmless the MacroGenics Indemnitees from and against any and all losses, damages, fees, expenses, settlement amounts or
costs (including reasonable attorneys’ fees and witness fees) (“Losses”) relating to or in connection with a Third Party claim in the Servier Territory arising out of (a) any actual death, personal bodily injury or damage
to real or tangible personal property proven to result, directly or indirectly, from the possession, use or consumption of, or treatment with, a Program Antibody or Licensed Product Researched, Developed, Manufactured or Commercialized in the
Servier Territory by or on behalf of Servier or its Affiliates or Sublicensees, including any product liability claims; (b) any breach by Servier of its representations, warranties or covenants made under this Agreement; or (c) any
negligent act or omission or willful misconduct of Servier or its Affiliates or Sublicensees or any of their employees, contractors or agents, in performing Servier’s obligations or exercising Servier’s rights under this Agreement;
provided, however, that the foregoing indemnity shall not apply to the extent that any such Losses (i) are attributable to the gross negligence or willful misconduct of the MacroGenics Indemnitees, or (ii) are otherwise
subject to an obligation by MacroGenics to indemnify the Servier Indemnitees under Section 13.2. For purposes of clarity, notwithstanding anything to the contrary in this Agreement, Servier shall not be liable for any Losses resulting from any
claim in the MacroGenics Territory that results from any acts or omissions of MacroGenics, its Affiliates or Sublicensees, even if Servier had knowledge of, reviewed, commented on, or approved such acts or omissions of MacroGenics’ or its
Affiliates’ or Sublicensees’ plans with respect thereto. 
 13.2 Indemnification by MacroGenics. MacroGenics
shall defend, indemnify and hold harmless the Servier Indemnitees from and against any and all Losses relating to or in connection with a Third Party claim in the MacroGenics Territory arising out of (a) any actual death, personal bodily injury
or damage to real or tangible personal property proven to result, directly 

  
 56 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
or indirectly, from the possession, use or consumption of, or treatment with, a Program Antibody or Licensed Product Researched, Developed, Manufactured or Commercialized in the MacroGenics
Territory by or on behalf of MacroGenics or its Affiliates or Sublicensees, including any product liability claims; (b) any breach by MacroGenics of its representations, warranties or covenants made under this Agreement; or (c) any
negligent act or omission or willful misconduct of MacroGenics or its Affiliates or Sublicenses or any of their employees, contractors or agents, in performing MacroGenics’ obligations or exercising MacroGenics’ rights under this
Agreement; provided, however, that the foregoing indemnity shall not apply to the extent that any such Losses are attributable to (i) the gross negligence or willful misconduct of the Servier Indemnitees, or (ii) are
otherwise subject to an obligation by Servier to indemnify the MacroGenics Indemnitees under Section 13.1. For purposes of clarity, notwithstanding anything to the contrary in this Agreement, MacroGenics shall not be liable for any Losses
resulting from any claim in the Servier Territory that results from any acts or omissions of Servier, its Affiliates or Sublicensees, even if MacroGenics had knowledge of, reviewed, commented on, or approved such acts or omissions of Servier’s
or its Affiliates’ or Sublicensees’ plans with respect thereto. 
 13.3 Procedure. In the event of a claim by a
Third Party against any Person entitled to indemnification under this Agreement, the Party claiming indemnification (in such capacity, the “Indemnified Party”) shall promptly notify the other Party (in such capacity, the
“Indemnifying Party”) in writing of the claim (it being understood that the failure by the Indemnified Party to give prompt notice of a Third Party claim as provided in this Section 13.3 shall not relieve the Indemnifying Party
of its indemnification obligation under this Agreement except and only to the extent that such Indemnifying Party is actually prejudiced as a result of such failure to give prompt notice). Within *** after delivery of such notification, the
Indemnifying Party may, upon written notice thereof to the Indemnified Party, undertake and solely manage and control, at its sole expense and with counsel reasonably satisfactory to the Indemnified Party, the defense of the claim. If the
Indemnifying Party does not undertake such defense, the Indemnified Party shall control such defense. The Party not controlling such defense shall cooperate with the other Party and may, at its option and expense, participate in such defense with
counsel of its choice; provided, that, if the Indemnifying Party assumes control of such defense and the Indemnified Party in good faith concludes, based on advice from counsel, that the Indemnifying Party and the Indemnified Party (or the
relevant MacroGenics Indemnitee or Servier Indemnitee seeking indemnification) have conflicting interests with respect to such action, suit, proceeding or claim, the Indemnified Party’s counsels may fully participate in such defense and the
Indemnifying Party shall be responsible for the reasonable fees and expenses of one counsel to the indemnified Persons solely in connection therewith. The Party controlling such defense shall keep the other Party advised of the status of such
action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the other Party with respect thereto. Except if the Indemnifying Party did not undertake defense of the claim or if the Indemnifying Party and the
Indemnified Party (or the relevant MacroGenics Indemnitee or Servier Indemnitee seeking indemnification) have conflicting interests with respect to such action, suit, proceeding or claim and the Indemnified Party engages separate counsel, as
provided above, the Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The Indemnified Party shall not settle any such action, suit,
proceeding or claim without the prior written consent of the Indemnifying Party, which shall 

  
 57 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
not be unreasonably withheld, delayed or conditioned. The Indemnifying Party shall not settle, without the prior written consent of the Indemnified Party, any such action, suit, proceeding or
claim, or consent to any judgment in respect thereof, that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto, that imposes any liability or obligation on the Indemnified Party or
that acknowledges fault by the Indemnified Party. 
 13.4 Allocation. In the event a claim is based partially on an
indemnified claim and partially on a non-indemnified claim or based partially on a claim indemnified by one Party and partially on a claim indemnified by the other Party, any payments in connection with such claims are to be apportioned between the
Parties in accordance with the degree of cause attributable to each Party. 
 13.5 EXCLUSION OF CONSEQUENTIAL DAMAGES.
EXCEPT WITH RESPECT TO A BREACH OF ARTICLE 11 OR THIRD PARTY CLAIMS THAT ARE SUBJECT TO INDEMNIFICATION UNDER THIS ARTICLE 13, NEITHER MACROGENICS NOR SERVIER, NOR ANY OF THEIR RESPECTIVE AFFILIATES, WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL,
CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER SUCH PARTY OR ANY REPRESENTATIVE OF SUCH PARTY
HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. 
 ARTICLE 14

 TERM AND TERMINATION 
 14.1 Agreement Term; Expiration. This Agreement shall become effective as of the Effective Date, and, in the event Servier does not exercise the Option by the end of the Option Period, shall expire
at the end of the Option Period, unless earlier terminated in accordance with this ARTICLE 14. In the event Servier exercises the Option in accordance with Section 3.3, this Agreement shall continue in full force until the last to expire
Royalty Term for a Licensed Product in the Servier Territory. After the last to expire Royalty Term for a Licensed Product in a country in the Servier Territory, Servier shall be granted a fully paid-up non-exclusive license to use MacroGenics
Know-How to Manufacture and Commercialize such Licensed Product in the Field in such country in the Servier Territory. 
 14.2
Termination for Cause. Either Party (the “Non-Breaching Party”) may, without prejudice to any other remedies available to it under applicable Law or in equity, terminate this Agreement if the other Party (the
“Breaching Party”) shall have materially breached or defaulted in the performance of its obligations hereunder, and such default shall have continued for *** after written notice thereof was provided to the Breaching Party by
the Non-Breaching Party, such notice describing the alleged breach. Any such termination of this Agreement under this Section 14.2 shall become effective at the end of such *** cure period, unless the Breaching Party has cured such
breach or default prior to the expiration of such cure period provided 

  
 58 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
however that if the Breaching Party notifies the Non-Breaching Party within such *** period that the Breaching Party disagrees in good faith with such asserted basis for termination, this
Agreement shall not terminate unless and until the matter has been finally resolved in accordance with section 16.2 “Arbitration” and the arbitration award rendered in accordance with section 16.2 specify that the Non-Breaching Party shall
have the right to terminate this Agreement based on such asserted Breach. The right of either Party to terminate this Agreement as provided in this Section 14.2 shall not be affected in any way by such Party’s waiver or failure to take
action with respect to any previous default. 
 14.3 Termination for Patent Challenge. If either Party or any of its
Affiliates or Sublicensees: (a) commences or otherwise voluntarily determines to participate in any action or proceeding (including any patent opposition or re-examination proceeding), challenging or denying the validity of any of the other
Party’s Patents or Joint Patents licensed hereunder or any claim thereof, or (b) actively assists any other Person in bringing or prosecuting any action or proceeding (including any patent opposition or re-examination proceeding)
challenging or denying the validity of any of such Patents or any claim thereof, the non-challenging Party shall have the right to terminate this Agreement upon *** written notice to the other Party. Any such termination shall only become
effective if the challenging Party or its Affiliate or Sublicensee, as applicable, has not withdrawn such action before the end of the above notice period. 
 14.4 Termination for Convenience. 
 14.4.1 During the Research Term.
***, Servier shall have the right to terminate this Agreement in its entirety upon not less than *** prior written notice thereof to MacroGenics. 
 14.4.2 During the License Term. At any time during the License Term, Servier shall have the right to terminate this Agreement in its entirety or on a country-by-country basis upon not less than
*** prior written notice thereof to MacroGenics. 
 14.5 Termination for Insolvency Event: Either Party may
terminate this Agreement upon written notice to the other Party if the other Party suffers an Insolvency Event. 
 14.6
Termination by Servier for Safety or Public Health Reasons. If Servier reasonably determines that a safety or public health issue has arisen which (a) is demonstrated by clinically relevant events which are documented and
(b) relates to a Program Antibody or a Licensed Product, such that the medical risk/benefit of such Program Antibody of Licensed Product is sufficiently unfavorable as to be incompatible with the welfare of patients to Develop or Commercialize
or to continue to Develop or Commercialize such Program Antibody or Licensed Product, Servier shall immediately notify MacroGenics, and Servier shall be permitted to terminate this Agreement in its entirety upon written notice to MacroGenics, but in
any event within *** of Servier’s determination of such issue. 
 14.7 Effect of Expiration or Termination.

 14.7.1 Upon termination of this Agreement by MacroGenics in whole or with respect to one or more Terminated Territories
pursuant to Sections 14.2, 14.3, or 14.5 or by 

  
 59 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
Servier in whole or with respect to one or more Terminated Territories pursuant to Sections 14.4 or 14.6: 
 (a) all rights, licenses and options granted by MacroGenics to Servier with respect to each Terminated Territories hereunder shall terminate and Servier shall not have any rights to use or exercise any
rights under the MacroGenics IP with respect to any Terminated Territory; 
 (b) if such termination occurs during the Research
Term, (i) Servier shall Complete any ongoing Clinical Studies for Licensed Product in the Servier Territory where such completion is required by any applicable Law, requested by any Regulatory Authority or would be dictated by any applicable
Institutional Review Board with oversight of such Clinical Study in the Servier Territory; and (ii) Servier shall promptly transfer and assign to MacroGenics all Supplemental Data and ***; and 

(c) if such termination occurs during the License Term: 
 (i) Servier shall provide to MacroGenics a fair and accurate detailed written description of the status of the Development and Commercialization of the Program Antibodies and Licensed Products in each
Terminated Territory through the effective date of termination within *** of such termination; 
 (ii) the licenses granted to
MacroGenics pursuant to Section 4.2 shall remain in effect and shall become irrevocable; 
 (iii) Servier hereby grants to
MacroGenics, effective upon the request of MacroGenics, ***. 
 (iv) In the event that MacroGenics requests a license under
clause (iii) above and Servier has previously Completed a Phase 3 Clinical Trial for a Licensed Product in the Terminated Territory before the effective date of termination, MacroGenics shall ***; 

(v) Servier shall promptly transfer and assign to MacroGenics all Regulatory Documentation and other technical and other information or
materials in Servier’s or its Affiliates’ possession or control which are necessary or useful for the Research, Development or Commercialization of the Program Antibodies or Licensed Products in each Terminated Territory or, if no country
remains in the Servier Territory, anywhere in the world; provided, that Servier may retain a single copy of such items for its records; 
 (vi) Promptly upon request by MacroGenics, but in no event commencing later than *** after the effective date of termination or continuing for more than *** (except to the extent that requirements of a
Regulatory Authority necessitate a longer period), Servier shall provide such assistance to MacroGenics as may be reasonably necessary or useful for MacroGenics to commence or continue Developing, Manufacturing or Commercializing Licensed Products
in the Terminated Territory, to the extent Servier is then 

  
 60 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
performing or having performed such activities, including transferring or amending as appropriate, upon request of MacroGenics, any agreements or arrangements with Third Party vendors to Develop,
Manufacture or Commercialize Licensed Products in such Terminated Territory. To the extent that any such contract between Servier and a Third Party is not assignable to MacroGenics, Servier shall reasonably cooperate with MacroGenics to arrange
to continue to provide such services for a reasonable time after termination, not exceeding ***. Within *** after MacroGenics’ receipt of a proper invoice therefor, MacroGenics shall reimburse Servier for Servier’s and its Affiliates’
reasonable Out-of-Pocket Costs incurred in connection with any technology transfer conducted pursuant to this clause (vi); and 

(vii) in the event this Agreement is terminated pursuant to Section 14.6, Servier shall reasonably cooperate with MacroGenics to
either (A) wind down any ongoing Global Clinical Trial conducted under a Global Development Plan previously approved by Servier or (B) which is conducted by Servier in the Servier Territory for the Licensed Product, and/or diligently
perform any follow-up of a clinical trial initiated in Servier Territory requested by any Regulatory Authority or dictated by any applicable Institutional Review Board. *** the activities mentioned in (A) above and *** shall entirely fund the
activities mentioned in (B) above. Servier and Servier’s Affiliates shall provide MacroGenics written notice of the quantity of Licensed Product that Servier has in inventory for sale in each Terminated Territory and permit MacroGenics, at
MacroGenics’ option, to purchase all or any part of Servier’s worldwide unsold inventory of such Licensed Product ***. 
 14.7.2 Upon termination of this Agreement by Servier pursuant to sections 14.2 or 14.3: 
 (a) all rights, licenses and options granted to Servier, its Affiliates or Sublicensees pursuant to this Agreement shall remain in effect; 

(b) all payment obligations under ARTICLE 8 shall remain in effect; and 

(c) all licenses granted by Servier, its Affiliates or Sublicensees pursuant to this Agreement, including pursuant to section 4.2, shall
terminate. 
 14.8 Accrued Rights; Surviving Provisions of the Agreement. 

14.8.1 Accrued Rights. Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that
shall have accrued to the benefit of any Party prior to such termination or expiration including the payment obligations under ARTICLE 9 hereof, and any and all damages or remedies arising from any breach hereunder. Such termination or expiration
shall not relieve any Party from obligations which are expressly indicated to survive termination of this Agreement. 
 14.8.2
Surviving Provisions of the Agreement. The provisions of Sections 3.3.3(c), 6.1.2, 9.6-9.9 (with regard to accrued but unpaid amounts), 9.10, 10.3.3, 12.5, 14.7 and 14.8 and ARTICLE 13 and ARTICLE 16, and any applicable definitions in ARTICLE
1, shall 

  
 61 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
survive the termination of this Agreement in its entirety or expiration of this Agreement for any reason, in accordance with their respective terms and conditions, and for the duration stated,
and where no duration is stated, shall survive indefinitely. ARTICLE 11 shall survive for a period of *** after the effective date of termination or expiration of this Agreement. 

ARTICLE 15 

STANDSTILL 

ARTICLE 16 

MISCELLANEOUS 
 16.1 Disputes. 
 16.1.1 In the event any dispute arises out of or in
relation to or in connection with this Agreement, including failure to perform under or breach of, this Agreement or any issue relating to the interpretation or application of this Agreement, the Parties shall use good faith efforts to resolve such
dispute within *** after a Party notifies the other Party of such dispute, whether through the JEC, JSC, JRDC or any subcommittee, as applicable, if the dispute is within the responsibilities of such a committee, or otherwise. If the Parties are
unable to resolve such dispute, at the JSC, JRDC or subcommittee level or otherwise, within such *** period, either Party may, by written notice to the other Party refer such dispute to the JEC for resolution, and the JEC shall attempt in good faith
to resolve such dispute within *** after such notice. 
 16.1.2 Any dispute with respect to which a Party has final
decision-making authority pursuant to Section 2.9.3 or any dispute between the Parties concerning the validity, scope, enforceability, inventorship, or ownership of intellectual property rights (each, a “Non-Arbitrable
Dispute”), shall not be subject to resolution by binding arbitration under 16.2. 
 16.2 Arbitration. If the JEC
is unable to resolve a given dispute referred to it pursuant to Section 2.9.3(b) or 16.1 within *** following such referral of such dispute to the JEC, except for any Non-Arbitrable Disputes, either Party may have the given dispute
settled by binding arbitration in the manner described below: 
 16.2.1 Arbitration Request. If a Party intends to begin
an arbitration to resolve a dispute arising under this Agreement, such Party shall provide written notice (the “Arbitration Request”) to the other Party of such intention and the issues for resolution. 

16.2.2 Additional Issues. Within *** after the receipt of the Arbitration Request, the other Party may, by written notice,
add additional issues for resolution. 
 16.2.3 Arbitration Rules; Location. Except as expressly provided herein, the
sole mechanism for resolution of any claim, dispute or controversy arising out of or in connection with or relating to this Agreement or the breach or alleged breach thereof shall be arbitration by the *** then in effect except as provided
herein. Neither Party shall be required to give general discovery of documents, but may be required to produce documents or testimony 

  
 62 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
which are considered relevant by the arbitrators to the dispute. The production of electronic documents shall be limited to those located in sources that are used in the ordinary course of
business. Neither Party shall be ordered to restore backup tapes; erased, damaged or fragmented data, or data normally deleted in the ordinary course of business. When the cost and burden of discovery are disproportionate to the likely importance of
the requested materials, the arbitrator may deny the requests or require that the requesting party advance the reasonable cost of production to the other Party. The Parties can further agree to limit the extent of discovery in any arbitration
undertaken pursuant to this Agreement. The arbitration shall take place in ***. 
 16.2.4 Privileges. If a Party is
entitled to attorney-client or attorney work product privileges from disclosure established under public policy provisions, such privileges shall apply and may be invoked by the other Party. 

16.2.5 English Language. All proceedings shall be held in English and a transcribed record prepared in English. Documents
submitted in the arbitration (the originals of which are not in English) shall be submitted together with a reasonably complete and accurate English translation. 
 16.2.6 Selection of Arbitrators. The Parties shall each choose one arbitrator within *** after receipt of notice of the intent to arbitrate and the said two arbitrators shall select by
mutual agreement a third arbitrator within *** after they have been selected as arbitrators. If no arbitrator is appointed within the times herein provided or any extension of time that is mutually agreed on, *** shall make such
appointment (i.e. shall appoint three arbitrators) within *** after such failure. Additionally, if the two arbitrators selected by the Parties fail to appoint a third arbitrator within the time provided, *** shall appoint the third
arbitrator. 
 16.2.7 Experience. If the issues in dispute involve scientific or technical matters, any arbitrators
chosen hereunder shall have educational training or experience sufficient to demonstrate a reasonable level of knowledge in the pharmaceutical and biotechnology fields. 
 16.2.8 Powers of Arbitrators. The arbitrators shall be limited in the scope of their authority to resolving only the specific matter which the Parties have referred to arbitration for resolution
and shall not have authority to render any decision or award on any other issues. Without limiting the foregoing, the arbitrators: 
 (a) shall not have any power or authority to add to, alter, amend or modify the terms of this Agreement but shall specify rules sufficient to allow reasonable discovery by the Parties; 

(b) shall establish and enforce appropriate rules to ensure that the proceedings, including the decision, be kept confidential and that
all Confidential Information of the Parties be kept confidential and be used for no purpose other than the arbitration; and 

(c) shall issue all preliminary awards and the final award in writing. 

  
 63 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 16.2.9 Injunctive Relief. Nothing in this Agreement shall be deemed as preventing
either Party from seeking injunctive relief (or any other provisional remedy such as temporary restraining order, preliminary injunction or other interim equitable relief) from the arbitrators or from any court having jurisdiction over the Parties
(and prior to or during any arbitration if necessary to protect the interests of such Party in avoiding irreparable harm or to preserve the status quo pending the arbitration proceeding) and the subject matter of the dispute as necessary to protect
either Party’s name, proprietary information, Know-How or any other proprietary right or otherwise to avoid irreparable harm. 
 16.2.10 Costs; Exclusion from Award. The award rendered by the arbitrators ***. 
 16.2.11 Survivability. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after termination of this Agreement. 

16.3 Governing Law. This Agreement and any dispute arising from the performance or breach hereof shall be governed by and
construed and enforced in accordance with the *** without reference to conflicts of laws principles. *** 
 16.4
Assignment. Neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred by any Party without the consent of the other Party; provided, however, that any Party may, without such consent,
assign this Agreement, in whole or in part: (a) to any of its respective Affiliates; provided that the assigning Party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned, or
(b) to any successor in interest by way of merger, acquisition or sale of all or substantially all of its assets to which this Agreement relates (an “M&A Event”); provided that such successor agrees in writing to be
bound by the terms of this Agreement as if it were the assigning party. Any assignment not in accordance with this Section 16.4 shall be void. Each Party agrees that, notwithstanding any provisions of this Agreement to the contrary, if this
Agreement is assigned by a Party in connection with an M&A Event, such assignment shall not provide the non-assigning Party with rights or access to any intellectual property or technology of the acquirer of the assigning Party. ***. 

16.5 Force Majeure. No Party shall be held liable or responsible to the other Party nor be deemed to be in default under, or in
breach of any provision of, this Agreement for failure or delay in fulfilling or performing any obligation (other than a payment obligation) of this Agreement when such failure or delay is due to force majeure, and without the fault or negligence of
the Party so failing or delaying. For purposes of this Agreement, force majeure is defined as causes beyond the control of the Party, including acts of God; war; civil commotion; destruction of production facilities or materials by fire, flood,
earthquake, explosion or storm; external labor disturbances; epidemic; and failure of public utilities or common carriers. In such event MacroGenics or Servier, as the case may be, shall immediately notify the other Party of such inability and of
the period for which such inability is expected to continue. The Party giving such notice shall thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled for up
to a maximum of 

  
 64 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 
***, after which time MacroGenics and Servier shall promptly meet to discuss in good faith how to best proceed in a manner that maintains and abides by this Agreement. To the extent possible,
each Party shall use reasonable efforts to minimize the duration of any force majeure. If a force majeure event prevents a Party from performing any of its Development obligations for a Global Clinical Trial or Manufacturing obligations hereunder
that would delay the Development or Manufacture of Licensed Product in the non-affected Party’s Territory, then, if the Parties can not agree on how to best proceed following such discussions, then, notwithstanding the exclusive license grants
hereunder, the Party not affected by the force majeure event shall be permitted to either perform directly or engage a Third Party clinical research organization or contract manufacturing organization to perform such Development and/or Manufacturing
obligations for the duration of such force majeure event. 
 16.6 Notices. Any notice or request required or permitted to
be given under or in connection with this Agreement shall be deemed to have been sufficiently given if in writing and personally delivered or sent by certified mail (return receipt requested), facsimile transmission (receipt verified), or reputable
international business courier (signature required), prepaid, to the Party for which such notice is intended, at the address set forth for such Party below: 
 If to MacroGenics, 
 addressed to: 

 

					
		  	Prior to December 1, 2011:	  	After December 1, 2011:
		  	MacroGenics, Inc.	  	MacroGenics, Inc.
		  	1500 East Gude Drive	  	9640 Medical Center Drive
		  	Rockville, MD 20850	  	Rockville, MD 20850
		  	Attention: Chief Executive Officer	  	Attention: Chief Executive Officer
		  	Facsimile: ***	  	Facsimile: ***

 with a copy to: 

Wilmer Cutler Pickering Hale and Dorr LLP 
 399
Park Avenue 
 New York, NY 10022 

Attention: *** 
 Facsimile:
*** 
 If to Servier, 
 addressed
to: 
 Les Laboratoires Servier 
 50 rue
Carnot 

  
 65 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 92284 Suresnes Cedex 

France 

Attention: *** 
 Facsimile: *** 
 or to such other address for such Party as it shall
have specified by like notice to the other Parties, provided that notices of a change of address shall be effective only upon receipt thereof. The effective date of any notice shall be the actual date of receipt by the Party receiving the
same. 
 16.7 Export Clause. Each Party agrees that, as of the Effective Date, it will not export or re-export restricted
commodities or the technical data of the other Party in any form without the appropriate United States and non-United States government licenses. 
 16.8 Waiver. Neither Party may waive or release any of its rights or interests in this Agreement except in writing. The failure of either Party to assert a right hereunder or to insist upon
compliance with any term of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition. No waiver by either Party of any condition or term in any one or more instances
shall be construed as a continuing waiver of such condition or term or of another condition or term. 
 16.9
Severability. If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original
intent of the Parties and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. Such
invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction. 
 16.10 Entire Agreement. This Agreement, together with the Schedules and Exhibits hereto, set forth all the covenants, promises, agreements, warranties, representations, conditions and
understandings between the Parties as to the subject matter of this Agreement and supersedes and terminates all prior agreements and understanding between the Parties with respect to the subject matter hereof. In particular, and without limitation,
this Agreement supersedes and replaces the Existing Confidentiality Agreement and any and all term sheets relating to the transactions contemplated by this Agreement and exchanged between the Parties prior to the Effective Date. There are no
covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties as to the subject matter of this Agreement other than as set forth herein and therein. No subsequent alteration,
amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. 

16.11 Independent Contractors. Nothing herein shall be construed to create any relationship of employer and employee, agent and
principal, partnership or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any liability of or for the other Party. Neither Party shall have the authority to bind
or obligate the other Party and neither Party shall represent that it has such authority. 

  
 66 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 16.12 Headings; Construction; Interpretation. Headings used herein are for
convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting this Agreement. The terms of this Agreement represent the results of negotiations between the Parties and their representatives, each
of which has been represented by counsel of its own choosing, and neither of which has acted under duress or compulsion, whether legal, economic or otherwise. Accordingly, the terms of this Agreement shall be interpreted and construed in accordance
with their usual and customary meanings, and each of the Parties hereto hereby waives the application in connection with the interpretation and construction of this Agreement of any rule of Law to the effect that ambiguous or conflicting terms or
provisions contained in this Agreement shall be interpreted or construed against the Party whose attorney prepared the executed draft or any earlier draft of this Agreement. Any reference in this Agreement to an Article, Section, subsection,
paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to any Article, Section, subsection, paragraph, clause, Schedule or Exhibit, of or to, as the case may be, this Agreement. Except where the context otherwise requires,
(a) any definition of or reference to any agreement, instrument or other document refers to such agreement, instrument other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein or therein), (b) any reference to any Law refers to such Law as from time to time enacted, repealed or amended, (c) the words “herein,” “hereof” and
“hereunder,” and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof, (d) the words “include,” “includes,” “including,” “exclude,”
“excludes,” and “excluding,” shall be deemed to be followed by the phrase “but not limited to,” “without limitation” or words of similar import. 

16.13 Further Actions. Each Party shall execute, acknowledge and deliver such further instruments, and do all such other acts, as
may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 

16.14 Parties in Interest. All of the terms and provisions of this Agreement shall be binding upon, and shall inure to the benefit
of and be enforceable by the Parties hereto and their respective successors, heirs, administrators and permitted assigns. 

16.15 Performance by Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees
to cause its Affiliates to perform such obligations. 
 16.16 Counterparts. This Agreement may be signed in counterparts,
each and every one of which shall be deemed an original, notwithstanding variations in format or file designation which may result from the electronic transmission, storage and printing of copies from separate computers or printers. Facsimile
signatures and signatures transmitted via portable document format (PDF) shall be treated as original signatures. 

[Signature page to follow] 

  
 67 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this
Agreement to be executed by their duly authorized representatives as of the Effective Date. 
  

					
		 	MACROGENICS, INC.
			
		 	By:	 	 /s/ Scott Koenig

		 	Name:	 	Scott Koenig
		 	Title:	 	CEO
		
		 	LES LABORATOIRES SERVIER
			
		 	By:	 	  

		 	Name:	 	***
		 	Title:	 	***
			
		 	By:	 	  

		 	Name:	 	***
		 	Title:	 	***
		
		 	INSTITUT DE RECHERCHES SERVIER
			
		 	By:	 	  

		 	Name:	 	***
		 	Title:	 	***

  
 68 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 Exhibit A-1 
 Back-Up Program Antibodies 
 *** 

  
 69 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 Exhibit A-2 
 MGA271 
 *** 

  
 1 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 Exhibit B 
 MacroGenics Patents 
  

							
	 Country
	  	 Appl Serial No.
	  	 Publication No.
	  	 Patent No.

	 ***

	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***

	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***

  
 1 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

							
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***

  
 2 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

							
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***
	***
	***	  	***	  	***	  	***
	***	  	***	  	***	  	***

  
 3 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 Exhibit C 
 MacroGenics Third Party Agreements 
  

	1.	*** 

  
 1 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 Exhibit D 
 Press Release 
 MacroGenics and Servier Enter Development and
Commercialization 
 Agreement for Novel Anti-Cancer Drug 

 

	 	•	 	 MGA271 is a therapeutic monoclonal antibody that recognizes B7-H3, a member of the B7 family of immune regulators, that is over-expressed on a wide
variety of solid tumors 

  

	 	•	 	 MacroGenics retains full program rights in North America, Japan, Korea and India 

 

	 	•	 	 Servier has an option to obtain an exclusive license to develop and commercialize MGA271 in the rest of the world. 

ROCKVILLE, Maryland and SURESNES , France –                  , 2011
– MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France’s largest privately-held pharmaceutical company, announced today that they have entered into an option and
license agreement for the development and commercialization of MGA271, MacroGenics’ proprietary product candidate. MGA271 is a first-in-class, Fc-optimized monoclonal antibody that targets B7-H3 and is currently being studied in a Phase 1
clinical trial for the treatment of solid tumors. 
 MGA271 is a next generation monoclonal antibody which incorporates multiple complementary
mechanisms of action including enhanced immuno-stimulatory properties and targeting of tumor vasculature. B7-H3 target is overexpressed in several malignancies requiring innovative therapeutic approaches. Following very promising pre-clinical
results, we will work together to define the clinical indications and the best drug combinations and to identify early biomarkers predictive of response”, said Dr. Stéphane Depil, MD, PhD, in charge of Oncology Research &
Development at Servier. “Today’s announcement underscores Servier’s commitment to develop novel targeted therapies that address significant unmet medical needs for cancer patients,” added Dr. Emmanuel Canet, MD, PhD,
President Research & development at Servier. “MGA271 is a novel immunotherapeutic with a compelling product profile and the potential to treat a broad spectrum of solid tumors. We have been deeply impressed by both the excellence of
science being conducted by MacroGenics and their world class antibody development capabilities. We are looking forward to building a long-term strategic collaboration with MacroGenics.” Under the terms of the agreement, MacroGenics retains full
development and commercialization rights to MGA271 in the U.S., Canada, Mexico, Japan, Korea and India, while Servier has an option to obtain an exclusive license covering the rest of the world. Prior to the exercise of Servier’s option, both
parties will fund and conduct specified research and development activities. MacroGenics will receive a $20 million upfront payment. If Servier exercises its option upon completion of the Phase 1 study and its expansion cohorts, MacroGenics will
receive an option exercise fee which, combined with the up-front and early development milestone payments, will total $60 million. In addition, MacroGenics could receive up to an additional $390 million in clinical, regulatory and commercialization
milestone payments. Finally, MacroGenics may receive tiered, double-digit royalties on future net sales. Both parties will share the clinical development costs following the option exercise. 
 “We are delighted to enter into this collaboration with Servier. It will significantly broaden and accelerate our clinical plans for MGA271, enabling us to further investigate the multiple solid
tumor types for which MGA271 may have activity,” said Dr. Scott Koenig, President and CEO of MacroGenics. “This important collaboration highlights the rapidly growing excitement surrounding the B7 family of immune regulators in
oncology immunotherapy as well as our Fc engineering platform.” 

  
 1 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission. 

 “Servier is a world-class pharmaceutical company with a long history of successful innovation and a
dedication to research for the benefit of patients,” Dr. Koenig continued. “They have an expansive global footprint and are an ideal partner to maximize the potential of MGA271.” 

MGA271 is currently being tested in an open-label, multi-dose, single-arm, dose-escalation Phase 1 study in patients with refractory B7-H3-expressing
neoplasms. The trial employs a companion diagnostic for B7-H3 which will enable prospective screening of patients for expression of the target antigen. Enrollment of the first dosing cohort has been completed. Clinical investigators include
Dr. Howard Burris at Sarah Cannon Research Institute, Dr. Roger Cohen at Hospital of the University of Pennsylvania/Abramson Cancer Center and Dr. Keith Flaherty at Massachusetts General Hospital. 

About MGA271 
 MGA271 is a humanized
IgG1/kappa monoclonal antibody that recognizes human B7-H3, a novel member of the B7 family of immune regulators. B7-H3 is an attractive target for immunotherapy, as it is over-expressed in a variety of solid tumors, including prostate, pancreatic,
melanoma, renal cell, ovarian, colorectal, gastric, bladder, and non-small cell lung cancers. MGA271 has been Fc-optimized using MacroGenics’ proprietary Fc-engineering platform to further augment its tumor killing activity. The product’s
Fc region imparts increased affinity for the human activating Fc-gamma receptor IIIA (Fc-gamma RIIIA, CD16A) and decreased affinity for the inhibitory Fc-gamma RIIB (CD32B). 
 About MacroGenics 
 MacroGenics is a private, venture-backed biotechnology company that
focuses on the discovery, development and delivery to patients of novel biologics for cancer, autoimmune disorders and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which
supports its innovative pipeline of clinical stage product candidates. MacroGenics’ proprietary research is based on three core technology platforms, which include: (1) a leading research capability for screening and targeting cancer
stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) technology, which allows the incorporation of multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector
functions. The company has global product development collaborations with Boehringer Ingelheim and Pfizer Inc. which employ its DART technology. For more information about MacroGenics, please visit www.macrogenics.com. 

About Servier 
 Servier is the leading
independent French pharmaceutical company with a 2011 turnover of €3.9 billion. The Servier Group is established in 140 countries with its main therapeutic products used to treat diabetes, cardiovascular disease, CNS disorders, oncology and
rheumatology. More than 25% of Servier’s revenue is invested in Research & Development. Servier has 20,000 employees worldwide, including nearly 3,000 in R&D. For further information, please visit www.servier.com. 

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as “expects,” “believes,” “intends,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in
any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, and risks related to
the Company’s ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of
new information, future events or developments, except as required by law. 
 Contacts: 

Scott Koenig, M.D., Ph.D., President and CEO 
 or
Jim Karrels, Vice President, CFO 
 both of MacroGenics, Inc., +1-301-251-5172, info@macrogenics.com 

  
 2 

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 

version of this exhibit has been filed separately with the Commission.EX-10.22

 Exhibit 10.22 
 Execution Version 
 Confidential Materials omitted and filed
separately with the Securities and Exchange Commission. 
 Triple asterisks denote omissions. 

 
 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

BY AND BETWEEN 
 PFIZER INC. 
 AND 

MACROGENICS, INC. 
 OCTOBER 13, 2010 
  
  

 

 TABLE OF CONTENTS 

 

									
	1.	 	DEFINITIONS.	  	 	1	  
	2.	 	RESEARCH PROGRAM.	  	 	15	  
		 	2.1.	  	Selection of Research Project Targets.	  	 	15	  
		 	2.2.	  	Scope and Conduct of the Research Program.	  	 	16	  
		 	2.3.	  	Research Plans.	  	 	17	  
		 	2.4.	  	Research Program Antibodies and Passed MacroGenics Antibodies.	  	 	18	  
		 	2.5.	  	Governance of the Research Program.	  	 	19	  
		 	2.6.	  	Alliance Managers.	  	 	21	  
		 	2.7.	  	Conformance with Law.	  	 	21	  
		 	2.8.	  	MacroGenics Personnel Matters.	  	 	21	  
		 	2.9.	  	Debarment Certification.	  	 	21	  
		 	2.10.	  	Subcontractors.	  	 	22	  
		 	2.11.	  	Inspections.	  	 	22	  
		 	2.12.	  	Records.	  	 	22	  
		 	2.13.	  	Transfer and Use of Pfizer Proprietary Materials.	  	 	23	  
	3.	 	PRODUCT DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION AND REGULATORY MATTERS.	  	 	24	  
		 	3.1.	  	General.	  	 	24	  
		 	3.2.	  	Diligence.	  	 	24	  
		 	3.3.	  	Regulatory Approvals.	  	 	26	  
		 	3.4.	  	Control of Commercialization Activities.	  	 	26	  
		 	3.5.	  	Manufacturing.	  	 	26	  
		 	3.6.	  	Progress Reporting.	  	 	26	  
	4.	 	LICENSES AND RELATED GRANTS OF RIGHTS.	  	 	27	  
		 	4.1.	  	Grants to Pfizer.	  	 	27	  
		 	4.2.	  	Grants to MacroGenics.	  	 	29	  
		 	4.3.	  	Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential Information.	  	 	29	  
		 	4.4.	  	Retained Rights to Antibodies.	  	 	30	  
		 	4.5.	  	Exclusivity.	  	 	30	  
		 	4.6.	  	Section 365(n) of Bankruptcy Code.	  	 	31	  
		 	4.7.	  	No Implied Rights.	  	 	31	  
	5.	 	PAYMENTS TO MACROGENICS.	  	 	31	  
		 	5.1.	  	Upfront License Payment.	  	 	31	  
		 	5.2.	  	Research Support Funding.	  	 	31	  
		 	5.3.	  	Milestones.	  	 	32	  
		 	5.4.	  	Royalties.	  	 	34	  
		 	5.5.	  	Reports and Payments.	  	 	36	  
		 	5.6.	  	Maintenance of Records; Audits.	  	 	37	  
		 	5.7.	  	Late Payments.	  	 	38	  
	6.	 	INTELLECTUAL PROPERTY.	  	 	39	  
		 	6.1.	  	Inventions.	  	 	39	  
		 	6.2.	  	Patent Rights.	  	 	39	  

  
 i 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

									
		 	6.3.	 	Recording.	  	 	46	  
		 	6.4.	 	Trademarks.	  	 	47	  
	7.	 	CONFIDENTIALITY	  	 	47	  
		 	7.1.	 	Confidentiality.	  	 	47	  
		 	7.2.	 	Authorized Disclosure.	  	 	47	  
		 	7.3.	 	Public Announcements; Publications.	  	 	50	  
		 	7.4.	 	Obligations in Connection with Change of Control.	  	 	51	  
	8.	 	REPRESENTATIONS AND WARRANTIES.	  	 	51	  
		 	8.1.	 	Mutual Representations and Warranties.	  	 	51	  
		 	8.2.	 	Representations and Warranties of MacroGenics.	  	 	52	  
		 	8.3.	 	Representations and Warranties of Pfizer.	  	 	53	  
		 	8.4.	 	MacroGenics Covenants.	  	 	54	  
		 	8.5.	 	Representation by Legal Counsel.	  	 	54	  
		 	8.6.	 	Disclaimer.	  	 	55	  
	9.	 	GOVERNMENT APPROVALS; TERM AND TERMINATION.	  	 	55	  
		 	9.1.	 	Government Approvals.	  	 	55	  
		 	9.2.	 	Term.	  	 	55	  
		 	9.3.	 	Termination by Either Party for Cause.	  	 	55	  
		 	9.4.	 	Termination by Pfizer without Cause.	  	 	55	  
		 	9.5.	 	Effects of Termination.	  	 	56	  
		 	9.6.	 	Disposition of Inventories of Products.	  	 	59	  
		 	9.7.	 	Survival of Certain Obligations.	  	 	59	  
		 	9.8.	 	Right to Termination of Research Project(s) or Research Program by Pfizer upon Change of Control of MacroGenics.	  	 	60	  
	10.	 	LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE.	  	 	60	  
		 	10.1.	 	No Consequential Damages.	  	 	60	  
		 	10.2.	 	Indemnification by Pfizer.	  	 	60	  
		 	10.3.	 	Indemnification by MacroGenics.	  	 	61	  
		 	10.4.	 	Procedure.	  	 	61	  
		 	10.5.	 	Insurance.	  	 	63	  
	11.	 	MISCELLANEOUS.	  	 	63	  
		 	11.1.	 	Assignment.	  	 	63	  
		 	11.2.	 	Further Actions.	  	 	63	  
		 	11.3.	 	Force Majeure.	  	 	63	  
		 	11.4.	 	Notices.	  	 	64	  
		 	11.5.	 	Amendment.	  	 	65	  
		 	11.6.	 	Waiver.	  	 	65	  
		 	11.7.	 	Severability.	  	 	65	  
		 	11.8.	 	Descriptive Headings.	  	 	65	  
		 	11.9.	 	Dispute Resolution.	  	 	65	  
		 	11.10.	 	Governing Law.	  	 	66	  
		 	11.11.	 	Consent to Jurisdiction.	  	 	66	  
		 	11.12.	 	Entire Agreement.	  	 	66	  
		 	11.13.	 	Independent Contractors.	  	 	66	  
		 	11.14.	 	Counterparts.	  	 	67	  
		 	11.15.	 	No Third Party Rights or Obligations.	  	 	67	  

  
 ii 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 EXHIBITS 

 

			
	Exhibit 2.3.1	  	Form of Research Plans
	Exhibit 7.3.1	  	Press Release

  
 i 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 SCHEDULES 

 

			
	Schedule 1.19	  	***
	Schedule 1.34	  	***
	Schedule 1.80	  	***
	Schedule 1.125	  	***
	Schedule 2.10	  	MacroGenics Subcontractors and Services
	Schedule 8.2.3	  	Patent Rights of MacroGenics
	Schedule 8.2.8	  	Funding Agreements
	Schedule 8.2.13	  	Litigation

  
 ii 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

This Research Collaboration and License Agreement (the “Agreement”) is entered into as of October 13, 2010 (the
“Effective Date”), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 500 Arcola Road, Collegeville, Pennsylvania 19426, United States
(“Pfizer”) and MacroGenics, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 1500 East Gude Drive, Rockville, MD 20850 (“MacroGenics”). Pfizer and
MacroGenics may each be referred to herein individually as a “Party” and collectively as the “Parties.” 
 WHEREAS, Pfizer is engaged in the research, development and commercialization of pharmaceutical and health care products; 
 WHEREAS, MacroGenics has developed a T-DART platform, which is focused on dual specificity “antibody-like” therapeutic proteins capable of targeting both immune effector cells and other
cells with a single recombinant molecule, and certain intellectual property useful in connection with the application of such T-DART platform; and 
 WHEREAS, Pfizer and MacroGenics desire to collaborate to discover and research T-DARTs active against certain designated targets and to provide for Pfizer to further research, develop, manufacture and
commercialize such T-DARTs and products containing such T-DARTs, as provided for herein. 
 NOW THEREFORE, in consideration of
the mutual promises and covenants set forth below and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 

 

	1.	DEFINITIONS. 

 When used
in this Agreement, the following capitalized terms shall have the meanings set forth in this Section 1. Any terms defined elsewhere in this Agreement shall be given equal weight and importance as though set forth in Section 1. 

 

	 	1.1.	“Additional Third Party Licenses” is defined in Section 5.4.3(b). 

1.2. “Affiliate” means, with respect to any Person, any other Person that controls, is controlled by or is under common
control with such Person. A Person shall be regarded as in control of another entity if it owns or controls at least fifty percent (50%) of the equity securities of the subject entity entitled to vote in the election of directors (or, in the
case of an entity that is not a corporation, for the election of the corresponding managing authority), provided, however, that the term “Affiliate” shall not include subsidiaries or other entities in which a Party or its Affiliates owns a
majority of the ordinary voting power necessary to elect a majority of the board of directors or other managing authority, but is restricted from electing such majority by contract or otherwise, until such time as such restrictions are no longer in
effect. 

  
 1 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.3. “Agreement” is defined in the introduction to this Agreement.

 1.4. “Agreement Product” means any product containing an Agreement T-DART. 

1.5. “Agreement T-DART” means any T-DART that is identified during the course of the Research Program as binding to a
Research Project Target, including any portion, fragment or subunit thereof, and any modified or derivative form of any of the foregoing, and the nucleic acid sequence encoding for any of the foregoing. 

1.6. “Agreement T-DART IP” means any invention that constitutes or comprises the composition or formulation of, or any
method of manufacture or use of, any Agreement T-DART or Agreement Product and that is invented by MacroGenics or any of its Affiliates, or any Subcontractor of MacroGenics or any of its Affiliates, solely or jointly with Pfizer or any of its
Affiliates, or any Subcontractor of Pfizer or any of its Affiliates, in the conduct of the Research Program during the Research Term, and excluding any invention included in the Pfizer Material Improvements. 

1.7. “Agreement T-DART Patent Right” means any Pfizer Patent Right filed after the Effective Date covering or claiming
any invention assigned to Pfizer as Agreement T-DART IP pursuant to Section 4.1.2. 
 1.8. “Alliance Manager” is
defined in Section 2.6. 
 1.9. “Annual Net Sales” means, with respect to any Agreement Product, the aggregate
Net Sales by Pfizer, its Affiliates and its Sublicensees from the sale of such Agreement Product in the Territory during each Pfizer Year of the applicable Royalty Term for such Agreement Product. 

1.10. “Antibody” means a molecule which comprises or contains: (a) one or more immunoglobulin variable domains;
(b) fragments, variants, modifications or derivatives of such immunoglobulin variable domains irrespective of origin or source; or (c) the nucleic acid consisting of a sequence of nucleotides encoding (or complementary to a nucleic acid
encoding) the foregoing molecules in (a) or (b). The term “Antibody” shall include any monospecific antibodies and less than full-length antibody forms such as Fv, Fab, and F(ab’). 

1.11. “Applicable Law” means the laws, statutes, rules, regulations, guidelines, or other requirements (including Good
Manufacturing Practices (“GMP”), Good Laboratory Practices and Good Clinical Practices), that may be in effect from time to time and apply to a Party’s activities to be performed under this Agreement, including any such laws,
statutes, rules, regulations, guidelines, or other requirements of the FDA or the EMEA. 
 1.12. “Bankruptcy
Code” is defined in Section 4.6. 
 1.13. “Binding Obligation” means, with respect to a Party
(a) any oral or written agreement or arrangement that binds or affects such Party’s operations or property, including any assignment, license agreement, loan agreement, guaranty, or financing

  
 2 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
agreement; (b) the provisions of such Party’s charter, bylaws or other organizational documents or (c) any order, writ, injunction, decree or judgment of any court or Governmental
Authority entered against such Party or by which any of such Party’s operations or property are bound. 
 1.14.
“Biosimilar Biologic Product” is defined in Section 5.4.3(b). 
 1.15. “Business Day” means a
day other than a Saturday, a Sunday or a day that is a national holiday in the United States. 
 1.16. “Calendar
Quarter” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 or December 31, for so long as this Agreement is in effect. 

1.17. “Calendar Year” means each successive period of twelve (12) calendar months commencing on January 1 and
ending on December 31. 
 1.18. “CD3” means the complex comprising the epsilon, delta and gamma subunits of
the CD3 receptor complex (including any subtypes, alleles, and splice variants). 
 1.19. *** 

1.20. “CPI” is defined in Section 1.43. 
 1.21. “Change of Control” means, with respect to a Party, (a) a merger, reorganization or consolidation of such Party with a Third Party which results in the voting securities of
such Party outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving or resulting entity immediately after such merger, reorganization or consolidation, (b) a
Third Party becoming the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such
Party’s business or assets to which this Agreement relates; provided that, for purposes of subsections (a), (b) and (c), such Third Party or an Affiliate of such Third Party is engaged immediately prior to the Change of Control in the
pharmaceutical or biotechnology business and is not a venture capital or other institutional investor. Change of Control shall not include any public offering of the shares of MacroGenics. 

1.22. “Combination Product” means an Agreement Product containing an Agreement T-DART and one or more other
therapeutically active ingredients. 
 1.23. “Commercialization” or “Commercialize” means
activities directed to marketing, promoting, distributing, importing, exporting, using for commercial purposes or selling or having sold an Agreement Product. Commercialization shall not include any activities related to Manufacturing or
Development. 

  
 3 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.24. “Commercially Reasonable Efforts” means, with respect to the efforts
to be expended by a Party with respect to any objective, those reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective under similar circumstances. With respect to any efforts
relating to the Development, Regulatory Approval or Commercialization of an Agreement T-DART or Agreement Product by a Party, generally or with respect to any particular country in the Territory, a Party will be deemed to have exercised Commercially
Reasonable Efforts if such Party has exercised those efforts normally used by such Party, in the relevant country, with respect to a compound, product or product candidate, as applicable of similar modality owned or Controlled by such Party, or to
which such Party has similar rights, which compound, product or product candidate is of similar market potential in such country, and is at a similar stage in its development or product life cycle as the Agreement T-DART or Agreement Product, taking
into account all Relevant Factors in effect at the time such efforts are to be expended. To the extent that the performance of a Party’s obligations hereunder is adversely affected by the other Party’s failure to perform its obligations
hereunder, the impact of such performance failure will be taken into account in determining whether such Party has used its Commercially Reasonable Efforts to perform any such affected obligations. 

1.25. “Confidential Information” of a Party means all Know-How or other information, including proprietary information
and materials (whether or not patentable) regarding such Party’s technology, products, business or objectives, that is communicated in any way or form by the Disclosing Party to the Receiving Party, either prior to or after the Effective Date
of this Agreement (including any information disclosed pursuant to the Confidentiality Agreements), and whether or not such Know-How or other information is identified as confidential at the time of disclosure. The terms and conditions of this
Agreement shall be considered the Confidential Information of each Party. 
 1.26. “Confidentiality Agreements”
means the Confidentiality Agreements between the Parties dated ***. 
 1.27. “Control” or
“Controlled” means, with respect to any (a) item of information, including Know-How, or (b) any other intellectual property right, the possession (whether by ownership interest or license, other than pursuant to this
Agreement) by a Party of the ability to grant to the other Party access to or a license under such item or right, as provided herein, without violating the terms of any agreement or other arrangements with any Third Party; provided that any item of
information or other intellectual property right that is licensed or acquired by a Party after the Effective Date and that would otherwise be considered to be under the Control of a Party shall not be deemed to be under the Control of such Party if
the application of such definition in the context of any licenses or sublicenses granted to the other Party under this Agreement would require the granting Party to make any additional payments or royalties to a Third Party in connection with such
license or sublicense grants, unless the other Party agrees to pay all such additional payments or royalties due to such Third Party. 

  
 4 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.28. “Develop” or “Development” means to discover,
research or otherwise develop a product, including conducting any pre-clinical, non-clinical or clinical research and any drug development activity, including discovery, research, toxicology, pharmacology and other similar efforts, test method
development and stability testing, manufacturing process development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, clinical studies (including pre- and post-approval
studies), diagnostic assays in connection with clinical studies, and all activities directed to obtaining any Regulatory Approval, including any marketing, pricing or reimbursement approval. Development shall not include any activities related to
Manufacturing or Commercialization. 
 1.29. “Development Milestone” is defined in Section 5.3.2. 

1.30. “Development Milestone Payment” is defined in Section 5.3.2. 

1.31. “Diligence Issue” is defined in Section 3.2.4. 

1.32. “Disclosing Party” is defined in Section 7.1. 

1.33. “Effective Date” is defined in the introduction to this Agreement. 

1.34. *** 

1.35. “EMEA” means the European Medicines Agency, or any successor agency thereto. 

1.36. “FD&C Act” means the United States Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.), as
amended, and the rules and regulations promulgated thereunder. 
 1.37. “FDA” means the United States Food and
Drug Administration or any successor agency thereto. 
 1.38. “Field” means all human and veterinary
therapeutic, diagnostic, prophylactic and prognostic purposes, provided, however, that for so long as MacroGenics has obligations under, and solely to the extent required in order for MacroGenics not to be in violation of its obligations under,
***, the “Field” shall not include the Development or Commercialization of any Agreement T-DART or Agreement Product that binds to CD3 and is intended to be Developed or Commercialized *** ***  

1.39. “First Commercial Sale” means, with respect to any Agreement Product and any country of the world, the first sale
of such Agreement Product under this Agreement by Pfizer, its Affiliates or its Sublicensees to a Third Party in such country, after such Agreement Product has been granted Regulatory Marketing Approval by the competent Regulatory Authorities in
such country. When used without reference to a specified Indication, First Commercial Sale means the First Commercial Sale for any Indication. 
 1.40. “First Research Project Target” is defined in Section 2.1.1. 

  
 5 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.41. “Foregone Agreement T-DART Patent Right” is defined 6.2.1(b).

 1.42. “FTE” means a full time equivalent scientific person *** *** year, consisting of a minimum of a
total of *** of scientific work directly related to and in support of the Research Program by an employee or full-time contractor or consultant of MacroGenics or any of its Affiliates. 

1.43. “FTE Rate” means ***, increased or decreased annually by the percentage increase or decrease in the Consumer
Price Index–Urban Wage Earners and Clerical Workers, United States City Average, All Items, 1982-84 = 100, published by the United States Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the United States
(“CPI”) as of December 31 of the then most recently ended Calendar Year over the level of the CPI on December 31, 2010 (i.e., the first such increase or decrease would occur on January 1, 2012). 

1.44. “GAAP” means generally accepted accounting principles, consistently applied. 

1.45. “GMP” is defined in Section 1.11. 
 1.46. “Generic Competition” is defined in Section 5.4.3(a). 

1.47. “Governmental Authority” means any court, agency, department, authority or other instrumentality of any national,
state, county, city or other political subdivision. 
 1.48. “IND” means an Investigational New Drug
Application, as defined in the FD&C Act, that is required to be filed with the FDA before beginning clinical testing of an Agreement Product in human subjects, or an equivalent foreign filing. 

1.49. “Indemnified Party” is defined in Section 10.4.1. 

1.50. “Indemnifying Party” is defined in Section 10.4.1. 

1.51. “Indication” means a disease, disease stage, discrete form of a disease or any precursor condition thereof or a
line of treatment thereof ***, for which a separate Regulatory Approval Application has been obtained or is being sought. 

1.52. “Initial Research Project Targets” is defined in Section 2.1.1. 

1.53. “Initial Reserved Targets” is defined in Section 2.1.2. 

1.54. “Joint Invention” is defined in Section 6.1.1(b). 

1.55. “Joint Know-How” is defined in Section 6.1.1(b). 

1.56. “Joint Patent Right” means any Patent Right claiming any Joint Invention. 

1.57. “Joint Steering Committee” or “JSC” is defined in Section 2.5.1. 

  
 6 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.58. “Joint Technology” means, collectively, the Joint Patent Rights, the
Joint Inventions and the Joint Know-How. 
 1.59. “Know-How” means any proprietary invention, discovery, data,
information, process, method, technique, material, technology, result or other know-how, whether or not patentable. 
 1.60.
“Liability” is defined in Section 10.2. 
 1.61. *** 

1.62. *** 

1.63. “Litigation Conditions” is defined in Section 10.4.2. 

1.64. “MacroGenics” is defined in the introduction to this Agreement. 

1.65. “MacroGenics Derived Terminated Agreement T-DART” is defined in Section 9.5.2(e)(i). 

1.66. “MacroGenics Excluded Target Schedule” is defined in Section 2.1.1. 

1.67. “MacroGenics Indemnified Party” is defined in Section 10.2. 

1.68. “MacroGenics Know-How” means any Know-How comprised in the MacroGenics Technology, excluding any Joint
Know-How. 
 1.69. “MacroGenics Patent Right” means any Patent Right comprised in the MacroGenics Technology,
excluding any Joint Patent Rights. 
 1.70. “MacroGenics Technology” means any Patent Right or Know-How that
(a) is Controlled by MacroGenics or any Affiliate of MacroGenics as of the Effective Date or that comes into the Control of MacroGenics or any of its Affiliates at any time during the Term and (b) is necessary or useful to Develop,
Manufacture or Commercialize Agreement T-DARTs and/or Agreement Products. 
 1.71. “MacroGenics Third Party
Agreement” means any agreement between MacroGenics and any Third Party under which MacroGenics obtains rights in or to any MacroGenics Technology. 
 1.72. “MacroGenics-Derived Terminated Agreement T-DART” is defined in Section 9.5.2(e) 
 1.73. “Major EU Market Country” means any of *** 
 1.74.
“Major Market Country” means any *** 

  
 7 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.75. “Manufacturing” or “Manufacture” means activities
directed to making, producing, manufacturing, processing, filling, finishing, packaging, labeling, quality assurance testing and release, shipping or storage of a product. Manufacturing shall not include any activities related to Development or
Commercialization. 
 1.76. “Marginal Royalty Rates” is defined in Section 5.4 

1.77. “Milestone Payment” means the Technical Milestones, Development Milestones, and Sales Milestones. 

1.78. “Net Sales” means: 
 1.78.1. with respect to an Agreement Product that is not a Combination Product, gross receipts from sales by Pfizer and its Affiliates and Sublicensees (each, a “Selling Person”)
of such Agreement Product to Third Parties in the Territory, less in each case, to the extent reasonably allocable to Agreement Products in accordance with GAAP, sales returns and allowances actually paid, granted or accrued, including trade,
quantity and cash discounts and any other adjustments, including those granted on account of price adjustments, billing errors, rejected goods, damaged or defective goods, recalls, returns, rebates, chargeback rebates, reimbursements or similar
payments granted or given to wholesalers or other distributors, buying groups, health care insurance carriers, chain pharmacies, mass merchandisers, staff model HMO’s, pharmacy benefit managers or other institutions, adjustments arising from
consumer discount programs or other similar programs, customs or excise duties, sales tax, consumption tax, value added tax, and other taxes (except income taxes) or duties relating to sales, any payment in respect of sales to the United States
government, any state government or any foreign government, or to any other Governmental Authority, or with respect to any government-subsidized program or managed care organization, and freight and insurance (to the extent that Pfizer bears the
cost of freight and insurance for the Agreement Product) (the deductions described above are referred to collectively herein as “Permitted Deductions”); and 

1.78.2. in the event an Agreement T-DART is sold as a Combination Product in any country, the Net Sales of the Combination Product, for
the purposes of determining royalty payments, shall be determined by multiplying the Net Sales (as defined above in this Section) of the Combination Product by the fraction, A/(A+B) where A is the weighted (by sales volume) average sale price in
such country of the Agreement T-DART when sold separately in finished form, and B is the aggregate weighted average sale price in such country of the other therapeutically active ingredients included in such Combination Product when sold separately
in finished form. In the event that such average sale price cannot be determined for both the Agreement T-DART and the other product(s) included in the Combination Product, Net Sales for purposes of determining royalty payments shall be agreed by
the Parties based on the relative value contributed by each component, such agreement not to be unreasonably withheld or delayed. 

  
 8 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 Sales between Pfizer and its Affiliates or Sublicensees shall be excluded from the
computation of Net Sales and no payments will be payable on such sales except where such Affiliates or Sublicensees are end users, but Net Sales shall include the subsequent final sales to Third Parties by such Affiliates or Sublicensees. Net Sales
shall be determined from books and records maintained in accordance with GAAP, as consistently applied by Pfizer with respect to sales of the Agreement Product. For clarity, in calculating Net Sales, except pursuant to Section 5.4.3, neither Party
shall be entitled to deduct any payments to Third Parties by way of royalties or similar payments. 
 The Parties acknowledge
that Pfizer does not currently intend to Commercialize any Agreement Product solely for diagnostic purposes and that the Parties anticipate that any sales of any Agreement Product for diagnostic purposes will occur only in connection with or in
support of sales of an Agreement Product for therapeutic purposes. Notwithstanding the foregoing, in the event Pfizer, its Affiliates or Sublicensees Commercialize any Agreement Product for diagnostic purposes, sales of such Agreement Product for
diagnostic purposes shall be included in the calculation of Net Sales provided that Pfizer and MacroGenics will negotiate in good faith a reasonable royalty applicable to Net Sales of any such Agreement Product for diagnostic purposes during the
applicable Royalty Term, which royalty shall be no greater than the Marginal Royalty Rates otherwise set forth for Agreement Products under this Agreement. 
 1.79. “Non-Disclosing Party” is defined in Section 7.3.2. 

1.80. *** 

1.81. “Notice of Dispute” is defined in Section 11.9.1. 

1.82. “Party” and “Parties” is defined in the introduction to this Agreement. 

1.83. “Passed MacroGenics Antibody” means any proprietary (to MacroGenics) Research Program Antibody contributed to the
Research Program by MacroGenics which the JSC has determined is no longer under Development or consideration for Development under the Research Program. 
 1.84. “Patent Rights” means any and all (a) patents, (b) pending patent applications, including all provisional applications, substitutions, continuations,
continuations-in-part, divisions and renewals, and all patents granted thereon, (c) all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent
term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor’s certificates, (e) any other form of government-issued right substantially similar to any of the foregoing and (f) all United States
and foreign counterparts of any of the foregoing. The Patent Rights owned by either Party include any Patent Right assigned to such party pursuant to the provisions of this Agreement. 

  
 9 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.85. “Permitted Deduction” is defined in Section 1.78.1. 

1.86. “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership,
corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision or department or agency of a government.

 1.87. “Pfizer” is defined in the introduction to this Agreement. 

1.88. “Pfizer Collaboration Patent Right” is defined in Section 9.5.2(e)(i). 

1.89. “Pfizer Diligence Obligations” means Pfizer’s diligence obligations under Sections 3.2.1 and 3.2.2,
collectively. 
 1.90. “Pfizer Indemnified Party” is defined in Section 10.3. 

1.91. “Pfizer Know-How” means any Know-How comprised in the Pfizer Technology, excluding any Joint Know-How. 

1.92. “Pfizer Patent Right” means any Patent Right comprised in the Pfizer Technology, excluding any Joint Patent Rights.

 1.93. “Pfizer Proprietary Material Improvement” means all intellectual property rights constituting,
comprising or covering any improvement or enhancement to, or any derivative or modification of, or any invention directly related to, any Pfizer Proprietary Material, which improvement, enhancement, derivative, modification or invention is
conceived, discovered, invented, developed, created, made or reduced to practice or tangible medium by MacroGenics or any of its Affiliates, solely or jointly with Pfizer or any of its Affiliates, in the course of performing activities under this
Agreement. For the avoidance of doubt, Pfizer Proprietary Material Improvement shall not include any Patent Right or Know-How that is directed to T-DARTs and any such Know-How or Patent Right that would otherwise of have been included as a Pfizer
Proprietary Material Improvement shall instead be included in Agreement T-DART IP or the Agreement T-DART Patent Rights. 
 1.94.
“Pfizer Proprietary Materials” means any and all biological and other materials Controlled by Pfizer and supplied by Pfizer to MacroGenics under this Agreement. 

1.95. “Pfizer Quarter” means each of the four thirteen week periods (a) with respect to the United States,
commencing on January 1 of any Pfizer Year and (b) with respect to any country in the Territory other than the United States, commencing on December 1 of any Pfizer Year. 

1.96. “Pfizer Technology” means any Patent Right or Know-How that is (a) Controlled by Pfizer or any Affiliate of
Pfizer as of the Effective Date or that comes into the Control of Pfizer or any of its Affiliates at any time during the Term and (b) is necessary or useful to Develop, Manufacture or Commercialize Agreement T-DARTs and/or Agreement Products.

  
 10 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.97. “Pfizer Year” means the twelve (12) month fiscal periods
observed by Pfizer (a) commencing on January 1 with respect to the United States and (b) commencing on December 1 with respect to any country in the Territory other than the United States. 

1.98. “Phase I Clinical Study” means a study of an Agreement Product in human subjects or patients with the endpoint of
determining initial tolerance, safety, metabolism or pharmacokinetic information and clinical pharmacology of such product as and to the extent defined for the United States in 21 C.F.R. § 312.21(a), or its successor regulation, or the
equivalent regulation in any other country. A so-called Phase I/II Clinical Study shall be deemed to be a Phase I Clinical Study unless such study, when completed, allows Pfizer to proceed directly to a Pivotal Study. 

1.99. “Phase II Clinical Study” means a study of an Agreement Product in human patients to determine the safe and
effective dose range in a proposed therapeutic Indication as and to the extent defined for the United Sates in 21 C.F.R. § 312.21(b), or its successor regulation, or the equivalent regulation in any other country. 

1.100. “Phase III Clinical Study” means a study of an Agreement Product in human patients with a defined dose or a set of
defined doses of an Agreement Product designed to (a) ascertain efficacy and safety of such Agreement Product for its intended use; (b) define warnings, precautions and adverse reactions that are associated with the Agreement Product in
the dosage range to be prescribed; and (c) support preparing and submitting applications for Regulatory Marketing Approval to the competent Regulatory Authorities in a country of the world, as and to the extent defined for the United States in
21 C.F.R.§ 312.21(c), or its successor regulation, or the equivalent regulation in any other country. 
 1.101.
“Pivotal Study” means (a) a Phase III Clinical Study, or (b) a Phase II Clinical Study, or a combination Phase II Clinical Study and Phase III Clinical Study, if Pfizer has determined at the time of first dosing that the
data generated in such trial, if successful, will be sufficient, without data from further studies, to support the filing of a Regulatory Marketing Approval Application for an Agreement Product. 

1.102. “Receiving Party” is defined in Section 7.1. 

1.103. “Regulatory Approval” means any technical, medical, scientific or other license, registration, authorization or
approval of any Regulatory Authority (including any approval of a New Drug Applications or Biologic License Applications) necessary for the Development, Manufacture or Commercialization of a pharmaceutical product in any regulatory jurisdiction.

 1.104. “Regulatory Approval Application” means any application submitted to an appropriate Regulatory
Authority seeking any Regulatory Approval. 

  
 11 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.105. “Regulatory Authority” means, with respect to any national,
supra-national, regional, state or local regulatory jurisdiction, any agency, department, bureau, commission, council or other governmental entity involved in the granting of a Regulatory Approval for such jurisdiction. 

1.106. “Regulatory Exclusivity” means the ability to exclude Third Parties from Commercializing an Agreement Product or a
Biosimilar Biologic Product with respect to any Agreement Product in a country, either through data exclusivity rights, orphan drug designation, or such other rights conferred by a Regulatory Authority in such country, other than through Patent
Rights. 
 1.107. “Regulatory Marketing Approval” means, with respect to any pharmaceutical product and any
Indication, Regulatory Approval (including any supplement thereto) to sell such pharmaceutical product for such Indication, including, in any jurisdiction other than the United States, to the extent required for any sale in such country, all pricing
and reimbursement approvals to be obtained from the Regulatory Authority granting such Regulatory Approval or any affiliated Regulatory Authority. 
 1.108. “Regulatory Marketing Approval Application” means any Regulatory Approval Application submitted to an appropriate Regulatory Authority seeking any Regulatory Marketing Approval.

 1.109. “Relevant Factors” means all relevant factors that may affect the Development, Regulatory Approval,
Manufacture, or Commercialization of an Agreement Product, including (as applicable): actual and potential issues of safety, efficacy and/or stability; product profile (including product modality, category and mechanism of action); stage of
development or life cycle status; actual and projected Development, Regulatory Approval, Manufacturing, and Commercialization costs, timelines and budgets; any issues regarding the ability to Manufacture or have Manufactured the Agreement Product;
the likelihood of obtaining Regulatory Approvals (including satisfactory reimbursement or pricing approvals); the timing of such approvals; labeling or anticipated labeling; the then-current competitive environment and the likely competitive
environment at the time of projected entry into the market; past performance of the product or similar products; present and future market potential; existing or projected pricing, sales, reimbursement and profitability; proprietary position,
strength and duration of patent protection and anticipated exclusivity; other relevant scientific, technical, operational and commercial factors. 
 1.110. “Representatives” is defined in Section 7.2.1. 
 1.111.
“Research Plan” is defined in Section 2.3.1. 
 1.112. “Research Plan Services” is defined in
Section 2.3.3. 
 1.113. “Research Program” is defined in Section 2.2. 

1.114. “Research Program Antibody” is defined in Section 2.4.1. 

  
 12 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.115. “Research Project” is defined in Section 2.3.1. 

1.116. “Research Project Target” means a cancer cell Target that has been selected for a Research Project, including the
Initial Research Project Targets and any Reserved Target substituted for an existing Research Project Target in accordance with Section 2.1.4.  
 1.117. “Research Term” means the period commencing on the Effective Date and continuing until three (3) years after the Effective Date, or until such later date as may be mutually
agreed to by the Parties. 
 1.118. “Reserved Target” means any Target designated as a Reserved Target pursuant
to Section 2.1.2 or 2.1.3 of this Agreement, including the Initial Reserved Targets. 
 1.119. “Review Period”
is defined in Section 7.3.2. 
 1.120. “Royalty Term” is defined in Section 5.4.2. 

1.121. “Sales Milestone” is defined in Section 5.3.3. 

1.122. “Sales Milestone Payment” is defined in Section 5.3.3. 

1.123. “Sales Threshold” is defined in Section 5.3.3. 

1.124. “SEC” means the United States Securities and Exchange Commission. 

1.125. *** 

1.126. “Second Research Project Target” is defined in Section 2.1.1. 

1.127. “Selling Person” is defined in Section 1.78.1. 

1.128. “Senior Executives” is defined in Section 2.5.5(b). 

1.129. “Sole Invention” is defined in Section 6.1.1(a). 

1.130. “Sole Know-How” is defined in Section 6.1.1(a). 

1.131. “Subcontractors” is defined in Section 2.10.1. 

1.132. “Subcontractor Information” is defined in Section 2.11. 

1.133. “Sublicensee” means any Third Party to whom Pfizer grants or has granted, directly or indirectly, a sublicense of
rights licensed by MacroGenics to Pfizer under this Agreement, in accordance with the provisions of this Agreement. 
 1.134.
“Subject Patent Right” is defined in Section 6.2.1(d). 

  
 13 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.135. “T-DART” means a dual affinity re-targeting molecule that binds with
one arm to a Target expressed on an immune effector cell *** *** and with the second arm to a different Target expressed on another non-immune effector cell. 
 1.136. “Target” means (a) a specific biological molecule that is identified by a GenBank accession number or other public database accession identifier or by its amino acid or
nucleic acid sequence; (b) all amino acid and nucleic acid variant forms of any biological molecule disclosed in clause (a), including naturally occurring variants, mutants, transcriptional and post-transcriptional isoforms (e.g., alternative
splice variants), and post-translational modification variants (e.g., protein processing, maturation and glycosylation variants); and (c) truncated forms (including fragments thereof) which have a biological function substantially similar to
that of any biological molecules disclosed in clause (a) or clause (b). 
 1.137. “Target Designation Date”
means, with respect to any Research Project Target or Reserved Target, the date on which a Target becomes a Research Project Target or Reserved Target, as provided in Section 2.1. With respect to the Initial Research Project Targets and the Initial
Reserved Targets, the Target Designation Date shall be deemed to be the Effective Date. 
 1.138. “Targeting”
means, when used to describe the relationship between a molecule and a Target, that the molecule (a) binds to the Target (or a portion thereof) and (b) is designed or being developed to exert its biological effect in whole or in part
through binding to such Target (or such portion thereof). 
 1.139. “Technical Milestone” is defined in Section
5.3.1. 
 1.140. “Technical Milestone Payment” is defined in Section 5.3.1. 

1.141. “Term” is defined in Section 9.2. 
 1.142. “Terminated Agreement Product” is defined in Section 9.5.1(b). 
 1.143. “Terminated T-DART” is defined in Section 9.5.1. 
 1.144.
“Territory” means the entire world. 
 1.145. “Third Party” means any Person other than Pfizer,
MacroGenics or their respective Affiliates. 
 1.146. “Third Party Claim” is defined in Section 10.4.1.

 1.147. “Trademark” means any trademark, trade dress, design, logo, slogan, house mark or name Controlled by
Pfizer or its Affiliates or Sublicensees and used in connection with the Commercialization of any Agreement Product by Pfizer or its Affiliates or Sublicensees hereunder, including any registration or application for registration of any of the
foregoing. For purposes of clarity, “Trademark” shall not include any trademark, trade dress, design, logo, slogan, house mark or name of MacroGenics, including “MacroGenics” or “DART”. 

  
 14 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.148. “Up-Front Payment” is defined in Section 5.1. 

1.149. “Valid Claim” means (a) a claim of any unexpired United States or foreign issued patent that shall not have
been dedicated to the public, disclaimed nor held invalid or unenforceable by a court or government agency of competent jurisdiction in an unappealed or unappealable decision or (b) *** 

1.150. Construction. Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed
to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words “include”, “includes” and “including” shall be deemed to be
followed by the phrase “without limitation,” (c) the word “will” shall be construed to have the same meaning and effect as the word “shall,” (d) any definition of or reference to any agreement, instrument or
other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set
forth herein), (e) any reference herein to any Person shall be construed to include the Person’s successors and assigns, (f) the words “herein”, “hereof” and “hereunder”, and words of similar import,
shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to sections or exhibits shall be construed to refer to sections or exhibits of this Agreement, and references to
this Agreement include all exhibits hereto, (h) the word “notice” means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this
Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in
writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to
include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, (k) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such
agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), and (l) the term “or” shall be
interpreted in the inclusive sense commonly associated with the term “and/or.” 
  

	2.	RESEARCH PROGRAM. 

 2.1.
Selection of Research Project Targets. 
 2.1.1. Selection of Initial Research Project Target. Pfizer hereby designates
*** as the Research Project Target for the first Research Project (the “First 

  
 15 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
Research Project Target”) and *** as the Research Project Target for the second Research Project (the “Second Research Project Target and together with the First Research
Project Target, the “Initial Research Project Targets”).  
 2.1.2. Selection of Initial Reserved
Targets. Pfizer hereby designates *** and *** as the initial reserved targets (“Initial Reserved Targets”). 

2.1.3. Substitution of Targets. Pfizer may request that additional Targets be substituted on a one-for-one basis for the Second
Research Project Target or any Reserved Target in accordance with this Section 2.1.3. 
 (a) At any time within *** following
the Effective Date, Pfizer may substitute, without limitation on the number of substitutions and on a one-for-one basis, for the Second Research Project Target and the Reserved Targets. 

(b) At any time beginning *** after the Effective Date and continuing until the earlier of (i) ***, and (ii) the allowance by
MacroGenics of the second new Target to be substituted for a Reserved Target under this Section 2.1.3(b), Pfizer may request that additional Targets be substituted on a one-for-one basis for any existing Reserved Targets. 

(c) MacroGenics will allow such substitutions set forth in (a) and (b), except that it may decline a proposed Target substitution
based on (i) *** 
 2.1.4. Elevation of Reserved Targets. At any time in the *** following the Effective Date,
Pfizer may submit a written notice to MacroGenics that up to two Reserved Targets will be substituted for any then-designated Research Project Target on a one-for-one basis. Any such Reserved Target substituted for an existing Research Project
Target will then be deemed to be included within the definition of Research Project Target. 
 2.1.5. Former Reserved
Targets. Any Reserved Targets shall cease to be a Reserved Target for all purposes under this Agreement (including under Section 4.5) upon the earlier of (a) replacement of such Reserved Target with a new Target in accordance with Section
2.1.3, or ***  
 2.1.6. Former Research Project Targets. Any Research Project Target, to the extent that it has
been substituted by a Reserve Target, shall cease to be a Research Project Target for all purposes of this Agreement (including under Section 4.5). 
 2.2. Scope and Conduct of the Research Program. Under the terms and conditions set forth herein, MacroGenics and Pfizer shall collaborate during the Research Term to conduct discovery and
pre-clinical Development activities to screen and identify Antibodies to the two (2) Research Project Targets (or the Reserved Targets that become Research Project Targets pursuant to Section 2.1.4) for construction of T-DARTs (the

  
 16 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
“Research Program”). The Research Program shall be conducted in accordance with the Research Plan for each Research Project (as more fully provided in Section 2.3 below), and
each Party shall use its Commercially Reasonable Efforts to perform all activities assigned to it and fulfill all of its obligations under each Research Plan. In addition, each Party shall conduct its activities under the Research Plan(s) in
accordance with Applicable Law. MacroGenics will not, without first providing prior written notice to Pfizer, take any action with respect to conducting the Research Program that would require MacroGenics to make any payments to a Third Party such
that any item of information or other intellectual property would be excluded from the definition of “Control” under this Agreement. For avoidance of doubt, upon expiration or termination of the Research Term, the Research Program and all
Research Projects shall automatically terminate. 
 2.3. Research Plans. 

2.3.1. Adoption of Research Plans. The Parties shall adopt a research plan (each a “Research Plan”) for all
activities conducted under the Research Program during the Research Term, including a Research Plan that covers each Research Project Target; a “Research Project” shall mean the work to be performed pursuant to such a Research Plan.
The form for each Research Plan for each Research Project Target is attached as Exhibit 23.1 The Research Plan for each Research Project Target shall be prepared by the JSC and adopted within *** after the Target Designation
Date for such Research Project Target by the JSC. Each Research Plan shall reference this Agreement and shall be subject to all of the provisions of this Agreement, in addition to the specific details set forth in such Research Plan. To the extent
any provisions of a Research Plan conflict or are inconsistent with the provisions of this Agreement, the provisions of this Agreement shall control. Unless otherwise expressly stated in a Research Plan, the provisions of each Research Plan shall be
independent of and shall not affect the provisions of any other Research Plan. If the Parties are unable to agree on a Research Plan within the specified time period, the JSC may specify the Research Plan, and all disputes regarding the preparation
or modification of any Research Plan (including the approval of any amendments thereto) shall be resolved by the JSC. 
 2.3.2.
Researchers. During the *** of the Research Term the Parties will dedicate *** to the Research Program and this number cannot be changed without agreement of the Parties. The Parties currently expect to dedicate an average of
*** to the Research Program for the remainder of the Research Term. The number of FTEs will be reviewed by the JSC on a semi-annual basis and may be updated as necessary by the JSC. 

  
 17 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 2.3.3. Responsibilities. Each Research Plan shall set forth the services and the
obligations and responsibilities assigned to each Party (collectively the “Research Plan Services”), and shall include the following minimum terms: 
 (a) For each Research Project, one or both of the Parties shall generate or provide Antibodies that bind to the Research Project Target for such Research Project. 

(b) In accordance with Section 2.4, Pfizer shall be entitled to select up to *** Antibodies to be investigated by MacroGenics for
possible construction of a T-DART to the extent Antibodies are generated under a Research Plan. 
 (c) MacroGenics will
investigate each Antibody selected by Pfizer in accordance with the applicable Research Plan. 
 (d) MacroGenics will support
the *** 
 (e) Pfizer will support additional in vivo modeling, completion of IND-enabling studies, clinical Development,
GMP-Manufacturing, and Commercialization. 
 (f) The Parties may jointly decide to expand MacroGenics’s research and
Development responsibilities to include additional *** 
 (g) In no event shall MacroGenics be required to commit more
than *** to support the Research Program during any Calendar Year during the Research Term. 
 2.4. Research Program
Antibodies and Passed MacroGenics Antibodies. 
 2.4.1. For each Research Project Target and prior to initiation of in vivo
modeling (as defined in the related Technical Milestone under Section 5.3.1) for such Research Project Target, Pfizer may identify in writing to MacroGenics up to *** Antibodies which Pfizer intends to evaluate for the relevant Research
Project (each a “Research Program Antibody”). 
 2.4.2. Upon MacroGenics’s request, the JSC will promptly
determine whether any proprietary (to MacroGenics) Research Program Antibody contributed to the Research Program by MacroGenics is no longer under Development or consideration for Development under the Research Program and has become a Passed
MacroGenics Antibody. 
 2.4.3. Other than as set forth in the Research Plan for the Initial Research Project Target that is
attached as Exhibit 2.3.1 or as subsequently agreed by the Parties and set forth in a Research Plan, MacroGenics shall have no obligation to provide Pfizer with any Antibodies developed or acquired by MacroGenics outside of this
Agreement. 

  
 18 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 2.5. Governance of the Research Program. 

2.5.1. Formation of the Joint Steering Committee. MacroGenics and Pfizer shall establish a “Joint Steering
Committee” (or “JSC”) to oversee and coordinate the activities of the Parties under this Agreement in regard to the Research Program. The Joint Steering Committee shall also serve as a forum to facilitate communications
between the Parties regarding the Research Program. The Joint Steering Committee shall be comprised of three (3) representatives from each Party as appointed by such Party. The Joint Steering Committee may change its size from time to time by
mutual consent of its members. A Party may replace one or more of its representatives from time to time upon written notice to the other Party. Each Party, respectively, shall designate its initial members of the Joint Steering Committee within
thirty (30) days after the Effective Date. The Joint Steering Committee shall exist until expiration of the Research Term, unless the Parties otherwise agree in writing. 
 2.5.2. Co-Chairpersons and Secretary of the Joint Steering Committee. Each Party shall designate a co-chairperson of the Joint Steering Committee and a secretary of the Joint Steering Committee
shall be designated in accordance with Section 2.6 below. A Party may change the designation of its co-chairperson from time to time upon written notice to the other Party. The co-chairpersons shall be responsible for scheduling meetings of
the Joint Steering Committee, preparing agendas for meetings and sending to all Joint Steering Committee members notices of all regular meetings and agendas for such meetings at least five (5) Business Days before such meetings. The
co-chairpersons shall solicit input from both Parties regarding matters to be included on the agenda, and any matter either Party desires to have included on the agenda shall be included for discussion. Nothing herein shall be construed to prohibit
the Joint Steering Committee from discussing or acting on matters not included on the applicable agenda. The secretary shall record the minutes of the meeting, circulate copies of meeting minutes to the Parties and each Joint Steering Committee
member promptly following the meeting for review, comment and approval by the Joint Steering Committee members and finalize approved meeting minutes. The co-chairpersons shall be members of the Joint Steering Committee but the secretary need not be
a member of the Joint Steering Committee. 
 2.5.3. Meetings. The Joint Steering Committee shall meet at least once each
Calendar Quarter until it has been terminated in accordance with Section 2.5.1 at dates and times mutually agreed by the Joint Steering Committee, unless otherwise mutually agreed by the Parties. The initial meeting of the Joint Steering Committee
shall be held within ninety (90) days after the Effective Date. Either Party may call a special meeting of the Joint Steering Committee on fifteen (15) days prior written notice to the other Party’s members of the Joint Steering
Committee (or upon such shorter notice as exigent circumstances may require). Such written notice shall include an agenda for the special meeting. In-person meetings, including special meetings, of the Joint Steering Committee shall alternate
between the offices of the Parties, unless otherwise agreed upon by the members of the Joint Steering Committee. Meetings of the Joint Steering 

  
 19 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
Committee may be held telephonically or by video conference; provided, however, that at least two (2) meetings per year shall be held in-person. Meetings of the Joint Steering Committee
shall be effective only if at least one representative of each Party is in attendance or participating in the meeting. Members of the Joint Steering Committee shall have the right to participate in and vote at meetings held by telephone or video
conference. In addition, the Joint Steering Committee may act on any matter or issue without a meeting if it is documented in a written consent signed by each member of the Joint Steering Committee. 

2.5.4. Responsibilities of the Joint Steering Committee. The JSC shall be responsible for (a) planning and supervising
research and development under this Agreement, including establishing, reviewing and recommending modifications and updates to the Research Plans; (b) receiving and reviewing all data and other information obtained by either Party in connection
with the Research Program and monitoring and reporting to the Parties on activities conducted pursuant to the Research Plans; (c) documenting and approving initiation and completion of each Research Project and the achievement of any Technical
Milestones, Development Milestones and Sales Milestones; (d) evaluating FTE requirements for the performance of the Research Plans; and (e) such other functions as expressly specified hereunder or as agreed by the Parties. 

2.5.5. Decisions by Consensus. 
 (a) All decisions of the Joint Steering Committee shall be made by unanimous agreement of both Parties’ representatives, with each Party having a single vote, irrespective of the number of JSC
representatives in attendance at a meeting. 
 (b) If, in accordance with Section 2.5.5(a), the JSC does not resolve any matter
within its purview by it within *** after the matter is first considered by it, the matter may be referred by either Party to MacroGenics’s *** to be resolved by negotiation in good faith as soon as practicable but in no event
later than *** after referral. Such resolution, if any, of a referred issue by the *** shall be final and binding on the Parties. 
 (c) If a dispute referred to the *** has not been resolved in accordance with Section 2.5.5(b), then, subject to Section 2.5.5(d), ***. Any decisions made by Pfizer under this Section
2.5.5(c) shall be deemed a decision of the JSC for purposes of this Agreement. 
 (d) Notwithstanding Section 2.5.5(c),
*** shall not have the right to exercise such decision-making authority (i) in a manner that excuses *** from any of its obligations specifically enumerated under this Agreement; (ii) in a manner that negates any consent
rights or other rights specifically allocated to MacroGenics under this Agreement; (iii) to resolve any 

  
 20 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
dispute regarding whether a Technical Milestone, Development Milestone or Sales Milestone has been achieved; (iv) in a manner that would require *** (A) *** will not
reimburse *** costs (except as expressly set forth in this Agreement ); (B) which would require *** to perform a category of services not previously contemplated as being performed by *** under the Research Program and
which *** does not have the existing capability to perform; or (C) which require *** to acquire from any Third Party any Know-How, Patent Right or other technology not contemplated in a Research Plan and that is not readily
available from such Third Party or readily capable of being developed internally by ***; or (vi) in a manner that would require *** to perform any act that it reasonably believes to be inconsistent with any Applicable Law or any
approval, order, policy, guidelines of a Regulatory Authority or ethical requirements or ethical guidelines. 
 2.6. Alliance
Managers. In addition to the foregoing governance provisions, each of the Parties shall appoint a single individual to serve as that Party’s alliance manager (“Alliance Manager”). The role of each Alliance Manager shall be
to facilitate the relationship between the Parties as established by this Agreement. The Alliance Managers shall attend meetings of the Joint Steering Committee and support the respective co-chairpersons of such committee in the discharge of their
responsibilities. Unless otherwise determined by the Joint Steering Committee, Pfizer’s Alliance Manager shall serve as secretary at each meeting of the Joint Steering Committee. Alliance Managers shall be non-voting participants in such
committee meetings. A Party may replace its Alliance Manager from time to time upon written notice to the other Party. 
 2.7.
Conformance with Law. Each Party shall perform and discharge its obligations under this Agreement and the Research Program in conformance with (a) professional standards and practices, (b) this Agreement and the Research Plan(s) and
(c) all Applicable Laws. Without limiting the generality of the foregoing, each Party shall retain all records relating to its performance of this Agreement and the Research Plan(s) for the time periods required by Applicable Laws. 

2.8. MacroGenics Personnel Matters. MacroGenics acknowledges and agrees that it is solely responsible for the compensation of the
personnel assigned to the Research Plan Services, and as employer shall be responsible for withholding all national, state, local or other applicable taxes and similar items. MacroGenics also shall be responsible for all other employer related
obligations, including providing appropriate insurance coverage and employee benefits, and making all other deductions required by law affecting the gross wages of each employee. MacroGenics personnel assigned to the Research Plan Services are not
nor shall they be deemed to be employees of Pfizer. 
 2.9. Debarment Certification. Neither Party nor any Person employed
or retained to perform services by either Party has been debarred under Section 306(a) or (b) of the FD&C Act or any comparable provision of foreign law and no debarred Person shall in the future be employed or retained to perform
services by either Party in connection with 

  
 21 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
any work to be performed for or on behalf of the other Party. If, at any time after execution of this Agreement, either Party becomes aware that such Party or any Person employed or retained to
perform services by such Party in connection with any work performed for or on behalf of such Party is, or is in the process of being, debarred, such Party shall so notify the other Party immediately. 

2.10. Subcontractors. 
 2.10.1. MacroGenics may not engage any contractor, subcontractor or other vendor (a “Subcontractor”) to perform any Research Plan Services or Research Program activities not specifically
contemplated or set forth in the applicable Research Plan without Pfizer’s prior written consent; provided, however, that Pfizer hereby provides its prior written consent to MacroGenics’s engagement of the Subcontractors set forth on
Schedule 2.10 attached hereto for performance of the Research Plan Services set forth on such Schedule 2.10. MacroGenics shall be responsible for the management of all permitted Subcontractors. The engagement by MacroGenics of any
Subcontractor in compliance with this Section 2.10 shall not relieve MacroGenics of its obligations under this Agreement or any applicable Research Plan. Any agreement between MacroGenics and a permitted Subcontractor pertaining to the Research Plan
Services shall be consistent with the provisions of this Agreement. Furthermore, unless otherwise agreed by Pfizer in writing, prior to or at the time of engagement of any Subcontractor to perform any obligations hereunder, MacroGenics shall cause
such Subcontractor to agree in writing to be bound by substantially equivalent obligations of confidentiality and use of proprietary materials as those in this Agreement. 
 2.10.2. *** 
 2.11. Inspections. Pfizer authorized representative(s), and
Regulatory Authorities to the extent required by law and applicable to the scope of the Research Plan Services performed, may, during regular business hours and, to the extent legally possible, at times arranged in advance with MacroGenics, audit,
inspect and copy all data, records and work products, and audit and inspect all facilities, relating to the Research Plan Services and MacroGenics’s performance under this Agreement and the applicable Research Plan(s) (including all data,
records, work products and facilities of Subcontractors); provided, however, that MacroGenics may limit the scope of any such audit or inspection to prevent the disclosure of confidential information of MacroGenics or the disclosure of confidential
information of MacroGenics’s Subcontractors (“Subcontractor Information”), unless such confidential information or Subcontractor Information is directly related to the performance of the Research Plan Services and the
disclosure is required for purposes of the audit or inspection. 
 2.12. Records. Each Party shall prepare, maintain and
retain complete and accurate written records, accounts, notes, reports and data of the Research Plan Services and its performance under this Agreement and the Research Plan(s), in a form and of quality reasonably acceptable to both Parties. All such
information generated by MacroGenics 

  
 22 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
shall be treated as Confidential Information of both Parties for the purpose of this Agreement and all such information generated by Pfizer shall be treated as Confidential Information of Pfizer
for the purposes of this Agreement. 
 2.13. Transfer and Use of Pfizer Proprietary Materials. 

2.13.1. Transfer. From time to time, pursuant to a Research Plan, or otherwise, Pfizer may provide MacroGenics with Pfizer
Proprietary Materials. Pfizer represents and warrants to MacroGenics that Pfizer has the right to provide the Pfizer Proprietary Materials to MacroGenics for the uses authorized herein. Except as expressly set forth in the preceding sentence, the
Pfizer Proprietary Materials are provided by Pfizer on an “as-is” basis without representation or warranty of any type, express or implied, including any representation or warranty of merchantability, non-infringement, title or fitness for
a particular purpose, each of which is hereby disclaimed by Pfizer. 
 2.13.2. Use of Pfizer Proprietary Materials.
MacroGenics shall use the Pfizer Proprietary Materials solely in connection with conducting the specific activities under this Agreement for which such Pfizer Proprietary Materials are provided to MacroGenics, including, if applicable, the
provisions of any specific Research Plan under which such Pfizer Proprietary Materials are provided, and for no other purpose. Without limiting the generality of the foregoing, except as expressly set forth in this Agreement or in any applicable
Research Plan, MacroGenics shall not make or attempt to make analogues, progeny or derivatives of, or modifications to, the Pfizer Proprietary Materials and MacroGenics shall not use the Pfizer Proprietary Materials for the benefit of any Third
Party or of its own internal research programs outside of the Research Program. MacroGenics shall not administer any of the Pfizer Proprietary Materials to any human. MacroGenics shall comply with all Applicable Laws regarding the handling and use
of the Pfizer Proprietary Materials. MacroGenics agrees to retain possession over the Pfizer Proprietary Materials and not to provide the Pfizer Proprietary Materials to any Third Party without Pfizer’s prior written consent, except as required
to perform the Research Program. 
 2.13.3. Unauthorized Use of Materials. In the event that MacroGenics uses the Pfizer
Proprietary Materials for any purpose other than the purposes authorized herein, the results of such unauthorized research, and any discoveries or inventions that arise from such unauthorized research, whether patentable or not, shall belong solely
and exclusively to Pfizer. If required in order to perfect or enforce Pfizer’s rights to such results, discoveries or inventions, MacroGenics hereby assigns and agrees to assign to Pfizer all of its right, title and interest in and to all such
results, discoveries or inventions. MacroGenics agrees to cooperate with Pfizer, and to execute and deliver any and all documents that Pfizer deems reasonably necessary, to perfect and enforce its rights hereunder. 

  
 23 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 2.13.4. Title to Pfizer Proprietary Materials. All right, title and interest in the
Pfizer Proprietary Materials shall remain the sole property of Pfizer notwithstanding the transfer to and use by MacroGenics of the same. 
 2.13.5. Return of Pfizer Proprietary Materials. Upon completion of the activities for which the Pfizer Proprietary Materials have been provided, or upon expiration or termination of this Agreement
or the applicable Research Plan, if earlier, MacroGenics shall, at Pfizer’s option and expense, either destroy or return to Pfizer all unused Pfizer Proprietary Materials. 
 2.13.6. Assignment. MacroGenics hereby assigns to Pfizer all of MacroGenics’s right, title and interest in and to any Pfizer Proprietary Material Improvements. During and after the Term,
MacroGenics shall promptly notify Pfizer of any Pfizer Proprietary Material Improvement developed by MacroGenics and shall cooperate fully in obtaining patent and other proprietary protection for such Pfizer Proprietary Material Improvement. Such
protection shall be obtained in the name of Pfizer and at Pfizer’s cost and expense, and MacroGenics, without limitation, shall execute and deliver all requested applications, assignments and other documents, and take such other measures, as
Pfizer shall reasonably request, in order to perfect and enforce Pfizer’s rights in any Pfizer Proprietary Material Improvement. MacroGenics appoints Pfizer its attorney to execute and deliver any such documents and take such actions on
MacroGenics’s behalf in the event MacroGenics fails to do so. 
  

	3.	PRODUCT DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION AND REGULATORY MATTERS. 

3.1. General. Except as expressly set forth in Section 2, Pfizer shall have sole authority over and control of the Development,
Manufacture and Commercialization of Agreement Products. 
 3.2. Diligence. 

3.2.1. Development Diligence. Pfizer will use Commercially Reasonable Efforts to Develop (including to seek Regulatory Approval
for) each Agreement Product in at least one Indication in the ***: (i) ***. Pfizer may determine in its sole discretion the order in which it seeks any such Regulatory Approval. Pfizer will have no other diligence obligations with
respect to the Development (including to seek Regulatory Approval of) of Agreement Products under this Agreement. For the avoidance of doubt, any actions taken by Pfizer’s Affiliates or Sublicensees under this Agreement shall be treated as
actions taken by Pfizer in regard to satisfaction of the requirements of this Section 3.2. 
 3.2.2. Commercial Diligence.
Pfizer will use Commercially Reasonable Efforts to Commercialize a given Agreement Product in each Major Market Country in the Field in the Territory where Pfizer or its Affiliates have received Regulatory

  
 24 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
Approval for such Agreement Product. Pfizer will have no other diligence obligations with respect to the Commercialization of Agreement Products under this Agreement. 

3.2.3. Exceptions to Diligence Obligations. Notwithstanding any provision of this Agreement to the contrary, Pfizer will be
relieved from and will have no obligation to undertake any efforts with respect to any Pfizer Diligence Obligation in the event that: 
 (a) Pfizer or MacroGenics receives or generates any safety, tolerability or other data reasonably indicating, as measured by Pfizer’s safety and efficacy evaluation criteria and methodology, or
signaling that an Agreement Product has or would have an unacceptable risk-benefit profile or is otherwise not reasonably suitable for initiation or continuation of clinical trials in humans; or 

(b) Pfizer or MacroGenics receive any notice, information or correspondence from any applicable Regulatory Authority, or any applicable
Regulatory Authority takes any action, that reasonably indicates that an Agreement Product is unlikely to receive Regulatory Approval. 
 3.2.4. Assertion of Pfizer Diligence Obligation Claims. If MacroGenics becomes aware of facts that might form a reasonable basis to allege that Pfizer has failed to meet any Pfizer Diligence
Obligation, then MacroGenics will notify Pfizer in writing of such potential alleged performance failure (each such potential alleged performance failure, a “Diligence Issue”). Promptly upon Pfizer’s receipt of any notice of a
Diligence Issue pursuant to this Section 3.2.3, the Pfizer Alliance Manager will contact the MacroGenics Alliance Manager to discuss the specific nature of such Diligence Issue and seek to identify an appropriate corrective course of action. If, no
later than thirty (30) days after Pfizer’s receipt of such a notice, (a) the Parties have not reached consensus regarding whether Pfizer has failed to satisfy the Pfizer Diligence Obligations and (b) the Parties’ respective
Alliance Managers have not agreed upon an appropriate corrective course of action for such Diligence Issue, then such Diligence Issue will be escalated and resolved pursuant to the dispute resolution provisions set forth in Section 11.9. Failure by
MacroGenics to provide notice of a Diligence Issue pursuant to this Section 3.2.4 shall not result in a waiver by MacroGenics of its rights under Section 3.2.5 of this Agreement. 

3.2.5. Remedies for Breach of Pfizer Diligence Obligations. If Pfizer materially breaches any Pfizer Diligence Obligation and fails
to remedy such breach within *** of Pfizer’s receipt of notice of such breach from MacroGenics, then MacroGenics may, in its sole discretion, elect to either (a) terminate this Agreement with the effects of the provisions of Section
9.5.2 on an Agreement Product-by-Agreement Product and country-by-country basis, but only to the 

  
 25 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
extent that an Agreement Product in a given country in the Territory is directly and adversely impacted by such uncured material breach, or (b) convert any exclusive licenses granted to
Pfizer under this Agreement with respect to an Agreement Product in a given country in the Territory into non-exclusive licenses, but only to the extent that such Agreement Product in such country is directly and adversely impacted by such uncured
material breach. In the event MacroGenics elects Section 3.2.5(b) as a remedy to address a Diligence Issue, Pfizer shall continue to have the same obligations to pay all milestones, FTE costs and Net Sales royalties for each Agreement T-DART and
Agreement Product affected by MacroGenics election. MacroGenics acknowledges and agrees that the elections set forth in this Section 3.2.5 (i) have been negotiated by the Parties to fully address any harm that MacroGenics may incur as a result
of Pfizer’s material breach of any Pfizer Diligence Obligation and (ii) constitute MacroGenics’s sole and exclusive remedies with respect to any breach by Pfizer of the Pfizer Diligence Obligations. 

3.3. Regulatory Approvals. Pfizer or its designated Affiliate(s) shall file, in its own name, all Regulatory Approval applications
for Agreement Products where, subject to the Pfizer Diligence Obligations, Pfizer, in its sole discretion, determines it is commercially advantageous to do so. Pfizer, or its designated Affiliate(s), shall have the sole responsibility for, and sole
authority with respect to, communications with any Regulatory Authority regarding any Regulatory Approval application or any Regulatory Approval for an Agreement Product once granted. Except to the extent necessary to fulfill its obligations under
Section 3.2.1, neither Pfizer nor any of its Affiliates shall have any obligation to seek Regulatory Approval for any Agreement Product. 
 3.4. Control of Commercialization Activities. 
 3.4.1.
General. Subject to the Pfizer Diligence Obligations, Pfizer shall have sole and exclusive control over all matters relating to the Commercialization of Agreement Products. 

3.4.2. Branding. Pfizer shall select and own all Trademarks, including all goodwill associated therewith. Neither MacroGenics nor
its Affiliates shall use or seek to register, anywhere in the world, any trademarks which are confusingly similar to any Trademarks. 
 3.5. Manufacturing. Subject to Section 2.3.3(f), Pfizer shall have the exclusive right to Manufacture Agreement Products itself or through one or more Affiliates or Third Parties selected by
Pfizer. Pfizer shall have no diligence obligations with respect to the Manufacture of Agreement Products except to the extent necessary to fulfill the Pfizer Diligence Obligations. 

3.6. Progress Reporting. Pfizer shall provide MacroGenics with semi-annual written reports on Pfizer’s activities to Develop
and Commercialize Agreement Products. Any information or written report provided by Pfizer to MacroGenics pursuant to this Section 3.6 

  
 26 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
shall be deemed to be Pfizer’s Confidential Information subject to the provisions of Section 7. MacroGenics shall have the opportunity to reasonably seek further explanation or clarification
of matters covered in such reports, and Pfizer shall provide such explanation or clarification. Furthermore, if after receiving such a report MacroGenics wishes to meet with Pfizer to discuss such report, Pfizer shall meet (in person or via
teleconference) with MacroGenics at a site reasonably requested by MacroGenics within thirty (30) days after MacroGenics requests such meeting. 
  

	4.	LICENSES AND RELATED GRANTS OF RIGHTS. 

 4.1. Grants to Pfizer. 
 4.1.1. Research License. Subject to the
terms and conditions of this Agreement and during the Research Term, MacroGenics hereby grants to Pfizer a non-exclusive, worldwide, royalty-free license under the MacroGenics Technology to (a) use, have used, make and have made any T-DART
directed to any Research Project Target for any and all uses in the Field, (b) conduct preclinical studies in vitro and in vivo in any non-human species with any T-DART directed to the Research Project Target for any and all uses in the Field
and (c) otherwise perform the activities assigned to Pfizer under the Research Plans. The foregoing license shall be sublicenseable by Pfizer as provided in Section 4.1.4. 
 4.1.2. Assignment of Agreement T-DART IP. MacroGenics shall assign and hereby does assign to Pfizer all of MacroGenics’s and its Affiliates’ right, title and interest in and to the
Agreement T-DART IP (including the right in and to any data, writings (irrespective of whether in written or electronic form) and information (tangible and intangible) covering the foregoing). MacroGenics shall execute, and cause its employees,
agents and subcontractors to execute (directly or through assignment to MacroGenics and assignment by MacroGenics to Pfizer), assignments to Pfizer of all right, title and interest in and to any such Agreement T-DART IP. Subject to the terms of
Section 9.5.2(a) and Section 9.5.2(b), any Agreement T-DART IP shall be the sole and exclusive property of Pfizer and shall constitute Confidential Information of Pfizer. MacroGenics will cooperate with Pfizer to execute and deliver any and all
documents that Pfizer deems reasonably necessary to perfect and enforce Pfizer’s rights under this Section 4.1.2. Pfizer shall not grant any license under or other right with respect to any rights in any Agreement T-DART IP subject to potential
reassignment to MacroGenics under Section 9.5.2 , that would prevent, survive or be otherwise inconsistent with the reassignment of such Agreement T-DART IP to MacroGenics if required by Section 9.5.2 free and clear of any such license or other
right and shall take no action with respect to any other Agreement T-DART IP that is inconsistent with Pfizer’s obligations under Section 9.5.2. 
 4.1.3. Exclusive License. Subject to the terms and conditions of this Agreement and effective on the Effective Date, MacroGenics hereby grants to Pfizer an exclusive (even as to MacroGenics, except
to the extent necessary for 

  
 27 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
MacroGenics to perform its obligations under the Research Program), license under the MacroGenics Technology and MacroGenics’s interest in the Joint Technology to use, have used, Develop,
have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized, import, have imported, export and have exported Agreement T-DARTs and Agreement Products in the Territory for use in the Field, with the right to sublicense as
provided in Section 4.1.4. 
 4.1.4. Right to Sublicense. Pfizer shall have the right to grant sublicenses under the
licenses granted to it (a) under Section 4.1.1 and 4.1.3 . to Affiliates of Pfizer at any time, and (b) (i) under Section 4.1.1 to Third Party contractors solely for the provision of services to Pfizer in connection with the
performance of activities assigned to Pfizer under the Research Plans; and (ii) under Section 4.1.3 to Third Parties; provided that any sublicense granted to a Third Party under this Agreement shall be pursuant to a written agreement that
subjects such sublicensee to all relevant restrictions and limitations set forth in this Agreement. Pfizer shall provide MacroGenics notice of any Third Party sublicense within *** after the execution thereof, including the name and address
of each permitted sublicensee, the date of the grant of the sublicense and a description of the rights granted. Pfizer shall be jointly and severally responsible with its sublicensees to MacroGenics for failure by its sublicensees to comply with,
and Pfizer guarantees the compliance by each of its sublicensees with, all such applicable restrictions and limitations in accordance with the terms and conditions of this Agreement. Pfizer shall remain responsible for the payment to MacroGenics of
all Sales Milestones and royalties payable with respect to Net Sales made by any of Pfizer’s Affiliates and Sublicensees. 

4.1.5. Direct License to Affiliates. Pfizer may at any time request and authorize MacroGenics to grant licenses directly to
Affiliates of Pfizer by giving written notice designating to which Affiliate a direct license is to be granted. Upon receipt of any such notice, MacroGenics shall enter into and sign a separate direct license agreement with such designated Affiliate
of Pfizer. All such direct license agreements shall be consistent with the terms and conditions of this Agreement, except for such modifications as may be required by the laws and regulations in the country in which the direct license will be
exercised. The Parties further agree to make any amendments to this Agreement that are necessary to conform the combined terms of such direct license agreements and this Agreement to the terms of this Agreement as set forth on the Effective Date. In
countries where the validity of such direct license agreements requires prior governmental approval or registration, such direct license agreements shall not become binding between the parties thereto until such approval or registration is granted,
which approval or registration shall be obtained by Pfizer. All costs of making such direct license agreement(s), including MacroGenics’s reasonable attorneys’ fees, under this Section 4.1.5 shall be borne by Pfizer. 

  
 28 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 4.1.6. Right of Reference. To the extent that MacroGenics does not breach any
contractual obligations it has with Third Parties, MacroGenics hereby grants to Pfizer a “Right of Reference,” as that term is defined in 21 C.F.R. § 314.3(b), to any data Controlled by MacroGenics or its Affiliates (a) that
relates to the Agreement T-DARTS, the Agreement Products or preclinical studies with respect to the Agreement Products and (b) that Pfizer reasonably believes may be necessary or useful to the Development, Manufacturing or Commercialization of
any Agreement T-DART or any Agreement Product pursuant to this Agreement, and MacroGenics will provide a signed statement to the foregoing effect, if so requested by Pfizer in accordance with 21 C.F.R. § 314.50(g)(3). 

4.2. Grants to MacroGenics. 
 4.2.1. Research License. Subject to the terms and conditions of this Agreement and during the Research Term, Pfizer hereby grants to MacroGenics a non-exclusive, worldwide, royalty-free license
under the Pfizer Technology solely to the extent necessary to conduct activities assigned to MacroGenics under the Research Plan, with the right to sublicense as provided in Section 4.2.1(a). 

(a) Right to Sublicense. MacroGenics may sublicense the foregoing license but only to any one or more of MacroGenics’
Affiliates or subcontractors. 
 4.2.2. Grant Back License with Respect to Agreement T-DART IP Assigned to Pfizer.
Subject to the terms and conditions of this Agreement, Pfizer hereby grants to MacroGenics a non-exclusive, worldwide, royalty-free license under the Agreement T-DART IP and the Agreement T-DART Patent Rights to use, have used, Develop, have
Developed, Manufacture, have Manufactured, Commercialize, have Commercialized, import, have imported, export and have exported any T-DART or other bi-specific targeting molecule (other than (a) any T-DART Targeting any Research Project Target
or any Reserved Target or (b) any other bi-specific targeting molecule that consists of or comprises any Research Program Antibody (other than a Passed MacroGenics Antibody) Targeting any Research Project Target or any Reserved Target), either
alone or as part of any pharmaceutical or other product, with the right to sublicense. 
 4.3. Reciprocal Non-Exclusive
Research License for Disclosed Know-How and Confidential Information. Without limiting any other license granted to either Party under this Agreement: 
 4.3.1. MacroGenics hereby grants to Pfizer and Pfizer’s Affiliates a non-exclusive, irrevocable, perpetual, royalty-free, fully paid-up, worldwide license to use any and all MacroGenics Know-How or
MacroGenics Confidential Information disclosed to Pfizer during the Term solely for internal research purposes. 

  
 29 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 4.3.2. Pfizer hereby grants to MacroGenics and MacroGenics Affiliates a non-exclusive,
irrevocable, perpetual, royalty-free, fully paid-up, worldwide license to use any and all Pfizer Know-How or Pfizer Confidential Information (other than any information regarding the identity of or Pfizer’s reasons for selecting any Research
Project Target or Reserved Target, which shall only be disclosed by MacroGenics to MacroGenics personnel as necessary to comply with the terms of this Agreement) disclosed to MacroGenics during the Term solely for internal research purposes.

 4.3.3. Notwithstanding the foregoing, neither Pfizer nor MacroGenics shall have any right under this Section 4.3 to make
any use of any physical material supplied by the other Party for use in the Research Program other than for use in the Research Program.
 4.4. Retained Rights to Antibodies. For the avoidance of doubt, except as expressly provided in regard to the assignments and licenses contained in this Section 4, neither Party will have any
rights in the other Party’s Antibodies and each Party will retain ownership of all of its Pfizer Technology, MacroGenics Technology or Joint Technology, as applicable, covering any Antibody that such Party contributes to the collaboration.

 4.5. Exclusivity. 
 4.5.1. Exclusivity Covenant. During the Research Term and for *** after the Research Term, except to the extent required for MacroGenics to fulfill its obligations under this Agreement,
neither MacroGenics nor any of its Affiliates will (i) (either directly or with or through a Third Party) Develop, Manufacture or Commercialize any T-DART or Research Program Antibody (other than a Passed MacroGenics Antibody) Targeting any
Research Project Target or any Reserved Target or (ii) license or otherwise grant any right to any Third Party to Develop, Manufacture or Commercialize any T-DART or Research Program Antibody (other than a Passed MacroGenics Antibody) Targeting
any Research Project Target or any Reserved Target. 
 4.5.2. Other Pfizer Programs. MacroGenics understands and
acknowledges that Pfizer may have present or future initiatives or opportunities, including initiatives or opportunities with its Affiliates or Third Parties, involving similar products, programs, technologies or processes that are similar to or
that may compete with a product, program, technology or process covered by this Agreement. MacroGenics acknowledges and agrees that nothing in this Agreement will be construed as a representation, warranty, covenant or inference that Pfizer will not
itself Develop, Manufacture or Commercialize or enter into business relationships with one or more of its Affiliates or Third Parties to Develop, Manufacture or Commercialize products, programs, technologies or processes that are similar to or that
may compete with any product, program, technology or process covered by this Agreement. 

  
 30 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 4.6. Section 365(n) of Bankruptcy Code. All rights and licenses now or
hereinafter granted by a Party to the other Party under or pursuant to any section of this Agreement, including Sections 4.1.1 , 4.1.3, 4.2.1 and 4.2.2 are rights to “intellectual property” (as defined in Section 101(35A) of Title 11
of the United States Code, as amended (such Title 11, the “Bankruptcy Code”)). The Parties hereto acknowledge and agree that the payments provided for under Sections 5.1, 5.2 and 5.3 and all other payments by Pfizer to MacroGenics
under this Agreement, other than royalty payments pursuant to Section 5.4, do not constitute royalties within the meaning of Section 365(n) of the Bankruptcy Code or relate to licenses of intellectual property under this Agreement. 

4.7. No Implied Rights. Except as expressly provided in this Agreement, neither Party shall be deemed by estoppel, implication or
otherwise, to have granted the other Party any license or other right with respect to any intellectual property of such Party. 
  

	5.	PAYMENTS TO MACROGENICS. 

5.1. Upfront License Payment. Within *** days after the Effective Date, Pfizer shall pay to MacroGenics the non-creditable,
non-refundable amount of Five Million Dollars ($5,000,000) (the “Up-Front Payment”). 
  

	 	5.2.	Research Support Funding. 

5.2.1. FTE Reimbursement. During the Research Term, Pfizer shall reimburse MacroGenics for the costs of the FTEs for the Research
Program at the FTE Rate per FTE per Calendar Year. *** 
 5.2.2. Out-of-Pocket Expenses. During the Research Term,
Pfizer shall reimburse MacroGenics’s out-of-pocket costs incurred by MacroGenics and paid to Third Parties in connection with executing the Research Plans, but only to the extent contemplated in the Research Plans or otherwise approved by
Pfizer in advance in writing. 
 5.2.3. Other Expenses. Except as expressly set forth in Section 5.2.1 and Section 5.2.2,
MacroGenics shall be solely responsible for all expenses it incurs in performing its obligations under the Research Program. 

5.2.4. Reimbursement Payments. Pfizer shall reimburse MacroGenics for expenses pursuant to Section 5.2 within *** days after
receipt of an invoice issued by MacroGenics within *** days after the end of each Calendar Quarter. 
 5.2.5. Audit
Rights. During the Research Term and for a period of thirty-six (36) months thereafter, MacroGenics shall keep and maintain accurate and complete records showing the time devoted and activities performed by each FTE in performing
MacroGenics’s obligations under the Research Program. Upon thirty (30) days prior written notice from Pfizer, MacroGenics shall permit an independent certified public accounting firm of internationally recognized standing selected by
Pfizer and reasonably acceptable to MacroGenics, to 

  
 31 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
examine, at Pfizer’s sole expense, the relevant books and records of MacroGenics as may be reasonably necessary to verify the accuracy of the invoices submitted to Pfizer under Section 5.2.4
for the number of FTEs applied to the performance of MacroGenics’s obligations under the Research Program. An examination by Pfizer under this Section 5.2.5 shall occur not more than once in any Calendar Year and shall be limited to the
pertinent books and records for any Calendar Year ending not more than thirty-six (36) months before the date of the request. Such examination shall be conducted during MacroGenics’s normal business hours at MacroGenics’s
facility(ies) where such books and records are normally kept. MacroGenics may require the accounting firm to sign a standard non-disclosure agreement before providing the accounting firm access to MacroGenics’s facilities or records. The
accounting firm shall provide both MacroGenics and Pfizer a written report disclosing whether the invoices submitted by MacroGenics are correct or incorrect and the specific details concerning any discrepancies. No other information shall be
provided to Pfizer. If the accounting firm determines the number of FTEs actually utilized by MacroGenics was materially less than the number funded by Pfizer during the period covered by the audit ***, MacroGenics shall, at Pfizer’s
sole discretion, either (a) refund the excess payments to Pfizer within *** after its receipt of the auditor’s report so concluding or (b) immediately offset all such excess payments against any outstanding or future amounts
payable by Pfizer to MacroGenics under this Agreement until Pfizer has received full credit for all such overpayments. Additionally, if the amount to be refunded exceeds more than five percent (5%) of the amount that was properly payable,
MacroGenics shall reimburse Pfizer for the cost of the audit. 
 5.2.6. Underpayments/Overpayments. If such accounting
firm concludes that MacroGenics under-billed Pfizer for such FTEs, Pfizer shall reimburse MacroGenics for such costs within *** after its receipt of the auditor’s report. 

5.3. Milestones 
 5.3.1. Technical Milestones. Pfizer shall pay to MacroGenics the amount set forth below within *** following the first occurrence of each event (each, a “Technical
Milestone”) described below for each Research Project Target, each such amount (a “Technical Milestone Payment”) to be payable only once with respect to each different Research Project Target regardless of how many
Agreement T-DARTs binding to such Research Project Target achieve such Technical Milestone. 
  

			
	 Technical Milestone
	  	Technical Milestone
Payment
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***

  
 32 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 If the Technical Milestone set forth in Section 5.3.1(c) is achieved prior to the
achievement of the Technical Milestone set forth in Section 5.3.1(a) and/or 5.3.1(b), then the unpaid Technical Milestone Payment set forth in Section 5.3.1(a) and/or 5.3.1(b) shall be due and payable simultaneously with the payment for achievement
of the milestone set forth in Section 5.3.1(c). For the avoidance of doubt, in the event that the Technical Milestone set forth in Section 5.3.1(b) is achieved prior to the achievement of the Technical Milestone set forth in Section 5.3.1(a), the
Technical Milestone Payment set forth in Section 5.3.1(a) shall not be due or payable simultaneously with the Technical Milestone Payment for achievement of the Technical Milestone set forth in Section 5.3.1(b), but instead shall only be due and
payable upon achievement of Technical Milestone Payment set forth in Section 5.3.1(a) or Section 5.3.1.(c). 
 5.3.2.
Development Milestones. Pfizer shall pay to MacroGenics the amount set forth below within *** days following the first occurrence of each event (each, a “Development Milestone”) described below for each Research
Project Target, each such amount (a “Development Milestone Payment”) to be payable only once with respect to each different Research Project Target regardless of how many Agreement T-DARTs binding to such Research Project Target
achieve such Development Milestone. 
  

			
	 Development Milestone
	  	Development Milestone
Payment
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***
	 ***
	  	***

 If the Development Milestone set forth in Section 5.3.2(b) is achieved prior to the achievement of the
milestone set forth in Section 5.3.2(a), then the Development Milestone Payment set forth in Section 5.3.2(a) shall be due and payable simultaneously with the Development Milestone Payment for achievement of the Development Milestone set forth in
Section 5.3.2(b); if the Development Milestone set forth in Section 5.3.2(c) is achieved prior to the achievement of the Development Milestone set forth in Section 5.3.2(a) and/or 5.3.2(b), then the unpaid Development Milestone Payment set forth in
Section 5.3.2(a) and/or 5.3.2(b) shall be due and payable simultaneously with the payment for achievement of the milestone set forth in Section 5.3.2(c); if the Development Milestone set forth in Section 5.3.2(d), (e) or (f) is achieved prior to the
achievement of the Development Milestone set forth in Section 5.3.2(a), 5.3.2(b) and/or 5.3.2(c), then the unpaid Development Milestone Payment set forth in Section 5.3.2(a), 5.3.2(b) and/or 5.3.2(c) shall be due and payable simultaneously with the
Development Milestone Payment for achievement of the milestone set forth in Section 5.3.2(d), (e) or (f). 

  
 33 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 5.3.3. Sales Milestones. Pfizer shall pay to MacroGenics the following one-time
payments (each, a “Sales Milestone Payment”) when aggregate Annual Net Sales of all Agreement Product in a Pfizer Year first reach the respective threshold (a “Sales Threshold”) indicated below (each, a
“Sales Milestone”): 
  

			
	 Total Annual Net Sales
	  	Sales Milestone Payment
	 Total Annual Net Sales exceeding *** 
	  	***
	 Total Annual Net Sales exceeding ***
	  	***
	 Total Annual Net Sales exceeding ***
	  	***
	 Total Annual Net Sales exceeding ***
	  	***

 If more than one unmet Sales Threshold is achieved with respect to the same Pfizer Year, payment will be
made with respect to the higher or highest Sales Threshold achieved in such Pfizer Year and all other previously unmet Sales Thresholds achieved with respect to such Pfizer Year will remain eligible to be met in future Pfizer Years. Any Sales
Milestone Payment shall be payable by Pfizer with respect to any Pfizer Year shall be payable within sixty (60) days of the end of such Pfizer Year in the United States. 
 5.4. Royalties. Subject to the provisions of Section 5.4.3, Pfizer shall pay MacroGenics royalties in the amount of the rates (“Marginal Royalty Rates”) set forth below of Annual
Net Sales of any Agreement Product during the Royalty Term: 
  

			
	 Annual Net Sales
	  	Marginal Royalty Rate
(% of 
the Annual Net Sales)
	 Annual Net Sales of such Agreement Product during a given Pfizer Year above $0, up to and including ***
	  	***
	 Annual Net Sales of such Agreement Product during a given Pfizer Year above ***, up to and including
***
	  	***
	 Annual Net Sales of such Agreement Product during a given Pfizer Year above ***, up to and including
***
	  	***
	 Annual Net Sales of such Agreement Product during a given Pfizer Year above ***
	  	***

 5.4.1. Marginal Royalty Rate Application. Each Marginal Royalty Rate set forth in the table above
shall apply only to that portion of the Annual Net Sales of a given Agreement Product in the Territory during a given Pfizer Year that falls within the indicated range. 

  
 34 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 5.4.2. Royalty Term. “Royalty Term” means, with respect to any
Agreement Product and any country in the Territory, the period of time from the First Commercial Sale of such Agreement Product in such country until the later of (a) ***  

5.4.3. Royalty Adjustments. The following adjustments shall be made, on Agreement Product-by-Agreement Agreement Product and
country-by-country basis, to the royalties payable pursuant to this Section 5.4: 
 (a) Generic Competition. Royalties
payable following establishment of Generic Competition with respect to the sale by a Third Party of product that is a Biosimilar Biologic Product to such Agreement Product in such country shall be payable at *** of the otherwise applicable
rate prior to application of this Section 5.4.3(a) “Generic Competition” means with respect to a given Calendar Year with respect to an Agreement Product in any country, that during such Calendar Year,
*** have received Regulatory Approval to sell in such country a Biosimilar Biologic Product, such Biosimilar Biologic Product shall be commercially available in such country and such Biosimilar Biologic Product shall have, in the aggregate,
*** or more market share of the aggregate of such Agreement Product and Biosimilar Biologic Product (based on data provided by IMS International, or if such data is not available, such other reliable data source as reasonably determined by
Pfizer and agreed by MacroGenics (such agreement not to be unreasonably withheld)) as measured by sales. In the event IMS International data (or such other agreed data source) is not sufficient to determine the percentage market share for each
country in the EU, the percent market share for the EU countries for which data is not available will be deemed to be the average percent market share for those EU countries in which the data is available. A product shall be a “Biosimilar
Biologic Product” with respect to an Agreement Product if such product (1) has been licensed as a biosimilar or interchangeable product by FDA pursuant to Section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)), as
may be amended, or any subsequent or superseding law, stature or regulation, (2) has been licensed as a similar biological medicinal product by EMEA pursuant to Directive 2001/83/EC, as may be amended, or any subsequent or superseding law,
stature or regulation, or (3) has otherwise achieved analogous Regulatory Marketing Approval from another applicable Regulatory Authority. 
 (b) Third Party Patents. If it is necessary for Pfizer to license one or more Patent Rights from one or more Third Parties in order to Develop, Manufacture or Commercialize or use any Agreement
Product, whether directly or through any Pfizer Affiliate or Sublicensee, then Pfizer may, in its sole discretion, negotiate and obtain a license under such Patent Right(s) (each such Third Party license referred to herein as an “Additional
Third Party License”). Any royalty otherwise payable to 

  
 35 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
MacroGenics under this Agreement with respect to Net Sales of any Agreement Product by Pfizer, its Affiliates or Sublicensees shall be reduced by *** of the royalties payable to Third
Parties that are reasonably allocable to Agreement Products pursuant to any Additional Third Party Licenses, such reduction to continue until all such amounts have been expended, provided that in no event shall the total royalty payable to
MacroGenics for any Agreement Product be less than *** of the royalty amounts otherwise payable for such Agreement Product. 
 (c) No Adjustment for MacroGenics Third Party Agreements. MacroGenics shall be solely responsible for all obligations (including any royalty or other obligations that relate to the MacroGenics
Technology) under its agreements with Third Parties that are in effect as of the Effective Date or that MacroGenics enters into during the Term. 
 5.4.4. Fully Paid-Up, Royalty Free License. After expiration of the Royalty Term for any Agreement Product in a country in the Territory, no further royalties shall be payable in respect of sales
of such Agreement Product in such country and thereafter, the license granted to Pfizer under Section 4.1.3 with respect to such Agreement Product in such country shall be a fully paid-up, perpetual, non-exclusive, irrevocable, royalty-free license.

 5.5. Reports and Payments. 
 5.5.1. Cumulative Royalties. The obligation to pay royalties under Section 5.4 shall be imposed only once with respect to a single unit of an Agreement Product regardless of how many Valid Claims
in Patent Rights included within the MacroGenics Patent Rights would, but for this Agreement, be infringed by the use or sale of such Agreement Product in the country in which such Agreement Product is used or sold. 

5.5.2. Royalty Statements and Payments. Within *** after the end of each Pfizer Quarter, Pfizer shall deliver to MacroGenics
a report setting forth for such Calendar Quarter the following information, on an Agreement Product-by-Agreement Product basis: (a) the Net Sales of each Agreement Product, (b) the basis for any adjustments to the royalty payable for the
sale of each Agreement Product and (c) the royalty due hereunder for the sale of each Agreement Product. No such reports shall be due for any Agreement Product before the First Commercial Sale of such Agreement Product in the Territory. The
total royalty due for the sale of Agreement Products during such Pfizer Quarter shall be remitted at the time such report is delivered to MacroGenics. 
 5.5.3. Taxes and Withholding. It is understood and agreed between the Parties that any payments made this Agreement are inclusive of any value added tax imposed upon such payments. In addition, in
the event any of the payments made by Pfizer pursuant to this Agreement become subject to withholding taxes under 

  
 36 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
the laws of any jurisdiction, Pfizer shall deduct and withhold the amount of such taxes for the account of MacroGenics, to the extent required by law, such amounts payable to MacroGenics shall be
reduced by the amount of taxes deducted and withheld, and Pfizer shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to MacroGenics an official tax certificate or other evidence of such
tax obligations together with proof of payment from the relevant Governmental Authority of all amounts deducted and withheld sufficient to enable MacroGenics to claim such payment of taxes. Any such withholding taxes required under applicable Law to
be paid or withheld shall be an expense of, and borne solely by, MacroGenics. Pfizer will provide MacroGenics with reasonable assistance to enable MacroGenics to recover such taxes as permitted by Law. 

5.5.4. Currency. All amounts payable and calculations hereunder shall be in United States dollars. As applicable, Net Sales and any
royalty deductions shall be converted into United States dollars in accordance with Pfizer’s customary and usual conversion procedures, consistently applied. 
 5.5.5. Additional Provisions Relating to Payments. MacroGenics acknowledges and agrees that nothing in this Agreement (including any schedules and exhibits hereto) shall be construed as
representing an estimate or projection of either (a) the number of Agreement Products that shall or may be successfully Developed or Commercialized or (b) anticipated sales or the actual value of any Agreement Product. PFIZER MAKES NO
REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT SHALL BE ABLE TO SUCCESSFULLY DEVELOP OR COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT IT WILL ACHIEVE ANY PARTICULAR SALES LEVEL OF SUCH PRODUCT(S), PROVIDED THAT THE FOREGOING
SHALL NOT LIMIT PFIZER’S OBLIGATIONS UNDER THIS AGREEMENT. 
 5.6. Maintenance of Records; Audits. 

5.6.1. Record Keeping. Pfizer shall keep, and shall cause its Affiliates and Sublicensees to keep, accurate books of account and
records in connection with the sale of Agreement Products, in sufficient detail to permit accurate determination of all figures necessary for verification of royalties to be paid hereunder. Pfizer shall maintain, and shall cause its Affiliates and
Sublicensees to maintain, such records for a period of at least three (3) years after the end of the Calendar Year in which they were generated. 
 5.6.2. Audits. Upon thirty (30) days prior written notice from MacroGenics, Pfizer shall permit an independent certified public accounting firm of internationally recognized standing selected
by MacroGenics and reasonably acceptable to Pfizer to examine, at MacroGenics’s sole expense, the relevant books and records of Pfizer during the period covered by such examination, as 

  
 37 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
may be reasonably necessary to verify the accuracy of the reports submitted by Pfizer in accordance with Section 5.5 and the payment of royalties hereunder. An examination by MacroGenics under
this Section 5.6.2 shall occur not more than once in any Calendar Year and shall be limited to the pertinent books and records for any Calendar Year ending not more than three (3) years before the date of the request. The accounting firm shall
be provided access to such books and records at Pfizer’s or its Affiliates’ facilities where such books and records are kept and such examination shall be conducted during Pfizer’s normal business hours. Pfizer may require the
accounting firm to sign a standard non-disclosure agreement before providing the accounting firm access to Pfizer’s facilities or records. Upon completion of the audit, the accounting firm shall provide both Pfizer and MacroGenics a written
report disclosing whether the reports submitted by Pfizer are correct or incorrect, whether the royalties paid are correct or incorrect and, in each case, the specific details concerning any discrepancies. No other information shall be provided to
MacroGenics. 
 5.6.3. Underpayments/Overpayments. If such accounting firm concludes that additional royalties were due to
MacroGenics, Pfizer shall pay to MacroGenics the additional royalties within thirty (30) days after the date Pfizer receives such accountant’s written report so concluding. If such underpayment exceeds five percent (5%) of the
royalties that were to be paid to MacroGenics, Pfizer also shall reimburse MacroGenics for all reasonable charges of such accountants for conducting the audit. If such accounting firm concludes that Pfizer overpaid royalties to MacroGenics, Pfizer
shall be entitled to offset all such overpayments against any outstanding or future amounts payable by Pfizer to MacroGenics under this Agreement until Pfizer has received full credit for all such overpayments. 

5.6.4. Confidentiality. All financial information of Pfizer which is subject to review under this Section 5.6 shall be deemed to be
Pfizer’s Confidential Information subject to the provisions of Section 7 hereof, and MacroGenics shall not disclose such Confidential Information to any Third Party or use such Confidential Information for any purpose other than verifying
payments to be made by Pfizer to MacroGenics hereunder, provided, however, that such Confidential Information may be disclosed by MacroGenics to Third Parties only to the extent necessary to enforce MacroGenics’s rights under this Agreement.

 5.7. Late Payments. If a Party shall fail to make a timely payment pursuant to the terms of this Agreement, interest
shall accrue on the past due amount at the ***, computed for the actual number of days the payment was past due (but in no event in excess of the maximum rate permissible under Applicable Law). 

  
 38 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

	6.	INTELLECTUAL PROPERTY. 

6.1. Inventions. 
 6.1.1. Ownership. 
 (a) Except for inventions and Know-How subject to
Section 2.13.6 or Section 4.1.2, each Party shall own all inventions and Know-How conceived or generated solely by it and its Affiliates and their respective employees, agents and independent contractors in the course of performing research or
development activities under this Agreement (a “Sole Invention” or “Sole Know-How,” respectively). 
 (b) Except for inventions and Know-How subject to Section 2.13.6 or Section 4.1.2, all inventions and Know-How that are conceived or generated jointly by employees, Affiliates, agents, or independent
contractors of each Party in the course of performing research or development activities under this Agreement shall be owned jointly by the Parties (a “Joint Invention” or “Joint Know-How,” respectively). During and
after the Term, either Party may exploit (including by license, sublicense, assignment of such Party’s interest or otherwise) any Joint Technology without accounting to or obtaining consent from the other Party, subject to the rights and
obligations of the Parties with respect to Joint Technology under this Agreement, including the exclusive license of MacroGenics’s interest in the Joint Technology granted to Pfizer under Section 4.1.3, the Joint Patent Right prosecution and
maintenance provisions set forth in Section 6.2 and Pfizer’s obligation to pay royalties on Agreement Products under Section 5.4. 
 (c) All determinations of inventorship under this Agreement shall be made in accordance with the patent law of the United States. 
 6.1.2. Disclosure. Each Party shall promptly disclose to the other Party any Joint Invention, Sole Invention, Agreement T-DART IP or Pfizer Proprietary Material Improvement, including all invention
disclosures or other similar documents submitted to such Party by its or its Affiliates’, employees, agents or independent contractors describing such foregoing invention, and shall cooperate to promptly determine each Party’s inventive
contribution thereto. The Parties shall cooperate with each other with respect to the timing, scope, and filing of patent applications and patent claims relating to any of the foregoing inventions to enhance the patent protection for Agreement
T-DARTs and Agreement Products, and their manufacture and use. 
 6.2. Patent Rights. 

6.2.1. Filing, Prosecution and Maintenance of Patent Rights. 

(a) Pfizer Patent Rights. Pfizer, at its own expense, shall have the sole right, but not the obligation, to prepare, file,
prosecute and maintain, throughout the world, any Pfizer Patent Right other than any Agreement T-DART Patent Right. 

  
 39 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 (b) Agreement T-DART Patent Rights. 

(i) Pfizer shall have the first right, but not the obligation, to file, prosecute and maintain, at Pfizer’s expense, any Agreement
T-DART Patent Right. Pfizer will provide MacroGenics with an opportunity to review the text of the initial application with respect to any Agreement T-DART Patent Right before filing, shall consult MacroGenics with respect thereto, shall not
unreasonably refuse to address any of MacroGenics’ comments, and shall provide MacroGenics promptly with a copy of the application as filed, together with notice of its filing date and serial number. Pfizer will keep MacroGenics advised of the
status of the Agreement T-DART Patent Rights annually or more often at MacroGenics’ reasonable request. Pfizer shall either provide MacroGenics with copies of, or require that Pfizer’s outside counsel copy MacroGenics on, substantive
official correspondence received from all patent offices related to the filing, prosecution and maintenance of the patent filings in those offices (e.g., office actions and any other correspondence of a similar nature), and of Pfizer’s proposed
responses to such correspondence or other substantive filings (e.g., responses to office actions, elections and any other responses or filings of a similar nature), in each case, reasonably in advance of Pfizer’s proposed responses or other
filings to allow MacroGenics to comment. 
 (ii) Pfizer shall file, prosecute and maintain each Agreement T-DART Patent Right in
all Major Market Countries and in such other countries as MacroGenics may request, provided, however, that if Pfizer at any time wishes not to file, prosecute or maintain any Agreement T-DART Patent Right in any country (a “Foregone
Agreement T-DART Patent Right”), Pfizer shall provide MacroGenics with *** prior written notice to such effect, provided that an Agreement T-DART Patent Right shall not constitute a Foregone Agreement T-DART Patent Right if
Pfizer’s discontinuation of filing, prosecution or maintenance of such Agreement T-DART Patent Right is in order to effect a settlement or to avoid an interference, opposition or other proceeding in which the validity of such Agreement T-DART
Patent Right may be determined or because another Agreement T-DART Patent Right of similar claim scope is being prosecuted or has been issued. For any such Foregone Agreement T-DART Patent Right for which Pfizer gives notice in accordance with the
foregoing sentence and of which MacroGenics, its Affiliates, or 

  
 40 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
Subcontractors of MacroGenics or any of its Affiliates are the sole inventors, MacroGenics shall have the right to request assignment within *** after MacroGenics’ receipt of the
notice provided by Pfizer and Pfizer shall assign to MacroGenics all of Pfizer’s right, title and interest in and to any such Foregone Agreement T-DART Patent Right so requested within *** of such request. Upon assignment of such
Foregone Agreement T-DART Patent Right, Pfizer shall have no responsibility for any further prosecution or maintenance of or expenses incurred in connection with such Foregone Agreement T-DART Patent Right. Pfizer shall execute, and cause its
employees, agents and subcontractors to execute, at MacroGenics’ expense, all documents necessary for MacroGenics to continue prosecution and maintenance of such Foregone Agreement T-DART Patent Right. Any Foregone Agreement T-DART Patent Right
assigned to MacroGenics will be included in MacroGenics Patent Rights for the purposes of this Agreement. 
 (iii) If, upon a
timely request by MacroGenics in connection with an Agreement T-DART Patent Right of which MacroGenics, its Affiliates, or Subcontractors of MacroGenics or any of its Affiliates are the sole inventors, Pfizer declines to file a continuation or
divisional application to pursue claims of a broader scope than those that have been allowed or are being or will be sought by Pfizer, MacroGenics shall have the right to file, in Pfizer’s name, such continuation or divisional application (but
not a continuation-in-part) and Pfizer shall have no responsibility for any further prosecution or maintenance of or expenses incurred in connection with such application. Pfizer shall execute, and cause its employees, agents and subcontractors to
execute, at MacroGenics’ expense, all documents necessary for MacroGenics to continue prosecution and maintenance of such application. The second, third and fourth sentences of this Section 6.2.1(b) shall apply to MacroGenics’ filing and
prosecution, provided that each Party’s name in those sentences shall be substituted with the other Party’s name. 

(c) MacroGenics Patent Rights Other than Subject T-DART Patent Rights. Except as provided in the Section 6.2.1(d) in regard to
Subject Patent Rights, MacroGenics, at its own expense, shall have the sole right, but not the obligation, to prepare, file, prosecute and maintain, throughout the world, any MacroGenics Patent Right. 

(d) Subject Patent Rights. MacroGenics shall have the first right, but not the obligation, to file, prosecute and maintain, at
MacroGenics’s expense, any Subject Patent Right. “Subject Patent Right” means any MacroGenics Patent Right covering the composition of, or any method of 

  
 41 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
making or method of using, any Agreement T-DART or Agreement Product. MacroGenics shall keep Pfizer advised of the status of Subject Patent Rights (once published) annually or more often at
Pfizer’s reasonable request. MacroGenics shall consider in good faith any comments provided by Pfizer concerning the prosecution of Subject Patent Rights, and MacroGenics shall not use any information generated in the Research Program in
connection with prosecution of any Subject Patent Rights without Pfizer’s prior written consent, which shall not be unreasonably withheld or delayed. MacroGenics shall file, prosecute and maintain each Subject Patent Right in all Major Market
Countries, provided, however, that if MacroGenics at any time wishes not to file, prosecute or maintain any Subject Patent Right in any country, MacroGenics shall provide Pfizer with *** prior written notice to such effect. Unless
MacroGenics’ discontinuation of filing, prosecution or maintenance of such Subject Patent Right is in order to effect a settlement or to avoid an interference, opposition or other proceeding in which the validity of such Subject T-DART Patent
Right may be determined or because another Subject T-DART Patent Right of similar claim scope is being prosecuted or has been issued, Pfizer shall have the first right to file, prosecute and maintain such Subject Patent Right (in MacroGenics’
name) in each such country, in which event the Subject Patent Right will no longer be deemed to be included in the MacroGenics Patent Rights for the purpose of determining the Royalty Term with respect to any Agreement Product. 

(e) Joint Patent Rights. In the event the Parties make any Joint Invention, the Parties shall promptly meet to discuss and
determine, based on mutual consent, whether to seek patent protection thereon and how prosecution, maintenance and enforcement of any Patent Right covering such Joint Invention will be handled. Neither Party will file any Patent Right covering or
claiming a Joint Invention without the consent of the other Party. 
 6.2.2. Enforcement of Patent Rights. 

(a) Notice. If either Pfizer or MacroGenics becomes aware of any infringement, anywhere in the world, of any issued Subject Patent
Right or Agreement T-DART Patent Right, such Party shall promptly notify the other Party in writing to that effect. 
 (b)
Infringement of Subject Patent Rights. 
 (1) If any infringement of a Subject Patent Right by a Third Party arises from the
Development, Manufacture or Commercialization of a product that competes with an Agreement Product, Pfizer shall have the first right, but not the obligation, to 

  
 42 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
take action to obtain a discontinuance of infringement or bring suit against a Third Party infringer of such Subject Patent Right within *** from the date of notice and to join MacroGenics as a
party plaintiff. 
 (2) Pfizer shall bear all the expenses of any suit brought by it claiming infringement of any such Subject
Patent Right. MacroGenics shall cooperate with Pfizer in any such suit and shall have the right to consult with Pfizer and to participate in and be represented by independent counsel in such litigation at its own expense. Pfizer shall incur no
liability to MacroGenics as a consequence of such litigation or any unfavorable decision resulting therefrom, including any decision holding any such Subject Patent Right invalid or unenforceable; provided, however, that Pfizer shall not, without
MacroGenics’ prior written consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any other liability to MacroGenics or admits the invalidity or unenforceabilty of any such Subject Patent Right.

 (3) If Pfizer has not obtained a discontinuance of infringement by, or filed suit against, any such Third Party infringer
within the *** period set forth in subsection (i) above, then MacroGenics shall have the right, but not the obligation, to bring suit against such Third Party infringer, at MacroGenics’ sole expense. provided that (x) Pfizer will not
be obligated to join such suit unless Applicable Law requires that Pfizer must be a party for MacroGenics to maintain the suit, and (y) MacroGenics shall indemnify Pfizer against any damages, penalties, attorney fees or other recoveries
assessed against Pfizer in or as a result of such suit. Pfizer may, at its sole discretion, elect to consult with MacroGenics and to participate in and be represented by independent counsel in such litigation at its own expense. MacroGenics shall
incur no liability to Pfizer as a consequence of such litigation or any unfavorable decision resulting therefrom, including any decision holding any such Subject Patent Right invalid or unenforceable; provided, however, that MacroGenics shall not,
without Pfizer’s prior written consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any other liability to Pfizer. 

  
 43 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 (4) The enforcing Party shall keep the other Party reasonably informed of all material
developments in connection with any such suit. Any recoveries obtained by either Party as a result of any proceeding against such a Third Party infringer shall be allocated as follows: 

(A) Such recovery shall first be used to reimburse each Party for all out-of-pocket litigation costs in connection with such litigation
paid by that Party; and 
 (B) With respect to any remaining portion of such recovery, if Pfizer was the enforcing Party,
MacroGenics shall receive either (1) if the reward to Pfizer is based on lost profits, an amount equal to the royalty that would be payable, pursuant to Section 5.4, on the corresponding amount (as determined by the court) of lost Net Sales of
the relevant Agreement Product(s) in the country(ies) where such infringement occurred; or (2) if the reward is based on reasonable royalty payments, such reward due to Pfizer (as determined by the court) shall be considered as Net Sales
subject to the applicable royalty in accordance with Section 5.4, unless MacroGenics is separately awarded its own royalty award, and Pfizer shall receive any remaining portion of such recovery; or 

(C) With respect to any remaining portion of such recovery, if MacroGenics was the enforcing Party, MacroGenics shall receive any
remaining portion of such recovery. 
 (c) Other Infringement of MacroGenics Patent Rights. If the infringement of any
MacroGenics Patent Right does not fall within the category of infringements covered by the first sentence of Section 6.2.2(b), MacroGenics shall have the sole right, but not the obligation, to take action against such infringement. 

(d) Infringement of Agreement T-DART Patent Rights. 
 (1) Pfizer shall have the sole right but not the obligation to bring an action against a Third Party infringer of an Agreement T-DART Patent Right or otherwise address such alleged infringement.
MacroGenics shall cooperate with Pfizer, at Pfizer’s expense, in any such suit brought by Pfizer and shall have the right to consult with Pfizer concerning the status and prosecution of such litigation Pfizer shall incur no liability to
MacroGenics as a consequence of such litigation or any unfavorable decision resulting therefrom, including any decision holding any such Agreement T-DART Patent Right invalid or unenforceable. 

  
 44 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 (2) Any recoveries obtained by Pfizer as a result of any proceeding against a Third Party
infringer shall be allocated as follows: 
 (A) Such recovery shall first be used to reimburse each Party for all out-of-pocket
litigation costs in connection with such litigation paid by that Party; and 
 (B) With respect to any remaining portion of
such recovery, MacroGenics shall receive either (1) if the reward to Pfizer is based on lost profits, an amount equal to the royalty that would be payable, pursuant to Section 5.4, on the corresponding amount (as determined by the court) of
lost Net Sales of the relevant Agreement Product(s) in the country(ies) where such infringement occurred; or (2) if the reward is based on reasonable royalty payments , such reward due to Pfizer (as determined by the court) shall be considered
as Net Sales subject to the applicable royalty in accordance with Section 5.4, and Pfizer shall receive any remaining portion of such recovery. 
 6.2.3. Infringement of Third Party Patent Rights. If the Development, Manufacture or Commercialization of any Agreement T-DART and/or Agreement Product is alleged by a Third Party to infringe a
Third Party’s patent or other intellectual property rights, the Party becoming aware of such allegation shall promptly notify the other Party. The Party that is alleged to infringe the Third Party’s patent or intellectual property shall
have the right to take such action as it deems appropriate in response to such allegation, and shall be solely responsible for all damages, costs and expenses in connection therewith, subject to Section 10. 

6.2.4. Patent Invalidity Claim. Each Party shall promptly notify the other in the event of any legal or administrative action by
any Third Party against any Subject Patent Right or Agreement T-DART Patent Right of which it becomes aware, including any opposition, interference, nullity, revocation, reexamination or compulsory license proceeding. Such action shall be treated as
part of the prosecution of such Patent Right under Section 6.2.1 unless such action is a declaratory judgment action or counterclaim in response to an assertion of infringement, in which cases such action shall be treated as an enforcement action
under Section 6.2.2. 
 6.2.5. Biosimilar Applications. Each Party shall immediately give written notice to the other of
any notice received from a Third Party of an application for FDA approval under the Biologics Price Competition and Innovation Act of 2009 (or any amendment or successor statute thereto) of a Biosimilar Biologic Product referencing an Agreement
Product or any certification under a similar statutory or regulatory requirement in any non-United States country in the Territory claiming that a Subject Patent Right or an Agreement T-DART Patent Right covering any Agreement Product is invalid or
that infringement will not arise from the Development, Manufacture or Commercialization of a proposed Biosimilar 

  
 45 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
Biologic Product by a Third Party. Upon the giving or receipt of such notice, Pfizer shall have the first right (or the sole right, in the case of an Agreement T-DART Patent Right) but not the
obligation, to bring an infringement action against such Third Party in connection with such certification. In the case of a Subject Patent Right, Pfizer shall notify MacroGenics at least *** to the date set forth by statute or regulation of
its intent to exercise, or not exercise, this right. Any infringement action against a Third Party arising under this Section 6.2.5 shall be governed by the provisions of Section 6.2.2(b). 

6.2.6. Patent Term Restoration and Extension. Pfizer shall have the first right, but not the obligation, to seek, in
MacroGenics’s name if so required, patent term extensions, and supplemental protection certificates and the like available under Applicable Law, including 35 U.S.C. § 156 and applicable foreign counterparts, in any country in the Territory
in relation to any Subject Patent Right and Agreement Products. MacroGenics and Pfizer shall cooperate in connection with all such activities. Pfizer, its agents and attorneys will give due consideration to all suggestions and comments of
MacroGenics regarding any such activities, but in the event of a disagreement between the Parties, Pfizer will have the final decision-making authority. If Pfizer does not do so, MacroGenics may seek to extend any Subject Patent Right in relation to
Agreement Products, including through the use of supplemental protection certificates and the like, unless in Pfizer’s reasonable legal determination such Subject Patent Right may not be extended under Applicable Law in relation to Agreement
Products without limiting Pfizer’s right to extend any other Patent Right in relation to Agreement Products. 
 6.2.7.
Joint Research Agreement. This Agreement shall be understood to be a joint research agreement under 35 U.S.C. § 103(c)(3) entered into for the purpose of researching, identifying and Developing Agreement T-DARTs and Agreement Products.

 6.2.8. Orange Book Information. Pfizer shall be responsible for all submissions of patent information pertaining to
each Agreement Product pursuant to 21 U.S.C. § 355(b)(1)(G) (or any amendment or successor statute thereto), any similar statutory or regulatory requirement enacted in the future regarding biologic products, or any similar statutory or
regulatory requirement in any non-United States country or other regulatory jurisdiction. 
 6.3. Recording. If Pfizer
deems it necessary or desirable to register or record this Agreement or evidence of this Agreement with any patent office or other appropriate government authorities in one or more jurisdictions in the Territory, then Pfizer shall submit to
MacroGenics any proposed evidence of such recording and the Parties will comply with the terms of Section 7.2.3 in respect of such filing. MacroGenics shall, at Pfizer’s expense, execute and deliver to Pfizer any documents necessary or
desirable, in Pfizer’s reasonable judgment, to complete such registration or recordation in accordance with the terms of Section 7.2.3; provided that such registration or recordation specifies

  
 46 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
the applicable limitations of such license, and provided further that such registration shall have no effect on the allocation of patent prosecution, maintenance and enforcement rights and
obligations set forth in this Section 6. In the event the licenses granted to Pfizer under this Agreement are terminated, Pfizer shall promptly take such actions and execute such documents as are reasonably requested by MacroGenics to cancel
such registration(s) or recordation(s) in the applicable countries with respect to the terminated license grants. 
 6.4.
Trademarks. Pfizer shall, in its sole discretion, select and own all Agreement Product-related Trademarks and copyrights to be used in connection with the Commercialization of any Agreement Product hereunder. MacroGenics shall neither use nor
seek to register, anywhere in the world, any Trademarks that are confusingly similar to any Trademark used by or on behalf of Pfizer or its Affiliates or Sublicensees in connection with any Agreement Product; provided, however, that nothing in this
Section 6.4 shall be construed to prevent MacroGenics from enforcing its own trademark rights or grant Pfizer any license or right in and to any MacroGenics trademark or house mark. 

 

	7.	CONFIDENTIALITY 

 7.1.
Confidentiality. Except to the extent expressly authorized by this Agreement, the Parties agree that, during the Term and for ***, each Party (the “Receiving Party”) receiving any Confidential Information of the other
Party (the “Disclosing Party”) hereunder shall: (a) keep the Disclosing Party’s Confidential Information confidential; (b) not disclose, or permit the disclosure of, the Disclosing Party’s Confidential
Information; and (c) not use, or permit to be used, the Disclosing Party’s Confidential Information for any purpose; provided, however, that a Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that
such Confidential Information (i) was already known by the Receiving Party (other than under an obligation of confidentiality to the Disclosing Party) at the time of disclosure by the Disclosing Party; (ii) was generally available to the
public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; (iii) became generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party, other than
through any act or omission of the Receiving Party in breach of its obligations under this Agreement; (iv) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the
Disclosing Party not to disclose such information to the Receiving Party; or (v) was independently discovered or developed by or on behalf of the Receiving Party without the use of any Confidential Information of the Disclosing Party. The terms
and conditions of this Agreement shall be considered Confidential Information of each Party. 
 7.2. Authorized
Disclosure. 
 7.2.1. Disclosure to Party Representatives. Notwithstanding the foregoing provisions of Section 7.1,
the Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the Receiving Party’s, its Affiliates’ and its Sublicensees’ officers, directors, employees, consultants,

  
 47 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
contractors and agents (collectively, “Representatives”) who (a) have a need to know such Confidential Information in connection with the performance of the Receiving
Party’s obligations or the exercise of the Receiving Party’s rights under this Agreement and (b) have agreed in writing to non-disclosure and non-use provisions with respect to such Confidential Information that are at least as
restrictive as those set forth in this Section 7. 
 7.2.2. Disclosure to Third Parties. 

(a) Notwithstanding the foregoing provisions of Section 7.1, each Party may disclose Confidential Information belonging to the other
Party: 
 (i) to Governmental Authorities (i) to the extent reasonably necessary to obtain or maintain INDs or Regulatory
Approvals for any Agreement T-DART or Agreement Product within the Territory, and (ii) in order to respond to inquiries, requests or investigations relating to this Agreement; 

(ii) to outside consultants, contractors, advisory boards, managed care organizations, and non-clinical and clinical investigators, in
each case to the extent reasonably necessary to develop, register or market any Agreement T-DART or Agreement Product; provided that the Receiving Party shall obtain the same confidentiality obligations from such Third Parties as it obtains with
respect to its own similar types of confidential information; 
 (iii) to the extent reasonably necessary in connection with
filing or prosecuting Patent Rights as permitted by this Agreement; 
 (iv) to the extent reasonably necessary in connection
with prosecuting or defending litigation as permitted by this Agreement; 
 (v) subject to Section 7.3.2, in connection with or
included in scientific presentations and publications relating to Agreement T-DARTs or Agreement Products, including abstracts, posters, journal articles and the like, and posting results of and other information about clinical trials to
clincialtrials.gov or PhRMA websites; and 
 (vi) to the extent necessary or desirable in order to enforce its rights under this
Agreement. 
 (b) Notwithstanding anything to the contrary in this Section 7, MacroGenics may disclose Pfizer’s
Confidential Information to: (i) Governmental Authorities in order to respond to inquiries, requests or investigations relating to this Agreement and (ii) to the extent necessary or desirable in order to enforce its rights under this
Agreement. In the event a 

  
 48 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
Party deems it reasonably necessary to disclose Confidential Information belonging to the other Party pursuant to this Section 7.2, the Disclosing Party shall to the extent possible give
reasonable advance written notice of such disclosure to the other Party and take all reasonable measures to ensure confidential treatment of such information. 
 7.2.3. SEC Filings and Other Disclosures. Notwithstanding any provision of this Agreement to the contrary: 
 (a) Either Party may disclose the terms of this Agreement to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with Applicable Law, including the rules and
regulations promulgated by the SEC or any equivalent governmental agency in any country in the Territory. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section 7.2.3, the Parties will
consult with one another on the terms of this Agreement to be redacted in making any such disclosure. Further, if a Party discloses this Agreement or any of the terms hereof in accordance with this Section 7.2.3, such Party shall, at its own
expense, seek such confidential treatment of confidential portions of this Agreement and such other terms, as may be reasonably requested by the other Party. 
 (b) Either Party may disclose the existence and terms of this Agreement in confidence: 
 (i) (A) to its attorneys, professional accountants, and auditors, and (B) bankers or other financial advisors in connection with an initial public offering, other strategic transaction, or
corporate valuation for internal purposes; provided that any such disclosure to such professional accountants, auditors, bankers or other financial advisors is under an agreement to keep the terms of confidentiality and non-use no less rigorous than
the terms contained in this Agreement and to use such information solely for the applicable purpose permitted pursuant to this Section 7.2.3(b)(i); 
 (ii) to potential acquirers (and their respective attorneys and professional advisors), in connection with a potential merger, acquisition or reorganization; provided that (A) the Party making the
disclosure has a bona fide offer from such Third Party for such a transaction, and (B) such disclosure is under an agreement to keep the terms of confidentiality and non-use no less rigorous than the terms contained in this Agreement and to use
such information solely for the purpose permitted pursuant to this Section 7.2.3(b)(i); 

  
 49 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 (iii) to existing or potential investors, lenders or permitted assignees of such Party (and
their respective attorneys and professional advisors); provided that such disclosure is under an agreement to keep the terms of confidentiality and non-use no less rigorous than the terms contained in this Agreement; and 

(iv) to potential licensees or sublicensees of such Party (and their respective attorneys and professional advisors); provided that
(A) such disclosure shall not include any financial terms or identify any Research Project Targets or Reserved Targets; and (B) such disclosure is under an agreement to keep the terms of confidentiality and non-use no less rigorous than
the terms contained in this Agreement. 
 7.3. Public Announcements; Publications. 

7.3.1. Announcements. Except as may be expressly permitted under Section 7.2.3, neither Party will make any public
announcement regarding this Agreement without the prior written approval of the other Party. For the sake of clarity, nothing in this Agreement shall prevent (a) either Party from making any public disclosure relating to this Agreement if the
contents of such public disclosure has previously been made public other than through a breach of this Agreement by the issuing Party or its Affiliates; (b) Pfizer from making any scientific publication (in accordance with Section 7.3.2) or
public announcement with respect to any Agreement Product under this Agreement; or (c) MacroGenics from making any public announcement approved in advance by Pfizer with respect to any Milestone Payment received by MacroGenics hereunder, which
approval may not be unreasonably withheld or delayed; provided, however, that, except as permitted under Section 7.2, Pfizer shall not disclose any of MacroGenics’s Confidential Information in any such publication or announcement without
obtaining MacroGenics’s prior written consent to do so. The Parties agree that MacroGenics may release the announcement attached hereto as Exhibit 7.3.1 regarding the signing of this Agreement following the Effective Date.

 7.3.2. Publications. During the Term, each Party shall submit to the other Party (the “Non-Disclosing
Party”) for review and approval any proposed academic, scientific and medical publication or public presentation which contains the Non-Disclosing Party’s Confidential Information. In addition, MacroGenics shall submit to Pfizer for
review and approval any proposed publication or public presentation relating to the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the MacroGenics Technology, the Pfizer
Technology, the Joint Technology, the rights granted to Pfizer hereunder and determining whether any portion of the proposed 

  
 50 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
publication or presentation containing the Non-Disclosing Party’s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required
to be submitted hereunder shall be submitted to the Non-Disclosing Party no later than *** before submission for publication or presentation (the “Review Period”). The Non-Disclosing Party shall provide its comments with
respect to such publications and presentations within *** after its receipt of such written copy. The Review Period may be extended for an additional *** in the event the Non-Disclosing Party can, *** after receipt of the
written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. MacroGenics and Pfizer will each comply with standard academic practice regarding authorship of scientific publications and
recognition of contribution of other parties in any publication governed by this Section 7.3.2. 
 7.4. Obligations in
Connection with Change of Control. If MacroGenics is subject to a Change of Control, MacroGenics will, and it will cause its Affiliates and Representatives to, ensure that no Confidential Information of Pfizer (except as may be expressly
permitted under Section 7.2.3 with respect to the terms of this Agreement and with respect to any royalty statements provided by Pfizer pursuant to Section 5.5.2) is released to (a) any Affiliate of MacroGenics that becomes an Affiliate as
a result of the Change of Control or (b) any Representatives of MacroGenics (or of the relevant surviving entity of such Change of Control) who become Representatives as a result of the Change of Control, unless such Representatives have signed
individual confidentiality agreements which include equivalent obligations to those set out in this Section 7. If any Change of Control of MacroGenics occurs, MacroGenics shall promptly notify Pfizer, *** 

 

	8.	REPRESENTATIONS AND WARRANTIES. 

 8.1. Mutual Representations and Warranties. Each of MacroGenics and Pfizer hereby represents and warrants to the other Party that: 

8.1.1. it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization; 

8.1.2. the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite action under the
provisions of its charter, bylaws and other organizational documents, and does not require any action or approval by any of its shareholders or other holders of its voting securities or voting interests; 

8.1.3. it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder 

8.1.4. this Agreement has been duly executed and is a legal, valid and Binding Obligation on each Party, enforceable against such Party in
accordance with its terms; and 

  
 51 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 8.1.5. the execution, delivery and performance by such Party of this Agreement and its
compliance with the terms and provisions hereof does not and will not conflict with or result in a breach of or default under any Binding Obligation existing as of the Effective Date. 

8.2. Representations and Warranties of MacroGenics. MacroGenics hereby represents and warrants to Pfizer that as of the Effective
Date: 
 8.2.1. MacroGenics is the sole and exclusive owner of the MacroGenics Technology, all of which is free and clear of any
claims, liens, charges or encumbrances; 
 8.2.2. it has and will have the full right, power and authority to grant all of the
right, title and interest in the licenses and other rights granted or to be granted to Pfizer or Pfizer’s Affiliates under this Agreement; 
 8.2.3. (a) Schedule 8.2.3 sets forth a true and complete list of all Patent Rights owned or otherwise Controlled by MacroGenics or its Affiliates that relate to the MacroGenics
Technology, (b) each such Patent Right remains in full force and effect and (c) MacroGenics or its Affiliates have timely paid all filing and renewal fees payable with respect to such Patent Rights; 

8.2.4. to its best knowledge: (a) the MacroGenics Patent Rights, are, or, upon issuance, will be, valid and enforceable patents and
(b) no Third Party (i) is infringing any MacroGenics Patent Right or (ii) has challenged or threatened to challenge the extent, validity or enforceability of any MacroGenics Patent Right (including, by way of example, through the
institution or written threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority); 

8.2.5. to its best knowledge, it has complied with all Applicable Laws, including any disclosure requirements, in connection with the
filing, prosecution and maintenance of the MacroGenics Patent Rights; 
 8.2.6. MacroGenics has independently developed all
MacroGenics Know-How or otherwise has a valid right to use, and to permit Pfizer, Pfizer’s Affiliates and Pfizer’s Sublicensees to use, the MacroGenics Know-How for all permitted purposes under this Agreement; 

8.2.7. it has obtained from all inventors of MacroGenics Technology existing as of the Effective Date, valid and enforceable agreements
assigning to MacroGenics each such inventor’s entire right, title and interest in and to all such MacroGenics Technology; 

  
 52 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 8.2.8. except as expressly disclosed in Schedule 8.2.8, no MacroGenics Technology
existing as of the Effective Date is subject to any funding agreement with any government or Governmental Authority; 
 8.2.9.
neither MacroGenics nor any of its Affiliates are subject to any agreement or obligation that limits any ownership or license right granted to Pfizer or its Affiliates under this Agreement, including any right granted to Pfizer or its Affiliates to
access, practice, grant any licenses or sublicenses under, or provide Pfizer’s Sublicensees with access to any intellectual property right or material (including any Patent Right, Know-How or other data or information), in each case, that
would, but for such agreement or obligation, be included in the rights licensed or assigned to Pfizer or its Affiliates pursuant to this Agreement; 
 8.2.10. (a) there are no MacroGenics Third Party Agreements and (b) no Third Party has any right, title or interest in or to, or any license under, any MacroGenics Technology; 

8.2.11. it has disclosed to Pfizer all provisions of *** relevant to determining the extent of any and all limitations on
Pfizer’s rights under this Agreement necessitated by MacroGenics’s obligations under ***; 
 8.2.12. except as
disclosed to Pfizer prior to the Effective Date in written form, referencing this Section 8.2.12 of the Agreement, to the best of its knowledge, the use, practice or application by MacroGenics or Pfizer (or their respective Affiliates or
Sublicensees) as contemplated under this Agreement of any MacroGenics Technology relating to T-DARTs (a) does not and will not infringe any issued patent of any Third Party or (b) would not infringe the claims of any published Third Party
patent application when and if such claims were to issue; 
 8.2.13. except as expressly disclosed in Schedule 8.2.13,
there is no (a) claim, demand, suit, proceeding, arbitration, inquiry, investigation or other legal action of any nature, civil, criminal, regulatory or otherwise, pending or, to the best knowledge of MacroGenics, threatened against MacroGenics
or any of its Affiliates or (b) judgment or settlement against or owed by MacroGenics or any of its Affiliates, in each case in connection with the MacroGenics Technology or relating to the transactions contemplated by this Agreement.

 8.3. Representations and Warranties of Pfizer. Pfizer hereby represents and warrants to MacroGenics that as of the
Effective Date: 
 8.3.1. there is no (a) claim, demand, suit, proceeding, arbitration, inquiry, investigation or other
legal action of any nature, civil, criminal, regulatory or otherwise, pending or, to the best knowledge of Pfizer, threatened against Pfizer or any of its Affiliates or (b) judgment or settlement against or owed by Pfizer or any of its
Affiliates, in each case in connection with the Pfizer Proprietary Materials or relating to the transactions contemplated by this Agreement. 

  
 53 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 8.4. MacroGenics Covenants. In addition to the covenants made by MacroGenics
elsewhere in this Agreement, and subject to the provisions of Section 6, MacroGenics hereby covenants to Pfizer that, from the Effective Date until expiration or termination of this Agreement: 

8.4.1. it will (a) not enter into any MacroGenics Third Party Agreement that is inconsistent with (i) the rights granted to
Pfizer or Pfizer’s Affiliates hereunder or (ii) MacroGenics’s ability to fully perform its obligations hereunder; (b) not amend or otherwise modify any MacroGenics Third Party Agreement (including any Disclosed Third Party
Agreement) or consent or waive rights with respect thereto in any manner that (i) is inconsistent with the rights granted to Pfizer or Pfizer’s Affiliates hereunder or (ii) MacroGenics’s ability to fully perform its obligations
hereunder; (c) promptly furnish Pfizer with copies of all (i) amendments to the Disclosed Third Party Agreements and (ii) MacroGenics Third Party Agreements and related amendments executed following the Effective Date;
(d) remain, and cause its Affiliates to remain, in compliance in all material respects with all MacroGenics Third Party Agreements (including Disclosed Third Party Agreements); and (e) furnish Pfizer with copies of all notices received by
MacroGenics or its Affiliates relating to any alleged breach or default by MacroGenics or its Affiliates under any MacroGenics Third Party Agreement (including and Disclosed Third Party Agreement) within fifteen (15) Business Days after receipt
thereof; 
 8.4.2. it will not enter into or otherwise allow itself or its Affiliates to be subject to any agreement or
arrangement which limits the ownership rights of Pfizer or its Affiliates with respect to, or limits the ability of Pfizer or its Affiliates to grant a license, sublicense or access, or provide or provide access or other rights in, to or under, any
intellectual property right or material (including any Patent Right, Know-How or other data or information), in each case, that would, but for such agreement or arrangement, be included in the rights licensed or assigned to Pfizer or its Affiliates
pursuant to this Agreement; 
 8.4.3. it will maintain valid and enforceable agreements with all Persons acting by or on behalf
of MacroGenics or its Affiliates under this Agreement which require such Persons to assign to MacroGenics their entire right, title and interest in and to all MacroGenics Technology and Joint Technology; and 

8.4.4. in the conduct of any Research Project, unless MacroGenics receives prior written consent from Pfizer, MacroGenics shall neither
use funding from any Government Authority nor use CHO-S cells. 
 8.5. Representation by Legal Counsel. Each Party hereto
represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree
that no presumption shall exist or be implied against the Party which drafted such terms and provisions. 

  
 54 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 8.6. Disclaimer. THE FOREGOING REPRESENTATIONS AND WARRANTIES OF EACH PARTY ARE IN
LIEU OF ANY OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, ANY IMPLIED WARRANTY OF NON-INFRINGEMENT OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE
HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED. 
  

	9.	GOVERNMENT APPROVALS; TERM AND TERMINATION. 

 9.1. Government Approvals. Each of MacroGenics and Pfizer shall cooperate with the other Party and use Commercially Reasonable Efforts to make all registrations, filings and applications, to give
all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications authorizations, permits and waivers, if any, and to do all other things necessary or desirable for the consummation of
the transactions as contemplated hereby. 
 9.2. Term. The term of this Agreement shall commence on the Effective Date and
shall extend, unless this Agreement is terminated earlier in accordance with this Section 9, until the expiration of the last-to-expire of all Royalty Terms with respect to all Agreement Products (the “Term”). 

9.3. Termination by Either Party for Cause. Either Party may terminate this Agreement, in its entirety or, at the terminating
Party’s option, on an Agreement T-DART-by-Agreement T-DART basis, at any time during the Term by giving written notice to the other Party if the other Party commits a material breach of its obligations under this Agreement and such breach
remains uncured for ***, measured from the date written notice of such breach is given to the breaching Party; provided, however, that if such breach (other than breach of an undisputed payment obligation) is not susceptible of cure within
the stated period and the breaching Party uses diligent, good faith efforts to cure such breach, the stated period shall be extended by an *** Notwithstanding the foregoing, a Party shall have the right to terminate this Agreement pursuant to
this Section 9.3 in part with respect to an individual Agreement T-DART only if the other Party’s material breach giving rise to such termination right relates solely to such Agreement T-DART. 

9.4. Termination by Pfizer without Cause. Pfizer shall have the right to terminate the Agreement at any time for any or no reason,
on a Research Project Target-by-Research Project Target basis, by providing *** advance written notice of such termination to MacroGenics; provided that, during the ***, Pfizer will retain at least one Research Project Target under the
Research Program. ***, Pfizer shall have the right, exercisable upon *** prior written notice to MacroGenics, to terminate this Agreement at any time for any or no reason either (a) in its entirety or (b) on a Research
Project Target-by-Research Project Target basis. 

  
 55 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 9.5. Effects of Termination. 

9.5.1. Effect of Termination by Pfizer for Cause. If Pfizer terminates this Agreement with respect to any or all Agreement T-DARTS
pursuant to Section 9.3 (each, a “Terminated T-DART”): 
 (a) all work under the applicable Research Plan(s)
with respect to each Terminated T-DART shall cease; 
 (b) (i) all licenses granted to Pfizer with respect to such
Terminated T-DART and any Agreement Product incorporating such Terminated T-DART (“Terminated Agreement Product”), including licenses under Section 4.1, shall continue and shall become perpetual, irrevocable licenses;
(ii) Pfizer’s rights under Section 4.1 shall remain in full force and effect with respect to any such Terminated T-DART or Terminated Agreement Product; and (iii) Pfizer shall have no further obligations to MacroGenics under this
Agreement with respect to any such Terminated T-DART or Terminated Agreement Product, other than (x) obligations to pay Milestones and royalties with respect to each Terminated Target and Net Sales of Agreement Products incorporating each
Terminated T-DART, as applicable, in an amount equal to *** of the amount that would otherwise have been payable under this Agreement, and (y) those other obligations that expressly survive termination in accordance with Section 9.7
shall survive; 
 (c) MacroGenics shall remain entitled to receive payments that accrued before the effective date of such
termination; 
 (d) nothing in this Section 9.5.1 shall limit any other remedy Pfizer may have for MacroGenics’s breach of
this Agreement; and 
 (e) the rights and obligations of the Parties with respect to all Agreement T-DARTs other than any such
Terminated T-DART shall remain in full force and effect. 
 9.5.2. Effect of Termination by MacroGenics for Cause or by Pfizer
without Cause. 
 (a) If MacroGenics terminates this Agreement with respect to any Agreement T-DARTs pursuant to
Section 9.3, or if Pfizer terminates this Agreement with respect to any Agreement T-DARTs pursuant to Section 9.4: (i) all licenses granted by MacroGenics to Pfizer under Section 4.1 with respect to any such Agreement T-DART and any
Agreement Product containing such Agreement T-DART shall terminate and (ii) on MacroGenics’s written request within *** of such termination, Pfizer shall reassign to MacroGenics all of the right, title and interest in Agreement
T-DART IP that was assigned by MacroGenics to Pfizer pursuant to Section 4.1.2 with respect to such Agreement T-DART, and in any Agreement 

  
 56 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
T-DART Patent Rights relating thereto that have been filed (unless another alternative approach has been agreed by the Parties in view of prosecution exigencies), any such assignment to be
completed within *** of such request. After such assignment, or if MacroGenics declines to request assignment or such *** period expires without a request by MacroGenics, Pfizer will have no further obligations to prosecute or maintain
such Agreement T-DART Patent Rights or to pay any costs related thereto. All rights and obligations with respect to all other Agreement T-DARTs and Agreement Products shall remain in full force and effect (and for avoidance of doubt, any Agreement
T-DART IP and Agreement T-DART Patent Rights assigned to MacroGenics pursuant to this Section 9.5.2(a) will be included in MacroGenics Technology and MacroGenics Patent Rights, respectively, for the purposes of such other Agreement T-DARTs and
Agreement Products). MacroGenics shall have a fully paid up, royalty free non-exclusive license under any such Agreement T-DART Patent Right not assigned to MacroGenics pursuant to the provisions of this Section 9.5.2(a). 

(b) If MacroGenics terminates this Agreement in its entirety pursuant to Section 9.3, or if Pfizer terminates this Agreement in its
entirety pursuant to Section 9.4: (i) all licenses granted by MacroGenics to Pfizer under Section 4.1 shall terminate, (ii) on MacroGenics’s written request within thirty (30) days of such termination, Pfizer shall reassign to
MacroGenics all of MacroGenics’ right, title and interest in Agreement T-DART IP that was assigned by MacroGenics to Pfizer pursuant to Section 4.1.2, and in any Agreement T-DART Patent Rights relating thereto that have been filed (unless
another alternative approach has been agreed by the Parties in view of prosecution exigencies), any such assignment to be completed within *** of such request, and MacroGenics shall have no further obligations to Pfizer under this Agreement
other than those obligations that expressly survive termination in accordance with Section 9.7. After assignment of any Agreement T-DART Patent Rights pursuant to this Section 9.5.2(b), or if MacroGenics declines to request assignment or ***
expires without a request by MacroGenics, Pfizer will have no further obligations to prosecute or maintain such Agreement T-DART Patent Rights or to pay any costs related thereto. MacroGenics shall have a fully paid up, royalty free non-exclusive
license under any Agreement T-DART Patent Right not assigned to MacroGenics pursuant to the provisions of this Section 9.5.2(b). 
 (c) For the avoidance of doubt, if MacroGenics terminates this Agreement with respect to any Agreement T-DARTs pursuant to Section 9.3, or if Pfizer terminates this Agreement with respect to any Agreement
T-DARTs pursuant to Section 9.4, in each case including all Agreement T-DARTs in the event that this Agreement is terminated in its entirety, (i) all rights granted by Pfizer to MacroGenics under Section 4.2

  
 57 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
shall survive such termination and (ii) any such Agreement T-DART will no longer be considered to be an Agreement T-DART for the purpose of this Agreement. 

(d) Nothing in this Section 9.5.3 shall limit MacroGenics’s right to receive payments that accrued before the effective date of
termination or limit any other remedy MacroGenics may have for Pfizer’s breach of this Agreement. 
 (e) At
MacroGenics’s request within thirty (30) days of any termination of this Agreement, Pfizer shall negotiate with MacroGenics regarding the possible grant to MacroGenics of some or all of the following rights, it being understood and agreed
that neither Party shall have any obligation to enter into any such arrangement and that if agreement is not reached within *** after such request there shall be no further obligation on either Party to conduct further negotiations:

 (i) Grant Back License with Respect to MacroGenics-Derived Terminated Agreement T-DARTs. The grant by Pfizer to
MacroGenics of an exclusive or non-exclusive, worldwide, royalty-bearing license under the Pfizer Collaboration Patent Rights to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized, import,
have imported, export and have exported any MacroGenics-Derived Terminated Agreement T-DART and, in each case in the form in which such MacroGenics-Derived Terminated Agreement T-DART or related Agreement Product exists as of termination, for a
commercially reasonable royalty rate and on terms and conditions regarding payment provisions based on the provisions of this Agreement regarding such matters as royalty term, adjustments, reports, audits and the like). “Pfizer Collaboration
Patent Right” means any Pfizer Patent Right covering or claiming any invention made solely by Pfizer or any of its Affiliates in the course of performing the Research Program and “MacroGenics-Derived Terminated Agreement
T-DART” means any Agreement T-DART for which (A) this Agreement is terminated by MacroGenics pursuant to Section 9.3, or by Pfizer pursuant to Section 9.4 and (B) MacroGenics provided Antibodies to Pfizer for the Research
Project for such Agreement T-DART. 
 (ii) Inventory. MacroGenics obtaining Pfizer’s inventory of any such
MacroGenics-Derived Terminated Agreement T-DART and/or related Agreement Product. 

  
 58 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 (iii) Supply. Pfizer supplying MacroGenics with quantities of such
MacroGenics-Derived Terminated Agreement T-DART and/or related Agreement Product for a limited period of time. 
 (iv)
Trademarks. Pfizer providing with MacroGenics with certain rights in and to the Trademark(s) used in connection with any such MacroGenics-Derived Terminated Agreement T-DART and/or related Agreement Product (but not any Pfizer house marks or
any trademark containing the word “Pfizer”). 
 (v) Regulatory Filings and Approvals. Pfizer providing
MacroGenics with certain rights in and regulatory filings and approvals with respect to and such MacroGenics-Derived Terminated Agreement T-DART and/or related Agreement Product. 

(vi) No Obligation. For the avoidance of doubt, the description here of these possible arrangements shall not imply any obligation
on either Party to enter into any such arrangement. 
 9.5.3. Satisfaction of Obligations During Notice Period. During the
period from providing a notice of termination pursuant to Section 9.4 through the termination of the Agreement, the Parties shall continue to perform their obligations under this Agreement. 

9.5.4. Pending Dispute Resolution. If a Party gives notice of termination under Section 9.3 and the other Party disputes whether
such notice was proper, then the issue of whether this Agreement has been terminated shall be resolved in accordance with Section 11.9 and each Party shall continue to perform its obligations hereunder pending the conclusion of such dispute
resolution proceeding. If as a result of such dispute resolution process it is determined that the notice of termination was proper, then such termination shall be effective immediately. If as a result of such dispute resolution process it is
determined that the notice of termination was improper, then no termination shall have occurred and this Agreement shall remain in effect. 
 9.6. Disposition of Inventories of Products. Following termination of this Agreement with respect to one or more Agreement T-DARTs, Pfizer, its Affiliates and its Sublicensees shall have the right
to continue to sell their existing inventories of Agreement Product(s) incorporating such Agreement T-DART(s) that have received Regulatory Marketing Approval prior to such termination for a period not to exceed *** after the effective date
of such termination or expiration and Pfizer shall pay any royalties payable in connection with such sales in accordance with Sections 5.4.4 and 5.5. 
 9.7. Survival of Certain Obligations. Expiration or termination of this Agreement shall not relieve the Parties of any obligation that accrued before such expiration or

  
 59 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
termination. The following provisions shall survive expiration or termination of this Agreement: Sections 1, 2.11, 2.12, 2.13.3, 2.13.4, 2.13.5, 4.3, 5.2.5, 5.6, 5.7, 6.1.1, 6.2.1(e), 7, 8.6,
9.5, 9.6, 9.7, 9.8, 10 and 11. 
 9.8. Right to Termination of Research Project(s) or Research Program by Pfizer upon Change
of Control of MacroGenics. If a Change of Control of MacroGenics is consummated during the Research Term, Pfizer shall have the right to terminate any Research Project or the Research Program in its entirety, at any time, upon written notice to
MacroGenics within 30 days after consummation of such Change of Control of MacroGenics. Such termination of any Research Project or the Research Program (a) shall not constitute termination of this Agreement, (b) shall not affect the
Parties’ rights and obligations under this Agreement other than those relating to such Research Project or the Research Program and (c) shall not relieve either Party of any obligation that arose prior to such termination. Following any
such termination of any Research Project or the Research Program, as applicable, Pfizer shall have no further funding obligation under Section 2 with respect to such Research Project or the Research Program, as applicable, other than that which may
have accrued prior to such termination. For the avoidance of doubt, in the event that Pfizer terminates a Research Project or the Research Program in accordance with this Section 9.8, such termination will not be deemed to be a termination for cause
under Section 9.3 or a termination without cause under Section 9.4, and the only effects of such termination are as set forth in this Section 9.8. 
  

	10.	LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE. 

 10.1. No Consequential Damages. Except with respect to liability arising from a breach of Section 7, or to the extent such Party may be required to indemnify the other Party under this Section 10,
in no event will either Party, its Affiliates, its Sublicensees or any of its, its Affiliates’ or its Sublicensees’ respective Representatives be liable under this Agreement for any special, indirect, incidental, consequential or punitive
damages, whether in contract, warranty, tort, negligence, strict liability or otherwise, including loss of profits or revenue suffered by either Party or any of its respective Affiliates, agents or representatives. Without limiting the generality of
the foregoing, “consequential damages” will be deemed to include, and neither Party will be liable to the other Party or any of such other Party’s Affiliates, Representatives or stockholders for any damages based on or measured by
loss of projected or speculative future sales of the Agreement Products, any Milestone Payment due upon any unachieved event under Section 5.2, any unearned royalties under Section 5.4 or any other unearned, speculative or otherwise contingent
payments provided for in this Agreement. 

  
 60 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 10.2. Indemnification by Pfizer. Pfizer will indemnify, defend and hold harmless
MacroGenics, each of its Affiliates, and each of its and its Affiliates’ employees, officers, directors and agents (each, a “MacroGenics Indemnified Party”) from and against any and all liability, loss, damage, expense
(including reasonable attorneys’ fees and expenses) and cost (collectively, a “Liability”) that the MacroGenics Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of: 

10.2.1. the Development, Manufacture, Commercialization or use of any Agreement T-DART or Agreement Product by, on behalf of, or under the
authority of, Pfizer (other than by any MacroGenics Indemnified Party), other than claims for which MacroGenics is required to indemnify Pfizer pursuant to Section 10.3; or 
 10.2.2. the material breach by Pfizer of any of its representations, warranties or covenants set forth in Section 2.13.1, 8.1 or 8.3; 

except, in each case, to the extent caused by the negligence, recklessness or intentional acts of MacroGenics or any MacroGenics
Indemnified Party. 
 10.3. Indemnification by MacroGenics. MacroGenics will indemnify, defend and hold harmless Pfizer, its
Affiliates, Sublicensees, contractors, distributors and each of its and their respective employees, officers, directors and agents (each, a “Pfizer Indemnified Party”) from and against any and all Liabilities that the Pfizer
Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of the material breach by MacroGenics of any of its representations, warranties or covenants set forth in Section 8.1 or 8.2, except to the extent
caused by the negligence, recklessness or intentional acts of Pfizer or any Pfizer Indemnified Party. 
 10.4. Procedure.

 10.4.1. Notice. Each Party will notify the other Party in writing in the event it becomes aware of a claim for which
indemnification may be sought hereunder. In the event that any Third Party asserts a claim or other proceeding (including any governmental investigation) with respect to any matter for which a Party (the “Indemnified Party”) is
entitled to indemnification hereunder (a “Third Party Claim”), then the Indemnified Party shall promptly notify the Party obligated to indemnify the Indemnified Party (the “Indemnifying Party”) thereof; provided,
however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced
thereby. 
 10.4.2. Control. Subject to Pfizer’s right to control any actions described in Sections 6.2 (even where
MacroGenics is the Indemnifying Party), the Indemnifying Party shall have the right, exercisable by notice to the Indemnified Party within *** after receipt of notice from the Indemnified Party of the commencement of or assertion of any Third
Party Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Third Party Claim (including the right to settle the claim solely for monetary consideration) with counsel selected by the
Indemnifying Party and reasonably acceptable to the Indemnified Party; provided that (a) the Indemnifying Party has sufficient financial resources, in the reasonable judgment of the Indemnified Party, to satisfy the amount of any adverse
monetary judgment that is sought, and 

  
 61 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
(b) the Indemnifying Party expressly agrees in writing that as between the Indemnifying Party and the Indemnified Party, the Indemnifying Party shall be solely obligated to satisfy and discharge
the Third Party Claim in full (the conditions set forth in clauses (a) and (b) above are collectively referred to as the “Litigation Conditions”). Within *** after the Indemnifying Party has given notice to the
Indemnified Party of its exercise of its right to defend a Third Party Claim, the Indemnified Party shall give notice to the Indemnifying Party of any objection thereto based upon the Litigation Conditions. If the Indemnified Party reasonably so
objects, the Indemnified Party shall continue to defend the Third Party Claim, at the expense of the Indemnifying Party, until such time as such objection is withdrawn. If no such notice is given, or if any such objection is withdrawn, the
Indemnifying Party shall be entitled, at its sole cost and expense, to assume direction and control of such defense, with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. During such time as the
Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party shall cooperate, and shall cause its Affiliates and agents to cooperate upon request of the Indemnifying Party, in the defense or prosecution of the Third
Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or appeals as may reasonably be requested by the Indemnifying Party. In the event that the
Indemnifying Party does not satisfy the Litigation Conditions or does not notify the Indemnified Party of the Indemnifying Party’s intent to defend any Third Party Claim within ten *** after notice thereof, the Indemnified Party may
(without further notice to the Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying Party’s expense (including reasonable, out-of-pocket attorneys’ fees and costs and expenses of enforcement
or defense). The Indemnifying Party or the Indemnified Party, as the case may be, shall have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not
control, at its own expense, the defense of any Third Party Claim that the other Party is defending as provided in this Agreement. 
 10.4.3. Settlement. The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, enter into any compromise or settlement that commits the Indemnified Party to take,
or to forbear to take, any action or declare that any Patent Right or Know-How is invalid or not properly owned or licensed by the Indemnified Party. The Indemnified Party shall have the sole and exclusive right to settle any Third Party Claim, on
such terms and conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief, but shall not have the right to settle such Third Party Claim to the extent such Third Party Claim
involves monetary damages without the prior written consent of the Indemnifying Party. Each of the Indemnifying Party and the Indemnified Party shall not make any admission of liability in respect of any Third Party Claim without the prior written
consent of the other Party, and the Indemnified Party shall use reasonable efforts to mitigate Liabilities arising from such Third Party Claim. 

  
 62 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 10.5. Insurance. Each Party shall obtain and maintain, during the Term, commercial
general liability insurance, including products liability insurance, with reputable and financially secure insurance carriers (or pursuant to a program of self-insurance reasonably satisfactory to the other Party) to cover its indemnification
obligations under Section 10.2 or Section 10.3, as applicable, in each case with limits of not less than *** and in the aggregate. Insurance shall be procured with carriers having an A.M. Best Rating of A-VII or better. The provisions of this
Section 10.5 will survive for ***. 
  

	11.	MISCELLANEOUS. 

 11.1.
Assignment. MacroGenics may not assign this Agreement or any interest hereunder without the prior written consent of Pfizer, which consent will not be unreasonably withheld or delayed. Pfizer may not assign this Agreement or any interest
hereunder without the prior written consent of MacroGenics, which consent will not be unreasonably withheld or delayed. Notwithstanding the foregoing, this Agreement may be assigned as follows: (a) either Party may assign its rights and
obligations under this Agreement by way of sale of itself or the sale of the portion of its business to which this Agreement relates, through merger, sale of assets or sale of stock or ownership interest, provided that the assignee shall expressly
agree to be bound by such Party’s obligations under this Agreement and that such sale is not primarily for the benefit of its creditors and (b) either Party may assign its rights and obligations under this Agreement to any of its
Affiliates, provided that the assignee shall expressly agree to be bound by such Party’s obligations under this Agreement and that such Party shall remain liable for all of its rights and obligations under this Agreement. This Agreement shall
be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent
of this Agreement. Any assignment not in accordance with this Section 11.1 shall be void. 
 11.2. Further Actions. Each
Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 

11.3. Force Majeure. Each Party shall be excused from the performance of its obligations under this Agreement to the extent that
such performance is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues
and the nonperforming Party takes Commercially Reasonable Efforts to remove the condition. For purposes of this Agreement, “force majeure” shall include conditions beyond the control of the Parties, including an act of God, voluntary or
involuntary compliance with any regulation, Law or order of any government, war, act of terror, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or
materials by fire, earthquake, storm or like catastrophe. 

  
 63 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 11.4. Notices. Any notice or notification required or permitted to be provided
pursuant to the terms and conditions of this Agreement (including any notice of force majeure, breach, termination, change of address, etc.) shall be in writing and shall be deemed given upon receipt if delivered personally or by facsimile
transmission (receipt verified), five (5) days after deposited in the mail if mailed by registered or certified mail (return receipt requested) postage prepaid, or on the next Business Day if sent by overnight delivery using a nationally
recognized express courier service and specifying next Business Day delivery (receipt verified), to the Parties at the following addresses or facsimile numbers (or at such other address or facsimile number for a Party as shall be specified by like
notice, provided, however, that notices of a change of address shall be effective only upon receipt thereof): 
 All
correspondence to Pfizer shall be addressed as follows: 
 Pfizer Worldwide Research & Development 

235 East 42nd Street 
 New York, NY 10017 
 Attention: *** 

with a copy to: 

Pfizer Inc. 

445 Eastern Point Road, MS 8200-30 
 Groton, CT 
 Attention: *** 

All correspondence to MacroGenics shall be addressed as follows: 

MacroGenics, Inc. 
 1500 East Gude Drive Rockville, MD 20850 
 Attention: *** 

Facsimile: *** 

with a copy to: 

Wilmer Cutler Pickering Hale and Dorr LLP 
 399 Park Avenue 
 New York, NY 10022 

Attention: ***  
 Facsimile: *** 

  
 64 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 11.5. Amendment. No amendment, modification or supplement of any provision of this
Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 
 11.6.
Waiver. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the
waiving Party. The waiver by either of the Parties of any breach of any provision hereof by the other Party shall not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 

11.7. Severability. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or
unenforceable, the same shall not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement shall be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent
possible. In any such event, this Agreement shall be construed as if such clause of portion thereof had never been contained in this Agreement, and there shall be deemed substituted therefor such provision as will most nearly carry out the intent of
the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law. 
 11.8. Descriptive
Headings. The descriptive headings of this Agreement are for convenience only and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement. 

11.9. Dispute Resolution. If any dispute or disagreement arises between Pfizer and MacroGenics in respect of this Agreement, they
shall follow the following procedures in an attempt to resolve the dispute or disagreement: 
 11.9.1. The Party claiming that
such a dispute exists shall give notice in writing (“Notice of Dispute”) to the other Party of the nature of the dispute. 
 11.9.2.*** after receipt of a Notice of Dispute, the Pfizer Alliance Manager and the MacroGenics Alliance Manager shall meet in person or by teleconference and exchange written summaries
reflecting, in reasonable detail, the nature and extent of the dispute, and at this meeting they shall use their reasonable endeavors to resolve the dispute. 
 11.9.3. If the Alliance Managers are unable to resolve the dispute during the meeting described in Section 11.9.2 or if for any reason such meeting does not take place within the period specified in
Section 11.9.2, then the dispute will be referred to the JSC which shall meet no later than *** following the initial receipt of the Notice of Dispute and use reasonable endeavors to resolve the dispute. 

11.9.4. If the JSC is unable to resolve the dispute during the meeting described in Section 11.9.3 or if for any reason such meeting does
not take place within the period specified in Section 11.9.3, then the Senior Executives shall meet at a mutually agreed-upon time and location for the purpose of resolving such dispute. 

  
 65 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 11.9.5. If, within *** initial receipt of the Notice of Dispute, the dispute has not
been resolved, or if, for any reason, the meeting described in Section 11.9.4 has not been held within *** following initial receipt of the Notice of Dispute, then the Parties agree that either Party may initiate litigation to resolve the
dispute. 
 11.9.6. Notwithstanding any provision of this Agreement to the contrary, either Party may immediately initiate
litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement. The provisions of this
Section 11.9 will survive for *** from the date of termination or expiration of this Agreement. 
 11.10. Governing
Law. This Agreement, and all claims arising under or in connection therewith, shall be governed by and interpreted in accordance with the substantive laws of ***, without regard to conflict of law principles thereof. 

11.11. Consent to Jurisdiction. Each Party to this Agreement, by its execution hereof, (a) hereby irrevocably submits to the
exclusive jurisdiction of the state courts of the State *** of any and all actions, suits or proceedings arising in whole or in part out of, related to, based upon or in connection with this Agreement or the subject matter hereof,
(b) hereby waives to the extent not prohibited by Applicable Law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such action, any claim that it is not subject personally to the jurisdiction of the above-named
courts, that its property is exempt or immune from attachment or execution, that any such action brought in one of the above-named courts should be dismissed on grounds of forum non conveniens, should be transferred to any court other than one of
the above-named courts, or should be stayed by reason of the pendency of some other proceeding in any other court other than one of the above-named courts, or that this Agreement or the subject matter hereof may not be enforced in or by such court,
and (c) hereby agrees not to commence any such action other than before one of the above-named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such action to any court other
than one of the above-named courts whether on the grounds of inconvenient forum or otherwise. 
 11.12. Entire Agreement.
This Agreement constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written,
between the Parties respecting the subject matter hereof and thereof, including the Confidentiality Agreement which is hereby terminated effective as of the Effective Date. 
 11.13. Independent Contractors. Both Parties are independent contractors under this Agreement. Nothing herein contained shall be deemed to create an employment, agency,

  
 66 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or
failure to act of the other Party. Neither Party shall have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any
respect whatsoever. 
 11.14. Counterparts. This Agreement may be executed in two counterparts, each of which shall be an
original and both of which shall constitute together the same document. Counterparts may be signed and delivered by facsimile or PDF file, each of which shall be binding when received by the applicable Party. 

11.15. No Third Party Rights or Obligations. No provision of this Agreement shall be deemed or construed in any way to result in
the creation of any rights or obligation in any Person not a Party to this Agreement. However, either Party may decide, in its sole discretion, to use one or more of its Affiliates to perform its obligations and duties hereunder, provided that such
Party shall remain liable hereunder for the performance by any such Affiliates of any such obligations. 
 (The remainder of this
page has been intentionally left blank. The signature page follows.) 

  
 67 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this
Agreement to be effective as of the Effective Date. 
  

									
	PFIZER INC.	 		 	MACROGENICS, INC.
					
	By:	 	 /s/ Dr. Mikael Dolsten
	 		 	By:	 	 /s/ Scott Koenig

	Name:	 	Mikael Dolsten	 		 	Name:	 	Scott Koenig
	Title:	 	President, Worldwide Research & Development	 		 	Title:	 	CEO

  
 Signature
Page to Research Collaboration and License Agreement 
  

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 EXHIBIT 2.3.1 

FORM OF RESEARCH PLANS 
 

 
  

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 EXHIBIT 7.3.1 

PRESS RELEASE 
 DRAFT 
 MacroGenics Enters Global Research Collaboration 

and License Agreement with Pfizer 
 ROCKVILLE, MD     , 2010 /PRNewswire/ — MacroGenics, Inc, a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global
research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DARTTM) products directed at two undisclosed cancer targets. MacroGenics’ DART technology is a proprietary,
bi-specific antibody platform in which a single recombinant molecule is able to target two different antigens. These DART proteins are amenable to several applications and can potentially be used to redirect the body’s cell-destroying, immune
effector cells against tumor cells. 
 “MacroGenics’ DART candidates represent a promising new approach to potentially expand
treatment options for cancer patients, and we look forward to a collaborative partnership with MacroGenics,” stated Dr. Mikael Dolsten, Senior Vice President & President, Worldwide Research and Development, Pfizer.
“MacroGenics has established the versatility of its novel DART platform by generating a large array of DART proteins against a variety of different targets.” 
 “We are delighted to establish this strategic collaboration with Pfizer,” said Dr. Scott Koenig, MacroGenics’ President and Chief Executive Officer. “As we continue to make
significant progress in the development of our pipeline of best-in-class product candidates for cancer, autoimmune disease, and infectious disease, this collaboration with Pfizer further validates the promise of our DART platform.” 

Under the terms of the agreement, MacroGenics will receive an upfront cash payment and research funding. In addition, MacroGenics will be eligible to
receive escalating preclinical, clinical, regulatory and commercial milestone payments as well as tiered royalties on sales of products resulting from the collaboration. Further details of the agreement have not been disclosed. 

DART Background 
 MacroGenics’ DART
technology enables the generation of highly stable antibody-based therapeutic molecules that can simultaneously target two different antigens. DART therapeutics can accommodate virtually any variable region sequence in a “plug-and-play”
fashion, are potent, and have very favorable manufacturing properties. To date, the company has engineered over 65 different DART proteins and has completed multiple in vitro and in vivo proof-of-concept studies in a variety of disease models. The
company has been able to produce DART 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 
proteins in both bacterial and mammalian expression systems. DARTs also have been engineered with an Fc domain, which confers them with additional properties, such as Fc receptor binding and
extended half-life. This functionality can be further expanded with the inclusion of MacroGenics’ proprietary Fc domain portfolio. MacroGenics has established and continues to expand a significant patent estate around its DART technology.

 About MacroGenics 

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for
autoimmune disorders, cancer and infectious diseases. Since its founding in 2000, the company has built a fully-integrated set of capabilities in antibody-based product development. The company has generated a proprietary pipeline of innovative
product candidates by leveraging its three core technology platforms. These proprietary platforms include: (1) cancer stem-like cells; (2) DART technology, which allows the company to incorporate multiple specificities within a single
molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. The company’s lead program, teplizumab, is an anti-CD3 antibody. Teplizumab is being investigated in Phase 3 trials for the treatment of autoimmune
diseases in collaboration with Eli Lilly and Company. For more information about MacroGenics, please visit www.macrogenics.com. 
 Statements
made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expects,” “believes,” “intends,” and
similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual
results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, and risks related to the Company’s ability to initiate, and enroll patients in, planned clinical trials. You should not place
undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law. 

Contacts: 
 *** 

### 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.19 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.19 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.34 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.34 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.34 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.80 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.80 *** 
 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.80 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.80 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.80 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.80 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.125 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.125 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 1.125 *** 
 *** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 2.10 
 SUBCONTRACTORS*** 

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

 SCHEDULE 8.2.3 

Patent Rights of MacroGenics 
  

									
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***
	 ***
	  	***	  	***	  	***	  	***

  

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 SCHEDULE 8.2.8 

FUNDING AGREEMENTS 
 ***

  

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 SCHEDULE 8.2.13 

LITIGATION 
 ***

  

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]